Modelling community-control strategies to protect hospital resources during an influenza pandemic in Ottawa, Canada
Identifieur interne : 000A74 ( Pmc/Corpus ); précédent : 000A73; suivant : 000A75Modelling community-control strategies to protect hospital resources during an influenza pandemic in Ottawa, Canada
Auteurs : Patrick Saunders-Hastings ; Bryson Quinn Hayes ; Robert Smith ; Daniel KrewskiSource :
- PLoS ONE [ 1932-6203 ] ; 2017.
Abstract
A novel influenza virus has emerged to produce a global pandemic four times in the past one hundred years, resulting in millions of infections, hospitalizations and deaths. There is substantial uncertainty about when, where and how the next influenza pandemic will occur.
We developed a novel mathematical model to chart the evolution of an influenza pandemic. We estimate the likely burden of future influenza pandemics through health and economic endpoints. An important component of this is the adequacy of existing hospital-resource capacity. Using a simulated population reflective of Ottawa, Canada, we model the potential impact of a future influenza pandemic under different combinations of pharmaceutical and non-pharmaceutical interventions.
There was substantial variation in projected pandemic impact and outcomes across intervention scenarios. In a population of 1.2 million, the illness attack rate ranged from 8.4% (all interventions) to 54.5% (no interventions); peak acute care hospital capacity ranged from 0.2% (all interventions) to 13.8% (no interventions); peak ICU capacity ranged from 1.1% (all interventions) to 90.2% (no interventions); and mortality ranged from 11 (all interventions) to 363 deaths (no interventions). Associated estimates of economic burden ranged from CAD $115 million to over $2 billion when extended mass school closure was implemented.
Children accounted for a disproportionate number of pandemic infections, particularly in household settings. Pharmaceutical interventions effectively reduced peak and total pandemic burden without affecting timing, while non-pharmaceutical measures delayed and attenuated pandemic wave progression. The timely implementation of a layered intervention bundle appeared likely to protect hospital resource adequacy in Ottawa. The adaptable nature of this model provides value in informing pandemic preparedness policy planning in situations of uncertainty, as scenarios can be updated in real time as more data become available. However—given the inherent uncertainties of model assumptions—results should be interpreted with caution.
Url:
DOI: 10.1371/journal.pone.0179315
PubMed: 28614365
PubMed Central: 5470707
Links to Exploration step
PMC:5470707Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Modelling community-control strategies to protect hospital resources during an influenza pandemic in Ottawa, Canada</title><author><name sortKey="Saunders Hastings, Patrick" sort="Saunders Hastings, Patrick" uniqKey="Saunders Hastings P" first="Patrick" last="Saunders-Hastings">Patrick Saunders-Hastings</name><affiliation><nlm:aff id="aff001"><addr-line>University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 850 Peter Morand Crescent, Ottawa, Ontario, Canada</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>University of Ottawa, School of Epidemiology, Public Health, and Preventive Medicine, Faculty of Medicine, Ottawa, ON, Canada</addr-line></nlm:aff></affiliation></author><author><name sortKey="Quinn Hayes, Bryson" sort="Quinn Hayes, Bryson" uniqKey="Quinn Hayes B" first="Bryson" last="Quinn Hayes">Bryson Quinn Hayes</name><affiliation><nlm:aff id="aff003"><addr-line>University of Ottawa, Department of Mathematics, Ottawa, ON, Canada</addr-line></nlm:aff></affiliation></author><author><name sortKey="Smith, Robert" sort="Smith, Robert" uniqKey="Smith R" first="Robert" last="Smith">Robert Smith</name><affiliation><nlm:aff id="aff002"><addr-line>University of Ottawa, School of Epidemiology, Public Health, and Preventive Medicine, Faculty of Medicine, Ottawa, ON, Canada</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff003"><addr-line>University of Ottawa, Department of Mathematics, Ottawa, ON, Canada</addr-line></nlm:aff></affiliation></author><author><name sortKey="Krewski, Daniel" sort="Krewski, Daniel" uniqKey="Krewski D" first="Daniel" last="Krewski">Daniel Krewski</name><affiliation><nlm:aff id="aff001"><addr-line>University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 850 Peter Morand Crescent, Ottawa, Ontario, Canada</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>University of Ottawa, School of Epidemiology, Public Health, and Preventive Medicine, Faculty of Medicine, Ottawa, ON, Canada</addr-line></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">28614365</idno><idno type="pmc">5470707</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470707</idno><idno type="RBID">PMC:5470707</idno><idno type="doi">10.1371/journal.pone.0179315</idno><date when="2017">2017</date><idno type="wicri:Area/Pmc/Corpus">000A74</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000A74</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Modelling community-control strategies to protect hospital resources during an influenza pandemic in Ottawa, Canada</title><author><name sortKey="Saunders Hastings, Patrick" sort="Saunders Hastings, Patrick" uniqKey="Saunders Hastings P" first="Patrick" last="Saunders-Hastings">Patrick Saunders-Hastings</name><affiliation><nlm:aff id="aff001"><addr-line>University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 850 Peter Morand Crescent, Ottawa, Ontario, Canada</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>University of Ottawa, School of Epidemiology, Public Health, and Preventive Medicine, Faculty of Medicine, Ottawa, ON, Canada</addr-line></nlm:aff></affiliation></author><author><name sortKey="Quinn Hayes, Bryson" sort="Quinn Hayes, Bryson" uniqKey="Quinn Hayes B" first="Bryson" last="Quinn Hayes">Bryson Quinn Hayes</name><affiliation><nlm:aff id="aff003"><addr-line>University of Ottawa, Department of Mathematics, Ottawa, ON, Canada</addr-line></nlm:aff></affiliation></author><author><name sortKey="Smith, Robert" sort="Smith, Robert" uniqKey="Smith R" first="Robert" last="Smith">Robert Smith</name><affiliation><nlm:aff id="aff002"><addr-line>University of Ottawa, School of Epidemiology, Public Health, and Preventive Medicine, Faculty of Medicine, Ottawa, ON, Canada</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff003"><addr-line>University of Ottawa, Department of Mathematics, Ottawa, ON, Canada</addr-line></nlm:aff></affiliation></author><author><name sortKey="Krewski, Daniel" sort="Krewski, Daniel" uniqKey="Krewski D" first="Daniel" last="Krewski">Daniel Krewski</name><affiliation><nlm:aff id="aff001"><addr-line>University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 850 Peter Morand Crescent, Ottawa, Ontario, Canada</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>University of Ottawa, School of Epidemiology, Public Health, and Preventive Medicine, Faculty of Medicine, Ottawa, ON, Canada</addr-line></nlm:aff></affiliation></author></analytic><series><title level="j">PLoS ONE</title><idno type="eISSN">1932-6203</idno><imprint><date when="2017">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="sec001"><title>Background</title><p>A novel influenza virus has emerged to produce a global pandemic four times in the past one hundred years, resulting in millions of infections, hospitalizations and deaths. There is substantial uncertainty about when, where and how the next influenza pandemic will occur.</p></sec><sec id="sec002"><title>Methods</title><p>We developed a novel mathematical model to chart the evolution of an influenza pandemic. We estimate the likely burden of future influenza pandemics through health and economic endpoints. An important component of this is the adequacy of existing hospital-resource capacity. Using a simulated population reflective of Ottawa, Canada, we model the potential impact of a future influenza pandemic under different combinations of pharmaceutical and non-pharmaceutical interventions.</p></sec><sec id="sec003"><title>Results</title><p>There was substantial variation in projected pandemic impact and outcomes across intervention scenarios. In a population of 1.2 million, the illness attack rate ranged from 8.4% (all interventions) to 54.5% (no interventions); peak acute care hospital capacity ranged from 0.2% (all interventions) to 13.8% (no interventions); peak ICU capacity ranged from 1.1% (all interventions) to 90.2% (no interventions); and mortality ranged from 11 (all interventions) to 363 deaths (no interventions). Associated estimates of economic burden ranged from CAD $115 million to over $2 billion when extended mass school closure was implemented.</p></sec><sec id="sec004"><title>Discussion</title><p>Children accounted for a disproportionate number of pandemic infections, particularly in household settings. Pharmaceutical interventions effectively reduced peak and total pandemic burden without affecting timing, while non-pharmaceutical measures delayed and attenuated pandemic wave progression. The timely implementation of a layered intervention bundle appeared likely to protect hospital resource adequacy in Ottawa. The adaptable nature of this model provides value in informing pandemic preparedness policy planning in situations of uncertainty, as scenarios can be updated in real time as more data become available. However—given the inherent uncertainties of model assumptions—results should be interpreted with caution.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Kuszewski, K" uniqKey="Kuszewski K">K Kuszewski</name></author><author><name sortKey="Brydak, L" uniqKey="Brydak L">L Brydak</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lau, Jtf" uniqKey="Lau J">JTF Lau</name></author><author><name sortKey="Griffiths, S" uniqKey="Griffiths S">S Griffiths</name></author><author><name sortKey="Choi, K" uniqKey="Choi K">K Choi</name></author><author><name sortKey="Lin, C" uniqKey="Lin C">C Lin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fiore, A" uniqKey="Fiore A">A Fiore</name></author><author><name sortKey="Shay, D" uniqKey="Shay D">D Shay</name></author><author><name sortKey="Broder, K" uniqKey="Broder K">K Broder</name></author><author><name sortKey="Iskander, J" uniqKey="Iskander J">J Iskander</name></author><author><name sortKey="Uyeki, T" uniqKey="Uyeki T">T Uyeki</name></author><author><name sortKey="Mootrey, G" uniqKey="Mootrey G">G Mootrey</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smith, K" uniqKey="Smith K">K Smith</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Thompson, M" uniqKey="Thompson M">M Thompson</name></author><author><name sortKey="Shay, D" uniqKey="Shay D">D Shay</name></author><author><name sortKey="Zhou, H" uniqKey="Zhou H">H Zhou</name></author><author><name sortKey="Bridges, C" uniqKey="Bridges C">C Bridges</name></author><author><name sortKey="Cheng, P" uniqKey="Cheng P">P Cheng</name></author><author><name sortKey="Burns, E" uniqKey="Burns E">E Burns</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schanzer, Dl" uniqKey="Schanzer D">DL Schanzer</name></author><author><name sortKey="Mcgeer, A" uniqKey="Mcgeer A">A McGeer</name></author><author><name sortKey="Morris, K" uniqKey="Morris K">K Morris</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schanzer, Dl" uniqKey="Schanzer D">DL Schanzer</name></author><author><name sortKey="Sevenhuysen, C" uniqKey="Sevenhuysen C">C Sevenhuysen</name></author><author><name sortKey="Winchester, B" uniqKey="Winchester B">B Winchester</name></author><author><name sortKey="Mersereau, T" uniqKey="Mersereau T">T Mersereau</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zambon, M" uniqKey="Zambon M">M Zambon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Guan, Y" uniqKey="Guan Y">Y Guan</name></author><author><name sortKey="Vijaykrishna, D" uniqKey="Vijaykrishna D">D Vijaykrishna</name></author><author><name sortKey="Bahl, J" uniqKey="Bahl J">J Bahl</name></author><author><name sortKey="Zhu, H" uniqKey="Zhu H">H Zhu</name></author><author><name sortKey="Wang, J" uniqKey="Wang J">J Wang</name></author><author><name sortKey="Smith, Gj" uniqKey="Smith G">GJ Smith</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Henderson, D" uniqKey="Henderson D">D Henderson</name></author><author><name sortKey="Courtney, B" uniqKey="Courtney B">B Courtney</name></author><author><name sortKey="Inglesby, T" uniqKey="Inglesby T">T Inglesby</name></author><author><name sortKey="Toner, E" uniqKey="Toner E">E Toner</name></author><author><name sortKey="Nuzzo, J" uniqKey="Nuzzo J">J Nuzzo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Humphries, M" uniqKey="Humphries M">M Humphries</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Simonsen, L" uniqKey="Simonsen L">L Simonsen</name></author><author><name sortKey="Spreeuwenberg, P" uniqKey="Spreeuwenberg P">P Spreeuwenberg</name></author><author><name sortKey="Lustig, R" uniqKey="Lustig R">R Lustig</name></author><author><name sortKey="Taylor, Rj" uniqKey="Taylor R">RJ Taylor</name></author><author><name sortKey="Fleming, Dm" uniqKey="Fleming D">DM Fleming</name></author><author><name sortKey="Kroneman, M" uniqKey="Kroneman M">M Kroneman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Saunders Hastings, P" uniqKey="Saunders Hastings P">P Saunders-Hastings</name></author><author><name sortKey="Krewski, D" uniqKey="Krewski D">D Krewski</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dawood, F" uniqKey="Dawood F">F Dawood</name></author><author><name sortKey="Luliano, D" uniqKey="Luliano D">D Luliano</name></author><author><name sortKey="Reed, C" uniqKey="Reed C">C Reed</name></author><author><name sortKey="Meltzer, M" uniqKey="Meltzer M">M Meltzer</name></author><author><name sortKey="Shay, D" uniqKey="Shay D">D Shay</name></author><author><name sortKey="Cheng, P" uniqKey="Cheng P">P Cheng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="House, T" uniqKey="House T">T House</name></author><author><name sortKey="Baguelin, M" uniqKey="Baguelin M">M Baguelin</name></author><author><name sortKey="Van Hoek, Aj" uniqKey="Van Hoek A">AJ Van Hoek</name></author><author><name sortKey="White, Pj" uniqKey="White P">PJ White</name></author><author><name sortKey="Sadique, Z" uniqKey="Sadique Z">Z Sadique</name></author><author><name sortKey="Eames, K" uniqKey="Eames K">K Eames</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Daly, P" uniqKey="Daly P">P Daly</name></author><author><name sortKey="Gustafson, R" uniqKey="Gustafson R">R Gustafson</name></author><author><name sortKey="Kendall, P" uniqKey="Kendall P">P Kendall</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Potter, C" uniqKey="Potter C">C Potter</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Horimoto, T" uniqKey="Horimoto T">T Horimoto</name></author><author><name sortKey="Kawaoka, Y" uniqKey="Kawaoka Y">Y Kawaoka</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Myers, Kp" uniqKey="Myers K">KP Myers</name></author><author><name sortKey="Olsen, Cw" uniqKey="Olsen C">CW Olsen</name></author><author><name sortKey="Gray, Gc" uniqKey="Gray G">GC Gray</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reperant, La" uniqKey="Reperant L">LA Reperant</name></author><author><name sortKey="Osterhaus, Ad" uniqKey="Osterhaus A">AD Osterhaus</name></author><author><name sortKey="Van Tam, J" uniqKey="Van Tam J">J Van-Tam</name></author><author><name sortKey="Sellwood, C" uniqKey="Sellwood C">C Sellwood</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wan, X F" uniqKey="Wan X">X-F Wan</name></author><author><name sortKey="Dong, L" uniqKey="Dong L">L Dong</name></author><author><name sortKey="Lan, Y" uniqKey="Lan Y">Y Lan</name></author><author><name sortKey="Long, L P" uniqKey="Long L">L-P Long</name></author><author><name sortKey="Xu, C" uniqKey="Xu C">C Xu</name></author><author><name sortKey="Zou, S" uniqKey="Zou S">S Zou</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Watson, Sj" uniqKey="Watson S">SJ Watson</name></author><author><name sortKey="Langat, P" uniqKey="Langat P">P Langat</name></author><author><name sortKey="Reid, Sm" uniqKey="Reid S">SM Reid</name></author><author><name sortKey="Lam, Tt Y" uniqKey="Lam T">TT-Y Lam</name></author><author><name sortKey="Cotten, M" uniqKey="Cotten M">M Cotten</name></author><author><name sortKey="Kelly, M" uniqKey="Kelly M">M Kelly</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tuite, Ar" uniqKey="Tuite A">AR Tuite</name></author><author><name sortKey="Fisman, Dn" uniqKey="Fisman D">DN Fisman</name></author><author><name sortKey="Kwong, Jc" uniqKey="Kwong J">JC Kwong</name></author><author><name sortKey="Greer, Al" uniqKey="Greer A">AL Greer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Coburn, B" uniqKey="Coburn B">B Coburn</name></author><author><name sortKey="Wagner, B" uniqKey="Wagner B">B Wagner</name></author><author><name sortKey="Blower, S" uniqKey="Blower S">S Blower</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arino, J" uniqKey="Arino J">J Arino</name></author><author><name sortKey="Brauer, F" uniqKey="Brauer F">F Brauer</name></author><author><name sortKey="Driessche, P" uniqKey="Driessche P">P Driessche</name></author><author><name sortKey="Watmough, J" uniqKey="Watmough J">J Watmough</name></author><author><name sortKey="Wu, J" uniqKey="Wu J">J Wu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wallinga, J" uniqKey="Wallinga J">J Wallinga</name></author><author><name sortKey="Lipsitch, M" uniqKey="Lipsitch M">M Lipsitch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carrasco, L" uniqKey="Carrasco L">L Carrasco</name></author><author><name sortKey="Jit, M" uniqKey="Jit M">M Jit</name></author><author><name sortKey="Chen, M" uniqKey="Chen M">M Chen</name></author><author><name sortKey="Lee, V" uniqKey="Lee V">V Lee</name></author><author><name sortKey="Milne, G" uniqKey="Milne G">G Milne</name></author><author><name sortKey="Cook, A" uniqKey="Cook A">A Cook</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Germann, Tc" uniqKey="Germann T">TC Germann</name></author><author><name sortKey="Kadau, K" uniqKey="Kadau K">K Kadau</name></author><author><name sortKey="Longini, Im" uniqKey="Longini I">IM Longini</name></author><author><name sortKey="Macken, Ca" uniqKey="Macken C">CA Macken</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Longini, I" uniqKey="Longini I">I Longini</name></author><author><name sortKey="Halloran, Me" uniqKey="Halloran M">ME Halloran</name></author><author><name sortKey="Nizam, A" uniqKey="Nizam A">A Nizam</name></author><author><name sortKey="Yang, Y" uniqKey="Yang Y">Y Yang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Longini, I" uniqKey="Longini I">I Longini</name></author><author><name sortKey="Nizam, A" uniqKey="Nizam A">A Nizam</name></author><author><name sortKey="Xu, S" uniqKey="Xu S">S Xu</name></author><author><name sortKey="Ungchusak, K" uniqKey="Ungchusak K">K Ungchusak</name></author><author><name sortKey="Hanshaoworakul, W" uniqKey="Hanshaoworakul W">W Hanshaoworakul</name></author><author><name sortKey="Cummings, Da" uniqKey="Cummings D">DA Cummings</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Andradottir, S" uniqKey="Andradottir S">S Andradottir</name></author><author><name sortKey="Chiu, W" uniqKey="Chiu W">W Chiu</name></author><author><name sortKey="Goldsman, D" uniqKey="Goldsman D">D Goldsman</name></author><author><name sortKey="Lee, Ml" uniqKey="Lee M">ML Lee</name></author><author><name sortKey="Tsui, Kl" uniqKey="Tsui K">KL Tsui</name></author><author><name sortKey="Sander, B" uniqKey="Sander B">B Sander</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Halloran, Me" uniqKey="Halloran M">ME Halloran</name></author><author><name sortKey="Ferguson, Nm" uniqKey="Ferguson N">NM Ferguson</name></author><author><name sortKey="Eubank, S" uniqKey="Eubank S">S Eubank</name></author><author><name sortKey="Longini, Im" uniqKey="Longini I">IM Longini</name></author><author><name sortKey="Cummings, Da" uniqKey="Cummings D">DA Cummings</name></author><author><name sortKey="Lewis, B" uniqKey="Lewis B">B Lewis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yang, Y" uniqKey="Yang Y">Y Yang</name></author><author><name sortKey="Sugimoto, Jd" uniqKey="Sugimoto J">JD Sugimoto</name></author><author><name sortKey="Halloran, Me" uniqKey="Halloran M">ME Halloran</name></author><author><name sortKey="Basta, Ne" uniqKey="Basta N">NE Basta</name></author><author><name sortKey="Chao, Dl" uniqKey="Chao D">DL Chao</name></author><author><name sortKey="Matrajt, L" uniqKey="Matrajt L">L Matrajt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chao, Dl" uniqKey="Chao D">DL Chao</name></author><author><name sortKey="Halloran, Me" uniqKey="Halloran M">ME Halloran</name></author><author><name sortKey="Obenchain, Vj" uniqKey="Obenchain V">VJ Obenchain</name></author><author><name sortKey="Longini, Im" uniqKey="Longini I">IM Longini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chao, Dl" uniqKey="Chao D">DL Chao</name></author><author><name sortKey="Matrajt, L" uniqKey="Matrajt L">L Matrajt</name></author><author><name sortKey="Basta, Ne" uniqKey="Basta N">NE Basta</name></author><author><name sortKey="Sugimoto, Jd" uniqKey="Sugimoto J">JD Sugimoto</name></author><author><name sortKey="Dean, B" uniqKey="Dean B">B Dean</name></author><author><name sortKey="Bagwell, Da" uniqKey="Bagwell D">DA Bagwell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Del Valle, Sy" uniqKey="Del Valle S">SY Del Valle</name></author><author><name sortKey="Hyman, Jm" uniqKey="Hyman J">JM Hyman</name></author><author><name sortKey="Hethcote, Hw" uniqKey="Hethcote H">HW Hethcote</name></author><author><name sortKey="Eubank, Sg" uniqKey="Eubank S">SG Eubank</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gojovic, Mz" uniqKey="Gojovic M">MZ Gojovic</name></author><author><name sortKey="Sander, B" uniqKey="Sander B">B Sander</name></author><author><name sortKey="Fisman, D" uniqKey="Fisman D">D Fisman</name></author><author><name sortKey="Krahn, Md" uniqKey="Krahn M">MD Krahn</name></author><author><name sortKey="Bauch, Ct" uniqKey="Bauch C">CT Bauch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Basta, Ne" uniqKey="Basta N">NE Basta</name></author><author><name sortKey="Chao, Dl" uniqKey="Chao D">DL Chao</name></author><author><name sortKey="Halloran, Me" uniqKey="Halloran M">ME Halloran</name></author><author><name sortKey="Matrajt, L" uniqKey="Matrajt L">L Matrajt</name></author><author><name sortKey="Longini, Im" uniqKey="Longini I">IM Longini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Del Valle, Sy" uniqKey="Del Valle S">SY Del Valle</name></author><author><name sortKey="Hyman, J" uniqKey="Hyman J">J Hyman</name></author><author><name sortKey="Chitnis, N" uniqKey="Chitnis N">N Chitnis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Den Driessche, P" uniqKey="Van Den Driessche P">P van den Driessche</name></author><author><name sortKey="Watmough, J" uniqKey="Watmough J">J Watmough</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hancock, K" uniqKey="Hancock K">K Hancock</name></author><author><name sortKey="Veguilla, V" uniqKey="Veguilla V">V Veguilla</name></author><author><name sortKey="Lu, X" uniqKey="Lu X">X Lu</name></author><author><name sortKey="Zhong, W" uniqKey="Zhong W">W Zhong</name></author><author><name sortKey="Butler, En" uniqKey="Butler E">EN Butler</name></author><author><name sortKey="Sun, H" uniqKey="Sun H">H Sun</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mills, C" uniqKey="Mills C">C Mills</name></author><author><name sortKey="Robins, J" uniqKey="Robins J">J Robins</name></author><author><name sortKey="Lipsitch, M" uniqKey="Lipsitch M">M Lipsitch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Viboud, C" uniqKey="Viboud C">C Viboud</name></author><author><name sortKey="Tam, T" uniqKey="Tam T">T Tam</name></author><author><name sortKey="Fleming, D" uniqKey="Fleming D">D Fleming</name></author><author><name sortKey="Handel, A" uniqKey="Handel A">A Handel</name></author><author><name sortKey="Miller, M" uniqKey="Miller M">M Miller</name></author><author><name sortKey="Simonsen, L" uniqKey="Simonsen L">L Simonsen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chowell, G" uniqKey="Chowell G">G Chowell</name></author><author><name sortKey="Ammon, C" uniqKey="Ammon C">C Ammon</name></author><author><name sortKey="Hengartner, N" uniqKey="Hengartner N">N Hengartner</name></author><author><name sortKey="Hyman, J" uniqKey="Hyman J">J Hyman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Flahault, A" uniqKey="Flahault A">A Flahault</name></author><author><name sortKey="Deguen, S" uniqKey="Deguen S">S Deguen</name></author><author><name sortKey="Valleron, A" uniqKey="Valleron A">A Valleron</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hall, I" uniqKey="Hall I">I Hall</name></author><author><name sortKey="Gani, R" uniqKey="Gani R">R Gani</name></author><author><name sortKey="Hughes, H" uniqKey="Hughes H">H Hughes</name></author><author><name sortKey="Leach, S" uniqKey="Leach S">S Leach</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sertsou, G" uniqKey="Sertsou G">G Sertsou</name></author><author><name sortKey="Wilson, N" uniqKey="Wilson N">N Wilson</name></author><author><name sortKey="Baker, M" uniqKey="Baker M">M Baker</name></author><author><name sortKey="Nelson, P" uniqKey="Nelson P">P Nelson</name></author><author><name sortKey="Roberts, M" uniqKey="Roberts M">M Roberts</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Burgess, D" uniqKey="Burgess D">D Burgess</name></author><author><name sortKey="Jenkins, G" uniqKey="Jenkins G">G Jenkins</name></author><author><name sortKey="Burgess, D" uniqKey="Burgess D">D Burgess</name></author><author><name sortKey="Jenkins, G" uniqKey="Jenkins G">G Jenkins</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Winquist, E" uniqKey="Winquist E">E Winquist</name></author><author><name sortKey="Bell, Cm" uniqKey="Bell C">CM Bell</name></author><author><name sortKey="Clarke, Jt" uniqKey="Clarke J">JT Clarke</name></author><author><name sortKey="Evans, G" uniqKey="Evans G">G Evans</name></author><author><name sortKey="Martin, J" uniqKey="Martin J">J Martin</name></author><author><name sortKey="Sabharwal, M" uniqKey="Sabharwal M">M Sabharwal</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Neumann, Pj" uniqKey="Neumann P">PJ Neumann</name></author><author><name sortKey="Cohen, Jt" uniqKey="Cohen J">JT Cohen</name></author><author><name sortKey="Weinstein, Mc" uniqKey="Weinstein M">MC Weinstein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Owens, Dk" uniqKey="Owens D">DK Owens</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sander, B" uniqKey="Sander B">B Sander</name></author><author><name sortKey="Bauch, Ct" uniqKey="Bauch C">CT Bauch</name></author><author><name sortKey="Fisman, D" uniqKey="Fisman D">D Fisman</name></author><author><name sortKey="Fowler, Ra" uniqKey="Fowler R">RA Fowler</name></author><author><name sortKey="Kwong, Jc" uniqKey="Kwong J">JC Kwong</name></author><author><name sortKey="Maetzel, A" uniqKey="Maetzel A">A Maetzel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sander, B" uniqKey="Sander B">B Sander</name></author><author><name sortKey="Mecdev, Mba" uniqKey="Mecdev M">MBA MecDev</name></author><author><name sortKey="Nizam, A" uniqKey="Nizam A">A Nizam</name></author><author><name sortKey="Garisson, Lp" uniqKey="Garisson L">LP Garisson</name></author><author><name sortKey="Postma, Mj" uniqKey="Postma M">MJ Postma</name></author><author><name sortKey="Halloran, Me" uniqKey="Halloran M">ME Halloran</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Perlroth, Dj" uniqKey="Perlroth D">DJ Perlroth</name></author><author><name sortKey="Glass, Rj" uniqKey="Glass R">RJ Glass</name></author><author><name sortKey="Davey, Vj" uniqKey="Davey V">VJ Davey</name></author><author><name sortKey="Cannon, D" uniqKey="Cannon D">D Cannon</name></author><author><name sortKey="Garber, Am" uniqKey="Garber A">AM Garber</name></author><author><name sortKey="Owens, Dk" uniqKey="Owens D">DK Owens</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Kelso, Jk" uniqKey="Kelso J">JK Kelso</name></author><author><name sortKey="Halder, N" uniqKey="Halder N">N Halder</name></author><author><name sortKey="Postma, Mj" uniqKey="Postma M">MJ Postma</name></author><author><name sortKey="Milne, Gj" uniqKey="Milne G">GJ Milne</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Jefferson, T" uniqKey="Jefferson T">T Jefferson</name></author><author><name sortKey="Rivetti, A" uniqKey="Rivetti A">A Rivetti</name></author><author><name sortKey="Di Pietrantonj, C" uniqKey="Di Pietrantonj C">C Di Pietrantonj</name></author><author><name sortKey="Demicheli, V" uniqKey="Demicheli V">V Demicheli</name></author><author><name sortKey="Ferroni, E" uniqKey="Ferroni E">E Ferroni</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Osterholm, Mt" uniqKey="Osterholm M">MT Osterholm</name></author><author><name sortKey="Kelley, Ns" uniqKey="Kelley N">NS Kelley</name></author><author><name sortKey="Sommer, A" uniqKey="Sommer A">A Sommer</name></author><author><name sortKey="Belongia, Ea" uniqKey="Belongia E">EA Belongia</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yin, Jk" uniqKey="Yin J">JK Yin</name></author><author><name sortKey="Chow, Myk" uniqKey="Chow M">MYK Chow</name></author><author><name sortKey="Khandaker, G" uniqKey="Khandaker G">G Khandaker</name></author><author><name sortKey="King, C" uniqKey="King C">C King</name></author><author><name sortKey="Richmond, P" uniqKey="Richmond P">P Richmond</name></author><author><name sortKey="Heron, L" uniqKey="Heron L">L Heron</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Basta, Ne" uniqKey="Basta N">NE Basta</name></author><author><name sortKey="Halloran, Me" uniqKey="Halloran M">ME Halloran</name></author><author><name sortKey="Matrajt, L" uniqKey="Matrajt L">L Matrajt</name></author><author><name sortKey="Longini, Im" uniqKey="Longini I">IM Longini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fiore, A" uniqKey="Fiore A">A Fiore</name></author><author><name sortKey="Uyeki, T" uniqKey="Uyeki T">T Uyeki</name></author><author><name sortKey="Broder, K" uniqKey="Broder K">K Broder</name></author><author><name sortKey="Finelli, L" uniqKey="Finelli L">L Finelli</name></author><author><name sortKey="Euler, Gl" uniqKey="Euler G">GL Euler</name></author><author><name sortKey="Singleton, Ja" uniqKey="Singleton J">JA Singleton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Greer, Al" uniqKey="Greer A">AL Greer</name></author><author><name sortKey="Schanzer, D" uniqKey="Schanzer D">D Schanzer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Flahault, A" uniqKey="Flahault A">A Flahault</name></author><author><name sortKey="Vergu, E" uniqKey="Vergu E">E Vergu</name></author><author><name sortKey="Boelle, Py" uniqKey="Boelle P">PY Boelle</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fraser, C" uniqKey="Fraser C">C Fraser</name></author><author><name sortKey="Donnelly, Ca" uniqKey="Donnelly C">CA Donnelly</name></author><author><name sortKey="Cauchemez, S" uniqKey="Cauchemez S">S Cauchemez</name></author><author><name sortKey="Hanage, Wp" uniqKey="Hanage W">WP Hanage</name></author><author><name sortKey="Van Kerkhove, Md" uniqKey="Van Kerkhove M">MD Van Kerkhove</name></author><author><name sortKey="Hollingsworth, Td" uniqKey="Hollingsworth T">TD Hollingsworth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Khazeni, N" uniqKey="Khazeni N">N Khazeni</name></author><author><name sortKey="Bravata, Dm" uniqKey="Bravata D">DM Bravata</name></author><author><name sortKey="Holty, Je" uniqKey="Holty J">JE Holty</name></author><author><name sortKey="Uyeki, Tm" uniqKey="Uyeki T">TM Uyeki</name></author><author><name sortKey="Stave, Cd" uniqKey="Stave C">CD Stave</name></author><author><name sortKey="Gould, Mk" uniqKey="Gould M">MK Gould</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jefferson, T" uniqKey="Jefferson T">T Jefferson</name></author><author><name sortKey="Jones, Ma" uniqKey="Jones M">MA Jones</name></author><author><name sortKey="Doshi, P" uniqKey="Doshi P">P Doshi</name></author><author><name sortKey="Del Mar, Cb" uniqKey="Del Mar C">CB Del Mar</name></author><author><name sortKey="Hama, R" uniqKey="Hama R">R Hama</name></author><author><name sortKey="Thompson, Mj" uniqKey="Thompson M">MJ Thompson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Borse, Rh" uniqKey="Borse R">RH Borse</name></author><author><name sortKey="Behravesh, Cb" uniqKey="Behravesh C">CB Behravesh</name></author><author><name sortKey="Dumanovsky, T" uniqKey="Dumanovsky T">T Dumanovsky</name></author><author><name sortKey="Zucker, Jr" uniqKey="Zucker J">JR Zucker</name></author><author><name sortKey="Swerdlow, D" uniqKey="Swerdlow D">D Swerdlow</name></author><author><name sortKey="Edelson, P" uniqKey="Edelson P">P Edelson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arino, J" uniqKey="Arino J">J Arino</name></author><author><name sortKey="Brauer, F" uniqKey="Brauer F">F Brauer</name></author><author><name sortKey="Driessche, P" uniqKey="Driessche P">P Driessche</name></author><author><name sortKey="Watmough, J" uniqKey="Watmough J">J Watmough</name></author><author><name sortKey="Jianhong, W" uniqKey="Jianhong W">W Jianhong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, J" uniqKey="Lee J">J Lee</name></author><author><name sortKey="Jung, E" uniqKey="Jung E">E Jung</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Godoy, P" uniqKey="Godoy P">P Godoy</name></author><author><name sortKey="Castilla, J" uniqKey="Castilla J">J Castilla</name></author><author><name sortKey="Delgado Rodriguez, M" uniqKey="Delgado Rodriguez M">M Delgado-Rodriguez</name></author><author><name sortKey="Martin, V" uniqKey="Martin V">V Martin</name></author><author><name sortKey="Soldevila, N" uniqKey="Soldevila N">N Soldevila</name></author><author><name sortKey="Alonso, J" uniqKey="Alonso J">J Alonso</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, T" uniqKey="Li T">T Li</name></author><author><name sortKey="Liu, Y" uniqKey="Liu Y">Y Liu</name></author><author><name sortKey="Di, B" uniqKey="Di B">B Di</name></author><author><name sortKey="Wang, M" uniqKey="Wang M">M Wang</name></author><author><name sortKey="Shen, J" uniqKey="Shen J">J Shen</name></author><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liu, Wt" uniqKey="Liu W">WT Liu</name></author><author><name sortKey="Pang, Xh" uniqKey="Pang X">XH Pang</name></author><author><name sortKey="Deng, Y" uniqKey="Deng Y">Y Deng</name></author><author><name sortKey="Yang, P" uniqKey="Yang P">P Yang</name></author><author><name sortKey="Li, Xy" uniqKey="Li X">XY Li</name></author><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Torner, N" uniqKey="Torner N">N Torner</name></author><author><name sortKey="Soldevila, N" uniqKey="Soldevila N">N Soldevila</name></author><author><name sortKey="Garcia, Jj" uniqKey="Garcia J">JJ Garcia</name></author><author><name sortKey="Launes, C" uniqKey="Launes C">C Launes</name></author><author><name sortKey="Godoy, P" uniqKey="Godoy P">P Godoy</name></author><author><name sortKey="Castilla, J" uniqKey="Castilla J">J Castilla</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y Zhang</name></author><author><name sortKey="Seale, H" uniqKey="Seale H">H Seale</name></author><author><name sortKey="Yang, P" uniqKey="Yang P">P Yang</name></author><author><name sortKey="Macintyre, Cr" uniqKey="Macintyre C">CR MacIntyre</name></author><author><name sortKey="Blackwell, B" uniqKey="Blackwell B">B Blackwell</name></author><author><name sortKey="Tang, S" uniqKey="Tang S">S Tang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Merk, H" uniqKey="Merk H">H Merk</name></author><author><name sortKey="Kuhlmann Berenzon, S" uniqKey="Kuhlmann Berenzon S">S Kuhlmann-Berenzon</name></author><author><name sortKey="Linde, A" uniqKey="Linde A">A Linde</name></author><author><name sortKey="Nyren, O" uniqKey="Nyren O">O Nyren</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tooher, R" uniqKey="Tooher R">R Tooher</name></author><author><name sortKey="Collins, Je" uniqKey="Collins J">JE Collins</name></author><author><name sortKey="Street, Jm" uniqKey="Street J">JM Street</name></author><author><name sortKey="Braunack Mayer, A" uniqKey="Braunack Mayer A">A Braunack-Mayer</name></author><author><name sortKey="Marshall, H" uniqKey="Marshall H">H Marshall</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Seale, H" uniqKey="Seale H">H Seale</name></author><author><name sortKey="Heywood, Ae" uniqKey="Heywood A">AE Heywood</name></author><author><name sortKey="Mclaws, M L" uniqKey="Mclaws M">M-L McLaws</name></author><author><name sortKey="Ward, Kf" uniqKey="Ward K">KF Ward</name></author><author><name sortKey="Lowbridge, Cp" uniqKey="Lowbridge C">CP Lowbridge</name></author><author><name sortKey="Van, D" uniqKey="Van D">D Van</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cheng, Vcc" uniqKey="Cheng V">VCC Cheng</name></author><author><name sortKey="Tai, Jwm" uniqKey="Tai J">JWM Tai</name></author><author><name sortKey="Wong, Lmw" uniqKey="Wong L">LMW Wong</name></author><author><name sortKey="Chan, Jfw" uniqKey="Chan J">JFW Chan</name></author><author><name sortKey="Li, Iws" uniqKey="Li I">IWS Li</name></author><author><name sortKey="To, Kkw" uniqKey="To K">KKW To</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Deng, Y" uniqKey="Deng Y">Y Deng</name></author><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y Zhang</name></author><author><name sortKey="Wang, Xl" uniqKey="Wang X">XL Wang</name></author><author><name sortKey="Liu, Wt" uniqKey="Liu W">WT Liu</name></author><author><name sortKey="Duan, W" uniqKey="Duan W">W Duan</name></author><author><name sortKey="Yang, P" uniqKey="Yang P">P Yang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jaeger, Jl" uniqKey="Jaeger J">JL Jaeger</name></author><author><name sortKey="Patel, M" uniqKey="Patel M">M Patel</name></author><author><name sortKey="Dharan, N" uniqKey="Dharan N">N Dharan</name></author><author><name sortKey="Hancock, K" uniqKey="Hancock K">K Hancock</name></author><author><name sortKey="Meites, E" uniqKey="Meites E">E Meites</name></author><author><name sortKey="Mattson, C" uniqKey="Mattson C">C Mattson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Remschmidt, C" uniqKey="Remschmidt C">C Remschmidt</name></author><author><name sortKey="Stocker, P" uniqKey="Stocker P">P Stocker</name></author><author><name sortKey="Mad, Heiden" uniqKey="Mad H">Heiden Mad</name></author><author><name sortKey="Suess, T" uniqKey="Suess T">T Suess</name></author><author><name sortKey="Luchtenberg, M" uniqKey="Luchtenberg M">M Luchtenberg</name></author><author><name sortKey="Schink, Sb" uniqKey="Schink S">SB Schink</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Suess, T" uniqKey="Suess T">T Suess</name></author><author><name sortKey="Remschmidt, C" uniqKey="Remschmidt C">C Remschmidt</name></author><author><name sortKey="Schink, Sb" uniqKey="Schink S">SB Schink</name></author><author><name sortKey="Schweiger, B" uniqKey="Schweiger B">B Schweiger</name></author><author><name sortKey="Nitsche, A" uniqKey="Nitsche A">A Nitsche</name></author><author><name sortKey="Schroeder, K" uniqKey="Schroeder K">K Schroeder</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, Co" uniqKey="Kim C">CO Kim</name></author><author><name sortKey="Nam, Cm" uniqKey="Nam C">CM Nam</name></author><author><name sortKey="Lee, Dc" uniqKey="Lee D">DC Lee</name></author><author><name sortKey="Chang, J" uniqKey="Chang J">J Chang</name></author><author><name sortKey="Lee, Jw" uniqKey="Lee J">JW Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bults, M" uniqKey="Bults M">M Bults</name></author><author><name sortKey="Beaujean, Dj" uniqKey="Beaujean D">DJ Beaujean</name></author><author><name sortKey="De Zwart, O" uniqKey="De Zwart O">O de Zwart</name></author><author><name sortKey="Kok, G" uniqKey="Kok G">G Kok</name></author><author><name sortKey="Van Empelen, P" uniqKey="Van Empelen P">P van Empelen</name></author><author><name sortKey="Van Steenbergen, Je" uniqKey="Van Steenbergen J">JE van Steenbergen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, Q" uniqKey="Zhang Q">Q Zhang</name></author><author><name sortKey="Wang, D" uniqKey="Wang D">D Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Michael, Jh" uniqKey="Michael J">JH Michael</name></author><author><name sortKey="Davis, Ks" uniqKey="Davis K">KS Davis</name></author><author><name sortKey="Xiaohong, Md" uniqKey="Xiaohong M">MD Xiaohong</name></author><author><name sortKey="Rajan, P" uniqKey="Rajan P">P Rajan</name></author><author><name sortKey="Xiaoping, J" uniqKey="Xiaoping J">J Xiaoping</name></author><author><name sortKey="Eric, W" uniqKey="Eric W">W Eric</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bondy, Sj" uniqKey="Bondy S">SJ Bondy</name></author><author><name sortKey="Russell, Ml" uniqKey="Russell M">ML Russell</name></author><author><name sortKey="Lafleche, Jm" uniqKey="Lafleche J">JM Lafleche</name></author><author><name sortKey="Rea, E" uniqKey="Rea E">E Rea</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gojovic, Mz" uniqKey="Gojovic M">MZ Gojovic</name></author><author><name sortKey="Sande, B" uniqKey="Sande B">B Sande</name></author><author><name sortKey="Fisman, D" uniqKey="Fisman D">D Fisman</name></author><author><name sortKey="Krahn, Md" uniqKey="Krahn M">MD Krahn</name></author><author><name sortKey="Bauch, Ct" uniqKey="Bauch C">CT Bauch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sander, B" uniqKey="Sander B">B Sander</name></author><author><name sortKey="Kwing, Jc" uniqKey="Kwing J">JC Kwing</name></author><author><name sortKey="Bauch, Ct" uniqKey="Bauch C">CT Bauch</name></author><author><name sortKey="Maetzel, A" uniqKey="Maetzel A">A Maetzel</name></author><author><name sortKey="Mcgeer, A" uniqKey="Mcgeer A">A McGeer</name></author><author><name sortKey="Raboud, Jm" uniqKey="Raboud J">JM Raboud</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tuite, Ar" uniqKey="Tuite A">AR Tuite</name></author><author><name sortKey="Greer, Al" uniqKey="Greer A">AL Greer</name></author><author><name sortKey="Whelan, M" uniqKey="Whelan M">M Whelan</name></author><author><name sortKey="Winter, Al" uniqKey="Winter A">AL Winter</name></author><author><name sortKey="Lee, B" uniqKey="Lee B">B Lee</name></author><author><name sortKey="Yan, P" uniqKey="Yan P">P Yan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chowell, G" uniqKey="Chowell G">G Chowell</name></author><author><name sortKey="Sattenspiel, L" uniqKey="Sattenspiel L">L Sattenspiel</name></author><author><name sortKey="Bansal, S" uniqKey="Bansal S">S Bansal</name></author><author><name sortKey="Viboud, C" uniqKey="Viboud C">C Viboud</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stroud, P" uniqKey="Stroud P">P Stroud</name></author><author><name sortKey="Sydoriak, S" uniqKey="Sydoriak S">S Sydoriak</name></author><author><name sortKey="Riese, J" uniqKey="Riese J">J Riese</name></author><author><name sortKey="Smith, J" uniqKey="Smith J">J Smith</name></author><author><name sortKey="Mniszewski, S" uniqKey="Mniszewski S">S Mniszewski</name></author><author><name sortKey="Romero, P" uniqKey="Romero P">P Romero</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jefferson, T" uniqKey="Jefferson T">T Jefferson</name></author><author><name sortKey="Demicheli, V" uniqKey="Demicheli V">V Demicheli</name></author><author><name sortKey="Di Pietrantonj, C" uniqKey="Di Pietrantonj C">C Di Pietrantonj</name></author><author><name sortKey="Rivetti, D" uniqKey="Rivetti D">D Rivetti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rahmandad, H" uniqKey="Rahmandad H">H Rahmandad</name></author><author><name sortKey="Sterman, J" uniqKey="Sterman J">J Sterman</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28614365</article-id><article-id pub-id-type="pmc">5470707</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0179315</article-id><article-id pub-id-type="publisher-id">PONE-D-17-02554</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Viral Diseases</subject><subj-group><subject>Influenza</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Demography</subject><subj-group><subject>Death Rates</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject><subj-group><subject>Preventive Medicine</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Population Groupings</subject><subj-group><subject>Age Groups</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Economics</subject><subj-group><subject>Health Economics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Health Care</subject><subj-group><subject>Health Economics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Health Care</subject><subj-group><subject>Health Care Facilities</subject><subj-group><subject>Hospitals</subject><subj-group><subject>Hospitalizations</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Infectious Disease Control</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Health Care</subject><subj-group><subject>Health Care Facilities</subject><subj-group><subject>Hospitals</subject><subj-group><subject>Intensive Care Units</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Modelling community-control strategies to protect hospital resources during an influenza pandemic in Ottawa, Canada</article-title><alt-title alt-title-type="running-head">Modelling pandemic influenza in Ottawa, Canada</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3602-0842</contrib-id><name><surname>Saunders-Hastings</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-1903-592X</contrib-id><name><surname>Quinn Hayes</surname><given-names>Bryson</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Smith?</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Krewski</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 850 Peter Morand Crescent, Ottawa, Ontario, Canada</addr-line></aff><aff id="aff002"><label>2</label><addr-line>University of Ottawa, School of Epidemiology, Public Health, and Preventive Medicine, Faculty of Medicine, Ottawa, ON, Canada</addr-line></aff><aff id="aff003"><label>3</label><addr-line>University of Ottawa, Department of Mathematics, Ottawa, ON, Canada</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Chowell</surname><given-names>Gerardo</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"></xref></contrib></contrib-group><aff id="edit1"><addr-line>Georgia State University, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>DK is the Chief Executive Officer of Risk Sciences International, a risk management consulting firm that has conducted research related to pandemic influenza. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</p></fn><fn fn-type="con"><p><list list-type="simple"><list-item><p><bold>Conceptualization:</bold> PSH.</p></list-item><list-item><p><bold>Data curation:</bold> PSH BH.</p></list-item><list-item><p><bold>Formal analysis:</bold> PSH BH.</p></list-item><list-item><p><bold>Investigation:</bold> PSH.</p></list-item><list-item><p><bold>Methodology:</bold> PSH BH RS?.</p></list-item><list-item><p><bold>Project administration:</bold> PSH.</p></list-item><list-item><p><bold>Software:</bold> BH.</p></list-item><list-item><p><bold>Supervision:</bold> DK RS?.</p></list-item><list-item><p><bold>Validation:</bold> PSH.</p></list-item><list-item><p><bold>Visualization:</bold> PSH.</p></list-item><list-item><p><bold>Writing – original draft:</bold> PSH.</p></list-item><list-item><p><bold>Writing – review & editing:</bold> PSH BH RS? DK.</p></list-item></list></p></fn><corresp id="cor001">* E-mail: <email>patrick.saundershastings@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>6</issue><elocation-id>e0179315</elocation-id><history><date date-type="received"><day>20</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>26</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>© 2017 Saunders-Hastings et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Saunders-Hastings et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0179315.pdf"></self-uri><abstract><sec id="sec001"><title>Background</title><p>A novel influenza virus has emerged to produce a global pandemic four times in the past one hundred years, resulting in millions of infections, hospitalizations and deaths. There is substantial uncertainty about when, where and how the next influenza pandemic will occur.</p></sec><sec id="sec002"><title>Methods</title><p>We developed a novel mathematical model to chart the evolution of an influenza pandemic. We estimate the likely burden of future influenza pandemics through health and economic endpoints. An important component of this is the adequacy of existing hospital-resource capacity. Using a simulated population reflective of Ottawa, Canada, we model the potential impact of a future influenza pandemic under different combinations of pharmaceutical and non-pharmaceutical interventions.</p></sec><sec id="sec003"><title>Results</title><p>There was substantial variation in projected pandemic impact and outcomes across intervention scenarios. In a population of 1.2 million, the illness attack rate ranged from 8.4% (all interventions) to 54.5% (no interventions); peak acute care hospital capacity ranged from 0.2% (all interventions) to 13.8% (no interventions); peak ICU capacity ranged from 1.1% (all interventions) to 90.2% (no interventions); and mortality ranged from 11 (all interventions) to 363 deaths (no interventions). Associated estimates of economic burden ranged from CAD $115 million to over $2 billion when extended mass school closure was implemented.</p></sec><sec id="sec004"><title>Discussion</title><p>Children accounted for a disproportionate number of pandemic infections, particularly in household settings. Pharmaceutical interventions effectively reduced peak and total pandemic burden without affecting timing, while non-pharmaceutical measures delayed and attenuated pandemic wave progression. The timely implementation of a layered intervention bundle appeared likely to protect hospital resource adequacy in Ottawa. The adaptable nature of this model provides value in informing pandemic preparedness policy planning in situations of uncertainty, as scenarios can be updated in real time as more data become available. However—given the inherent uncertainties of model assumptions—results should be interpreted with caution.</p></sec></abstract><funding-group><funding-statement>PSH currently holds the Queen Elizabeth II Graduate Scholarship in Science and Technology (QEII-GSST, grant number 005-709-285, <ext-link ext-link-type="uri" xlink:href="https://www.uottawa.ca/graduatestudies/">https://www.uottawa.ca/graduatestudies/</ext-link> students/awards/queen-elizabeth-ii-graduate-scholarships). DK is the Natural Sciences and Engineering Council of Canada Chair in Risk Science at the University of Ottawa. DK and RS? both hold an NSERC Discovery Grant (<ext-link ext-link-type="uri" xlink:href="http://www.nserc-crsng.gc.ca/Professors-Professeurs/Grants-Subs/DGIGPPSIGP_eng.asp">http://www.nserc-crsng.gc.ca/Professors-Professeurs/Grants-Subs/DGIGPPSIGP_eng.asp</ext-link>). DK is the Chief Executive Officer at Risk Sciences International, but no specific funding was allocated for this study. The funders identified above had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="5"></fig-count><table-count count="14"></table-count><page-count count="26"></page-count></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec id="sec005"><title>1. Introduction</title><p>Influenza is an infectious disease that transmits between humans via inhalation of viral particles expelled by infected individuals during coughing or sneezing and carried in aerosol, respiratory droplets and fomites [<xref rid="pone.0179315.ref001" ref-type="bibr">1</xref>]. Though individuals experience infection differently, it often involves a combination of respiratory and systemic symptoms [<xref rid="pone.0179315.ref002" ref-type="bibr">2</xref>]. While generally self-limiting, influenza-related hospitalization and death is commonly associated with lower respiratory tract and neurological complications; in fact, influenza is the most deadly vaccine-preventable disease in North America [<xref rid="pone.0179315.ref003" ref-type="bibr">3</xref>]. As an RNA virus with a high mutation rate, humans are unable to maintain adequate long term immunity to influenza infection, leading to annual outbreaks of seasonal influenza [<xref rid="pone.0179315.ref004" ref-type="bibr">4</xref>]. In the United States, seasonal influenza accounts for between 3,000 and 49,000 deaths each year [<xref rid="pone.0179315.ref005" ref-type="bibr">5</xref>]. In recent years, the average number of influenza-associated hospitalizations and deaths in Canada is estimated to be approximately 12,000 and 3,500, respectively [<xref rid="pone.0179315.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0179315.ref007" ref-type="bibr">7</xref>].</p><p>These figures do not, however, reflect the more catastrophic potential of a pandemic influenza outbreak. Triggered by an antigenic shift—a reassortment of viral segments creating a new influenza strain—that creates a novel influenza virus to which humans possess little to no immunity, an influenza pandemic has the potential to transmit and spread rapidly across the globe [<xref rid="pone.0179315.ref008" ref-type="bibr">8</xref>]. This has happened on four occasions over the past one hundred years, leading to tens of millions of infections, hospitalizations and deaths [<xref rid="pone.0179315.ref009" ref-type="bibr">9</xref>–<xref rid="pone.0179315.ref013" ref-type="bibr">13</xref>]. While most of this burden was driven by the 1918 Spanish flu pandemic, even the most recent 2009 Swine flu pandemic is estimated to have resulted in as many as 575,400 deaths globally [<xref rid="pone.0179315.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0179315.ref014" ref-type="bibr">14</xref>], even though it is considered to be a mild strain compared to past pandemics [<xref rid="pone.0179315.ref015" ref-type="bibr">15</xref>]. Were a pandemic strain of a pathogenicity comparable to that of the 1918 outbreak to emerge today, projections suggest it could result in 21–31 million deaths worldwide [<xref rid="pone.0179315.ref016" ref-type="bibr">16</xref>].</p><p>Influenza pandemics emerge at uneven and unpredictable intervals [<xref rid="pone.0179315.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0179315.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0179315.ref018" ref-type="bibr">18</xref>]. The current global landscape, however, is one that is supportive of pandemic emergence. Unprecedented levels of human–animal interaction, viral diversity and extensive international travel collectively increase the threat of viral reassortment, crossover to humans and global spread [<xref rid="pone.0179315.ref019" ref-type="bibr">19</xref>–<xref rid="pone.0179315.ref024" ref-type="bibr">24</xref>]. The threat of a global pandemic and its potential consequences present major challenges for public health and emergency preparedness policy efforts.</p><p>Given that the epidemiological features of a pandemic cannot be known until after its emergence, there is significant uncertainty regarding best practices in resource- and control-strategy planning [<xref rid="pone.0179315.ref025" ref-type="bibr">25</xref>, <xref rid="pone.0179315.ref026" ref-type="bibr">26</xref>]. This is problematic, as pandemic planning is crucial to limiting illness, death and essential-service disruption, thereby mitigating the health, social and economic burden of pandemics. Mathematical models of disease transmission, accounting for the uncertainty and randomness inherent in pandemic emergence and spread, have become valuable tools in pandemic planning and management [<xref rid="pone.0179315.ref027" ref-type="bibr">27</xref>, <xref rid="pone.0179315.ref028" ref-type="bibr">28</xref>]. Given that empirical field studies in pandemic situations are generally infeasible or unethical, they are of vital importance. Unfortunately, important gaps persist in the field of pandemic modelling, particularly with respect to accessibility, assessment of resource capacity and economic evaluation [<xref rid="pone.0179315.ref029" ref-type="bibr">29</xref>]. The model presented herein seeks to address these gaps.</p><p>This paper presents initial findings generated by InFluNet, a new, discrete-time simulation model that combines ordinary differential equations (ODEs) with stochastic approaches. Designed to capture the range of factors influencing pandemic transmission—while remaining accessible to public-health practitioners lacking formal modelling training—InFluNet combines epidemiological and demographic data to allow prediction of the health and economic burdens associated with future pandemics. Emphasizing the adequacy of hospital-resource capacity, the model allows evaluation of the potential for community intervention strategies to contain pandemic spread and ensure hospital resource adequacy. Results should inform policy-planning for interventions targeting specific stages of the disease life-cycle, and specific settings (household, school, workplace, and community), supporting more efficient and cost-effective control strategies.</p></sec><sec id="sec006"><title>2. Methods</title><p>InFluNet is a population-level, discrete-time simulation model that builds on previous deterministic and stochastic influenza models [<xref rid="pone.0179315.ref030" ref-type="bibr">30</xref>–<xref rid="pone.0179315.ref037" ref-type="bibr">37</xref>]. The model combines differential equations estimating the rate of transmission contacts and disease progression with stochastic methods of estimating social-mixing behaviour and transmission probability. This dual approach effectively describes the average behaviour of larger urban populations, while incorporating the uncertainty associated with transmissibility and pathogenicity of a new influenza strain. This section describes the InFluNet simulation model, as well as the data inputs and outputs associated with the model. No ethical approval was required for this study, as all hospital data analyzed were previously anonymized and publically available. No individual patient data were independently analyzed in this research. The model is described in brief below, with a more detailed discussion of the model structure, background and approach included in <bold><xref ref-type="supplementary-material" rid="pone.0179315.s001">S1 File</xref></bold>.</p><sec id="sec007"><title>2.1 Social contact network</title><p>The model is structured to represent three independent transmission–time/location steps over the course of the day: household, school/work and community. These estimates are based upon empirical data from a representative North American municipality [<xref rid="pone.0179315.ref038" ref-type="bibr">38</xref>] and closely resemble contact rate assumptions from past influenza modelling studies of Ontario cities [<xref rid="pone.0179315.ref033" ref-type="bibr">33</xref>, <xref rid="pone.0179315.ref039" ref-type="bibr">39</xref>]. InFluNet uses ODEs to estimate age-specific contact rates between various age groups. Five age groups are identified: infant (0–4), child (5–18), young adult (19–29), adult (30–64) and senior (65+). This reflects age groupings of past studies [<xref rid="pone.0179315.ref030" ref-type="bibr">30</xref>, <xref rid="pone.0179315.ref036" ref-type="bibr">36</xref>, <xref rid="pone.0179315.ref037" ref-type="bibr">37</xref>, <xref rid="pone.0179315.ref040" ref-type="bibr">40</xref>], based on previously observed patterns of pandemic influenza transmission and outcomes. Individuals will interact with others at different rates, both within and outside their age groups; daily contact rates by age and location are included in <bold><xref ref-type="supplementary-material" rid="pone.0179315.s001">S1 File</xref> (S1.1)</bold>.</p></sec><sec id="sec008"><title>2.2 Transmissibility</title><p>InFluNet uses a “next-generation operator” approach described previously in a model of smallpox [<xref rid="pone.0179315.ref041" ref-type="bibr">41</xref>] and reflective of a heterogeneous population [<xref rid="pone.0179315.ref042" ref-type="bibr">42</xref>]. In this approach, transmissibility can be described as follows:
<disp-formula id="pone.0179315.e001"><alternatives><graphic xlink:href="pone.0179315.e001.jpg" id="pone.0179315.e001g" mimetype="image" position="anchor" orientation="portrait"></graphic><mml:math id="M1"><mml:mrow><mml:mi>β</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mi>C</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mi>A</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>V</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives><label>(1)</label></disp-formula>where
<disp-formula id="pone.0179315.e002"><alternatives><graphic xlink:href="pone.0179315.e002.jpg" id="pone.0179315.e002g" mimetype="image" position="anchor" orientation="portrait"></graphic><mml:math id="M2"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>C</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>γ</mml:mi><mml:mo>⋅</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mi>C</mml:mi></mml:msub><mml:mo>⋅</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mi>C</mml:mi></mml:msub><mml:mo>⋅</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>σ</mml:mi><mml:mi>τ</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>⋅</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>C</mml:mi></mml:msub></mml:mrow><mml:mi>N</mml:mi></mml:mfrac></mml:mrow></mml:math></alternatives><label>(2)</label></disp-formula><disp-formula id="pone.0179315.e003"><alternatives><graphic xlink:href="pone.0179315.e003.jpg" id="pone.0179315.e003g" mimetype="image" position="anchor" orientation="portrait"></graphic><mml:math id="M3"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>A</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>γ</mml:mi><mml:mo>⋅</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mi>A</mml:mi></mml:msub><mml:mo>⋅</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mi>A</mml:mi></mml:msub><mml:mo>⋅</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>σ</mml:mi><mml:mi>τ</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>⋅</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>A</mml:mi></mml:msub></mml:mrow><mml:mi>N</mml:mi></mml:mfrac></mml:mrow></mml:math></alternatives><label>(3)</label></disp-formula>and
<disp-formula id="pone.0179315.e004"><alternatives><graphic xlink:href="pone.0179315.e004.jpg" id="pone.0179315.e004g" mimetype="image" position="anchor" orientation="portrait"></graphic><mml:math id="M4"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>V</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>γ</mml:mi><mml:mo>⋅</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>V</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>V</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>⋅</mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>σ</mml:mi><mml:mi>τ</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>⋅</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>V</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mi>N</mml:mi></mml:mfrac></mml:mrow></mml:math></alternatives><label>(4)</label></disp-formula></p><p>The rate of disease transmission from symptomatic (β<sub>C</sub>), asymptomatic (β<sub>A</sub>) and symptomatic treated (β<sub>AV</sub>) individuals depends on the six parameters [<xref rid="pone.0179315.ref038" ref-type="bibr">38</xref>, <xref rid="pone.0179315.ref041" ref-type="bibr">41</xref>] described in <bold><xref ref-type="table" rid="pone.0179315.t001">Table 1</xref></bold>. More information on our transmissibility assumptions is available in <bold><xref ref-type="supplementary-material" rid="pone.0179315.s001">S1 File</xref> (S1.2)</bold>.</p><table-wrap id="pone.0179315.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0179315.t001</object-id><label>Table 1</label><caption><title>Transmissibility function parameters.</title></caption><alternatives><graphic id="pone.0179315.t001g" xlink:href="pone.0179315.t001"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Symbol</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Definition</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Sample value</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">References</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Range</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">γ</td><td align="center" rowspan="1" colspan="1">Number of effective contacts</td><td align="center" rowspan="1" colspan="1">As per contact tables</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref041" ref-type="bibr">41</xref>]</td><td align="center" rowspan="1" colspan="1">0.01–10 (contacts/day)</td></tr><tr><td align="center" rowspan="1" colspan="1">α</td><td align="center" rowspan="1" colspan="1">Susceptibility</td><td align="center" rowspan="1" colspan="1">1.0 for infants, children, and young adults;<break></break>0.95 for adults;<break></break>0.65 for seniors</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref043" ref-type="bibr">43</xref>]</td><td align="center" rowspan="1" colspan="1">0–1</td></tr><tr><td align="center" rowspan="1" colspan="1">η</td><td align="center" rowspan="1" colspan="1">Infectivity</td><td align="center" rowspan="1" colspan="1">1.0</td><td align="center" rowspan="1" colspan="1">Assumed</td><td align="center" rowspan="1" colspan="1">0–1</td></tr><tr><td align="center" rowspan="1" colspan="1">σ</td><td align="center" rowspan="1" colspan="1">Duration of contacts</td><td align="center" rowspan="1" colspan="1">As per contact tables</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref041" ref-type="bibr">41</xref>]</td><td align="center" rowspan="1" colspan="1">1/2–1/6 (days/contact)</td></tr><tr><td align="center" rowspan="1" colspan="1">τ</td><td align="center" rowspan="1" colspan="1">Mean number of infections per time within a contact between a susceptible and infected individual, assuming full infectivity and susceptibility</td><td align="center" rowspan="1" colspan="1">0.275</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0179315.ref026" ref-type="bibr">26</xref>, <xref rid="pone.0179315.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0179315.ref045" ref-type="bibr">45</xref>]</td><td align="center" rowspan="1" colspan="1">0.17–0.42</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec009"><title>2.3 Model structure</title><p>InFluNet combines demographic, hospital and intervention data, allowing simulation of a pandemic influenza outbreak under millions of possible scenarios. A simulation is run five times, with the output value being averaged across simulations and reported with 95% confidence intervals calculated via the standard-deviation approach. The InFluNet model follows the general structure of an age-dependent SEIR (susceptible-exposed-infected-recovered) model, a structure that has predicted outbreaks with relative accuracy in the past [<xref rid="pone.0179315.ref046" ref-type="bibr">46</xref>–<xref rid="pone.0179315.ref049" ref-type="bibr">49</xref>]. The transmission model flow diagram is illustrated in <bold><xref ref-type="fig" rid="pone.0179315.g001">Fig 1</xref></bold>.</p><fig id="pone.0179315.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0179315.g001</object-id><label>Fig 1</label><caption><title>Transmission model flow diagram.</title></caption><graphic xlink:href="pone.0179315.g001"></graphic></fig><p>Susceptible individuals (S) can receive successful vaccination (V), failed vaccination (S<sub>V</sub>) or antiviral prophylaxis (AVP). While individuals in the “V” group are protected, individuals in “S”, “S<sub>V</sub>” or “AVP” compartments can be infected, moving into a latent period (E). From here they become either symptomatically (I<sub>C</sub>) or asymptomatically (I<sub>A</sub>) infectious. Of those in the “I<sub>C</sub>” group, some will require antiviral therapy (AVT), hospitalization (H) and ICU care (ICU). A small proportion of those in the “I<sub>C</sub>”, “H”, and “ICU” groups will experience a fatal infection. From the flow chart in <bold><xref ref-type="fig" rid="pone.0179315.g001">Fig 1</xref></bold>, we arrive at the system of ODEs presented below. A detailed discussion of the model structure and parameters is included in <bold><xref ref-type="supplementary-material" rid="pone.0179315.s001">S1 File</xref> (S1.3)</bold>. Intervention parameters are discussed in <bold>Section 2.4</bold>.</p><disp-formula id="pone.0179315.e005"><alternatives><graphic xlink:href="pone.0179315.e005.jpg" id="pone.0179315.e005g" mimetype="image" position="anchor" orientation="portrait"></graphic><mml:math id="M5"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>C</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>ζ</mml:mi><mml:mo>+</mml:mo><mml:mi>β</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>⋅</mml:mo></mml:mrow><mml:mi>S</mml:mi><mml:mspace width="7em"></mml:mspace><mml:mi mathvariant="normal">Susceptible</mml:mi></mml:mrow></mml:math></alternatives><label>(5)</label></disp-formula><disp-formula id="pone.0179315.e006"><alternatives><graphic xlink:href="pone.0179315.e006.jpg" id="pone.0179315.e006g" mimetype="image" position="anchor" orientation="portrait"></graphic><mml:math id="M6"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>β</mml:mi><mml:mo>⋅</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>S</mml:mi><mml:mo>+</mml:mo><mml:mi>ϕ</mml:mi><mml:mo>⋅</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mi>V</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mi>E</mml:mi><mml:mo>⋅</mml:mo><mml:mi>ϵ</mml:mi><mml:mspace width="5em"></mml:mspace><mml:mi mathvariant="normal">Latent</mml:mi><mml:mspace width="0.25em"></mml:mspace><mml:mi mathvariant="normal">Infected</mml:mi></mml:mrow></mml:math></alternatives><label>(6)</label></disp-formula><disp-formula id="pone.0179315.e007"><alternatives><graphic xlink:href="pone.0179315.e007.jpg" id="pone.0179315.e007g" mimetype="image" position="anchor" orientation="portrait"></graphic><mml:math id="M7"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mi>V</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>V</mml:mi><mml:mi>e</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo><mml:mo>⋅</mml:mo></mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>C</mml:mi></mml:msub><mml:mo>⋅</mml:mo><mml:mi>S</mml:mi><mml:mo>−</mml:mo><mml:mi>ϕ</mml:mi><mml:mo>⋅</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mi>V</mml:mi></mml:msub><mml:mo>⋅</mml:mo><mml:mo>β</mml:mo><mml:mi mathvariant="normal">Susceptible</mml:mi><mml:mspace width="0.25em"></mml:mspace><mml:mi mathvariant="normal">with</mml:mi><mml:mspace width="0.25em"></mml:mspace><mml:mi mathvariant="normal">failed</mml:mi><mml:mspace width="0.25em"></mml:mspace><mml:mi mathvariant="normal">vaccination</mml:mi></mml:mrow></mml:math></alternatives><label>(7)</label></disp-formula><disp-formula id="pone.0179315.e008"><alternatives><graphic xlink:href="pone.0179315.e008.jpg" id="pone.0179315.e008g" mimetype="image" position="anchor" orientation="portrait"></graphic><mml:math id="M8"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mi>e</mml:mi></mml:msub></mml:mrow><mml:mo>⋅</mml:mo></mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>C</mml:mi></mml:msub><mml:mo>⋅</mml:mo><mml:mi>S</mml:mi><mml:mspace width="5em"></mml:mspace><mml:mi mathvariant="normal">Vaccinated</mml:mi></mml:mrow></mml:math></alternatives><label>(8)</label></disp-formula><disp-formula id="pone.0179315.e009"><alternatives><graphic xlink:href="pone.0179315.e009.jpg" id="pone.0179315.e009g" mimetype="image" position="anchor" orientation="portrait"></graphic><mml:math id="M9"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>V</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>ζ</mml:mi><mml:mo>⋅</mml:mo><mml:mi>S</mml:mi><mml:mo>−</mml:mo><mml:mi>β</mml:mi><mml:mo>⋅</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>V</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mspace width="5em"></mml:mspace><mml:mi mathvariant="normal">Antiviral</mml:mi><mml:mspace width="0.25em"></mml:mspace><mml:mi mathvariant="normal">prophylaxis</mml:mi></mml:mrow></mml:math></alternatives><label>(9)</label></disp-formula><disp-formula id="pone.0179315.e010"><alternatives><graphic xlink:href="pone.0179315.e010.jpg" id="pone.0179315.e010g" mimetype="image" position="anchor" orientation="portrait"></graphic><mml:math id="M10"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>V</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>β</mml:mi><mml:mo>⋅</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>V</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>V</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi>ϵ</mml:mi><mml:mspace width="5em"></mml:mspace><mml:mi mathvariant="normal">Latent</mml:mi><mml:mspace width="0.25em"></mml:mspace><mml:mi mathvariant="normal">infected</mml:mi><mml:mspace width="0.25em"></mml:mspace><mml:mi mathvariant="normal">treated</mml:mi><mml:mspace width="0.25em"></mml:mspace><mml:mi mathvariant="normal">with</mml:mi><mml:mspace width="0.25em"></mml:mspace><mml:mi mathvariant="normal">prophylaxis</mml:mi></mml:mrow></mml:math></alternatives><label>(10)</label></disp-formula><disp-formula id="pone.0179315.e011"><alternatives><graphic xlink:href="pone.0179315.e011.jpg" id="pone.0179315.e011g" mimetype="image" position="anchor" orientation="portrait"></graphic><mml:math id="M11"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mi>C</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mn>2</mml:mn><mml:mn>3</mml:mn></mml:mfrac><mml:mo>⋅</mml:mo><mml:mi>E</mml:mi><mml:mo>⋅</mml:mo><mml:mi>ϵ</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi>C</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>θ</mml:mi><mml:mo>+</mml:mo><mml:mi>r</mml:mi><mml:mo>+</mml:mo><mml:mi>ζ</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mspace width="5em"></mml:mspace><mml:mi mathvariant="normal">Infected</mml:mi><mml:mspace width="0.25em"></mml:mspace><mml:mi mathvariant="normal">Symptomatic</mml:mi></mml:mrow></mml:mrow></mml:math></alternatives><label>(11)</label></disp-formula><disp-formula id="pone.0179315.e012"><alternatives><graphic xlink:href="pone.0179315.e012.jpg" id="pone.0179315.e012g" mimetype="image" position="anchor" orientation="portrait"></graphic><mml:math id="M12"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mi>A</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>3</mml:mn></mml:mfrac><mml:mo>⋅</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>V</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>⋅</mml:mo><mml:mi>ϵ</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi>A</mml:mi></mml:msub><mml:mo>⋅</mml:mo><mml:mi>r</mml:mi><mml:mspace width="5em"></mml:mspace><mml:mi mathvariant="normal">Infected</mml:mi><mml:mspace width="0.25em"></mml:mspace><mml:mi mathvariant="normal">Asymptomatic</mml:mi></mml:mrow></mml:math></alternatives><label>(12)</label></disp-formula><disp-formula id="pone.0179315.e013"><alternatives><graphic xlink:href="pone.0179315.e013.jpg" id="pone.0179315.e013g" mimetype="image" position="anchor" orientation="portrait"></graphic><mml:math id="M13"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>A</mml:mi><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi>C</mml:mi></mml:msub><mml:mo>⋅</mml:mo><mml:mi>ζ</mml:mi><mml:mo>+</mml:mo><mml:mfrac><mml:mn>2</mml:mn><mml:mn>3</mml:mn></mml:mfrac><mml:mo>⋅</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>V</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi>ϵ</mml:mi><mml:mo>−</mml:mo><mml:mi>A</mml:mi><mml:mi>V</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>θ</mml:mi><mml:mo>+</mml:mo><mml:mi>r</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mspace width="5em"></mml:mspace><mml:mi mathvariant="normal">Treated</mml:mi><mml:mspace width="0.25em"></mml:mspace><mml:mi mathvariant="normal">with</mml:mi><mml:mspace width="0.25em"></mml:mspace><mml:mi mathvariant="normal">Antivirals</mml:mi></mml:mrow></mml:mrow></mml:math></alternatives><label>(13)</label></disp-formula><disp-formula id="pone.0179315.e014"><alternatives><graphic xlink:href="pone.0179315.e014.jpg" id="pone.0179315.e014g" mimetype="image" position="anchor" orientation="portrait"></graphic><mml:math id="M14"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>C</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>A</mml:mi><mml:mi>V</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>⋅</mml:mo><mml:mi>θ</mml:mi><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>χ</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>U</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>⋅</mml:mo><mml:mi>H</mml:mi><mml:mspace width="5em"></mml:mspace><mml:mi mathvariant="normal">Hospitalized</mml:mi></mml:mrow></mml:math></alternatives><label>(14)</label></disp-formula><disp-formula id="pone.0179315.e015"><alternatives><graphic xlink:href="pone.0179315.e015.jpg" id="pone.0179315.e015g" mimetype="image" position="anchor" orientation="portrait"></graphic><mml:math id="M15"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>U</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>U</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi>H</mml:mi><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>U</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>χ</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>U</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>⋅</mml:mo><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>U</mml:mi><mml:mspace width="5em"></mml:mspace><mml:mi mathvariant="normal">Intensive</mml:mi><mml:mspace width="0.25em"></mml:mspace><mml:mi mathvariant="normal">Care</mml:mi><mml:mspace width="0.25em"></mml:mspace><mml:mi mathvariant="normal">Unit</mml:mi></mml:mrow></mml:math></alternatives><label>(15)</label></disp-formula><p>Patient-demand data is plotted against hospital-resource data obtained from the Canadian Institute for Health Information and Québec Ministry of Health and Social Services [<xref rid="pone.0179315.ref050" ref-type="bibr">50</xref>, <xref rid="pone.0179315.ref051" ref-type="bibr">51</xref>]. Combining these hospital-resource data with the Census demographic data, we generated individual profiles for each Canadian CMA; details on hospital-resource estimation are included in <bold><xref ref-type="supplementary-material" rid="pone.0179315.s001">S1 File</xref> (S1.4)</bold>, while the Ottawa–Gatineau profile used for the following analysis is included in <bold><xref ref-type="supplementary-material" rid="pone.0179315.s002">S1 Table</xref></bold>.</p><p>The model generates results relating to health and economic outcomes. Health outcomes summarize consequences in terms of the number of symptomatic cases, hospitalizations, ICU admissions, ventilator demand and deaths by age, location and as a percentage of existing capacity. These data are reported on a daily basis and summarized over the course of the entire outbreak. Economic evaluations are conducted in two ways: by estimating the overall economic burden associated with a pandemic by aggregating influenza- and intervention-associated costs, and by calculating the relative cost-effectiveness of different intervention strategies. The latter is assessed by calculating the cost per life-year saved, relative to a “no intervention” scenario. Economic estimates are generated by scaling health and intervention endpoints (as generated by the model) by a per-case economic cost, as given in <bold><xref ref-type="table" rid="pone.0179315.t002">Table 2</xref></bold>. The internationally proposed cost-effectiveness threshold of CAD $50,000 and a 1.5% annual discounting rate were used to calculate costs associated with mortality [<xref rid="pone.0179315.ref052" ref-type="bibr">52</xref>–<xref rid="pone.0179315.ref055" ref-type="bibr">55</xref>]. A more detailed discussion of model outputs is included in <bold><xref ref-type="supplementary-material" rid="pone.0179315.s001">S1 File</xref> (S1.5)</bold>.</p><table-wrap id="pone.0179315.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0179315.t002</object-id><label>Table 2</label><caption><title>Economic cost ($CAD) for outcomes of interest.</title></caption><alternatives><graphic id="pone.0179315.t002g" xlink:href="pone.0179315.t002"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="center" colspan="3" style="background-color:#BFBFBF" rowspan="1">Economic consequences</th></tr><tr><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Category</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Unit Cost</th><th align="center" rowspan="1" colspan="1">Citation</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Total hospital bed days</td><td align="center" rowspan="1" colspan="1">$1,042/day</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref056" ref-type="bibr">56</xref>, <xref rid="pone.0179315.ref057" ref-type="bibr">57</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Total ICU + ventilator days</td><td align="center" rowspan="1" colspan="1">$2,084/day</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref056" ref-type="bibr">56</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Total deaths</td><td align="center" rowspan="1" colspan="1">0–4: $2,355,172<break></break>5–18: $2,207,744<break></break>19–29: $1,956,694<break></break>30–64: $1,374,086<break></break>65+: $424,296</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref052" ref-type="bibr">52</xref>, <xref rid="pone.0179315.ref053" ref-type="bibr">53</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Total lost school days</td><td align="center" rowspan="1" colspan="1">$91.85/day</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref033" ref-type="bibr">33</xref>, <xref rid="pone.0179315.ref058" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Total lost work days</td><td align="center" rowspan="1" colspan="1">$192.55/day</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref059" ref-type="bibr">59</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Total vaccinations</td><td align="center" rowspan="1" colspan="1">$20.00/vaccination</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref056" ref-type="bibr">56</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Total courses of antivirals</td><td align="center" rowspan="1" colspan="1">$25.00</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref056" ref-type="bibr">56</xref>, <xref rid="pone.0179315.ref057" ref-type="bibr">57</xref>, <xref rid="pone.0179315.ref060" ref-type="bibr">60</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Total masks</td><td align="center" rowspan="1" colspan="1">$4.00/mask</td><td align="center" rowspan="1" colspan="1">Estimated</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec010"><title>2.4 Intervention effectiveness</title><p>InFluNet allows the evaluation of eight different interventions (vaccination, antiviral treatment, antiviral prophylaxis, school closure, community-contact reduction, personal protective measures, voluntary isolation and quarantine), with coverage, intensity and effectiveness measures determined by user inputs. In this study, we provide a “Best Guess” (BG), “Worst Case” (WC), and “Best Case” (BC) for each parameter, in order to generate a range of estimated intervention impacts. <bold>Tables <xref ref-type="table" rid="pone.0179315.t003">3</xref></bold> and <bold><xref ref-type="table" rid="pone.0179315.t004">4</xref></bold> summarize the parameter definitions and user input ranges for each intervention parameter. The tables also gives the parameter values we used in this modelling study, as well as the sources that informed these values. Where possible, empirical values from the 2009 pandemic were used; where these were unavailable, we used assumptions employed in past modelling studies. Each intervention is also discussed in detail in <bold><xref ref-type="supplementary-material" rid="pone.0179315.s001">S1 File</xref> (S1.6)</bold>.</p><table-wrap id="pone.0179315.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0179315.t003</object-id><label>Table 3</label><caption><title>Pharmaceutical intervention parameters.</title><p>Best-guess scenarios reflect pooled estimates as available. Worst- and best-case scenarios (in terms of disease transmission but not necessarily resource allocation) reflect 95% confidence intervals where available; otherwise, they reflect ranges of estimates reported.</p></caption><alternatives><graphic id="pone.0179315.t003g" xlink:href="pone.0179315.t003"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Intervention</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Parameter<xref ref-type="table-fn" rid="t003fn001"><sup>τ</sup></xref></th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Theoretical Range</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Worst Case Scenario</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Best Guess</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Best Case Scenario</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Citation</th></tr></thead><tbody><tr><td align="center" rowspan="5" colspan="1">Pandemic vaccination</td><td align="center" rowspan="1" colspan="1">Time delay (weeks)</td><td align="center" rowspan="1" colspan="1">0–4</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">Pre-vaccination</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0179315.ref031" ref-type="bibr">31</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Coverage (%)<xref ref-type="table-fn" rid="t003fn001">*</xref></td><td align="center" rowspan="1" colspan="1">0–100</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref056" ref-type="bibr">56</xref>, <xref rid="pone.0179315.ref061" ref-type="bibr">61</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Effectiveness (susceptibility) (%) <xref ref-type="table-fn" rid="t003fn001">*</xref>/<xref ref-type="table-fn" rid="t003fn002">**</xref></td><td align="center" rowspan="1" colspan="1">0–100</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">65 </td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref040" ref-type="bibr">40</xref>, <xref rid="pone.0179315.ref062" ref-type="bibr">62</xref>–<xref rid="pone.0179315.ref065" ref-type="bibr">65</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Effectiveness (infectivity) (%)<xref ref-type="table-fn" rid="t003fn002">**</xref></td><td align="center" rowspan="1" colspan="1">0–100</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">35 </td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1"> [<xref rid="pone.0179315.ref040" ref-type="bibr">40</xref>, <xref rid="pone.0179315.ref065" ref-type="bibr">65</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Reduction in hospitalization rate (%)<xref ref-type="table-fn" rid="t003fn001">*</xref></td><td align="center" rowspan="1" colspan="1">0–100</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1"> 60</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref066" ref-type="bibr">66</xref>]</td></tr><tr><td align="center" rowspan="4" colspan="1">Antiviral treatment</td><td align="center" rowspan="1" colspan="1">Coverage (% infected that seek treatment)<xref ref-type="table-fn" rid="t003fn002">**</xref></td><td align="center" rowspan="1" colspan="1">0–100</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">50 </td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">70</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref067" ref-type="bibr">67</xref>] </td></tr><tr><td align="center" rowspan="1" colspan="1">Effectiveness (infectivity) (%)<xref ref-type="table-fn" rid="t003fn001">*</xref></td><td align="center" rowspan="1" colspan="1">0–100</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">75 </td><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref031" ref-type="bibr">31</xref>, <xref rid="pone.0179315.ref039" ref-type="bibr">39</xref>, <xref rid="pone.0179315.ref068" ref-type="bibr">68</xref>–<xref rid="pone.0179315.ref070" ref-type="bibr">70</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Reduction in hospitalization rate (%)<xref ref-type="table-fn" rid="t003fn001">*</xref></td><td align="center" rowspan="1" colspan="1">0–100</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"> 10</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref071" ref-type="bibr">71</xref>] </td></tr><tr><td align="center" rowspan="1" colspan="1">Resistant strain</td><td align="center" rowspan="1" colspan="1">Yes/No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">None</td></tr><tr><td align="center" rowspan="5" colspan="1">Antiviral prophylaxis</td><td align="center" rowspan="1" colspan="1">Coverage (% of households, workplaces, and schools receiving prophylaxis)<xref ref-type="table-fn" rid="t003fn002">**</xref></td><td align="center" rowspan="1" colspan="1">0–100</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref030" ref-type="bibr">30</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Effectiveness (susceptibility) (%)<xref ref-type="table-fn" rid="t003fn001">*</xref></td><td align="center" rowspan="1" colspan="1">0–100</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref032" ref-type="bibr">32</xref>, <xref rid="pone.0179315.ref071" ref-type="bibr">71</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Effectiveness (infectivity) (%)<xref ref-type="table-fn" rid="t003fn001">*</xref>/<xref ref-type="table-fn" rid="t003fn002">**</xref></td><td align="center" rowspan="1" colspan="1">0–100</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">75 </td><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref031" ref-type="bibr">31</xref>, <xref rid="pone.0179315.ref039" ref-type="bibr">39</xref>, <xref rid="pone.0179315.ref068" ref-type="bibr">68</xref>–<xref rid="pone.0179315.ref070" ref-type="bibr">70</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Reduction in hospitalization rate (%)<xref ref-type="table-fn" rid="t003fn001">*</xref></td><td align="center" rowspan="1" colspan="1">0–100</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"> 10</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref071" ref-type="bibr">71</xref>] </td></tr><tr><td align="center" rowspan="1" colspan="1">Resistant strain</td><td align="center" rowspan="1" colspan="1">Yes/No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">None</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p><sup>τ </sup>* approximated from empirical studies</p></fn><fn id="t003fn002"><p>** approximated from modelling studies</p></fn><fn id="t003fn003"><p>*** approximated from qualitative studies</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0179315.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0179315.t004</object-id><label>Table 4</label><caption><title>Non-pharmaceutical intervention parameters.</title><p>Best-guess scenarios reflect pooled estimates as available. Worst- and best-case scenarios (in terms of disease transmission but not necessarily resource allocation) reflect 95% confidence intervals where available; otherwise they reflect ranges of estimates reported.</p></caption><alternatives><graphic id="pone.0179315.t004g" xlink:href="pone.0179315.t004"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Intervention</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Parameter<xref ref-type="table-fn" rid="t004fn001"><sup>τ</sup></xref></th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Theoretical Range</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Worst Case Scenario</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Best Guess</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Best Case Scenario</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Citation</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">School closure</td><td align="center" rowspan="1" colspan="1">Adults that will be redistributed (%)<xref ref-type="table-fn" rid="t004fn001">*</xref></td><td align="center" rowspan="1" colspan="1">0–100</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref072" ref-type="bibr">72</xref>] </td></tr><tr><td align="center" rowspan="1" colspan="1">Community-contact reduction</td><td align="center" rowspan="1" colspan="1">Reduction in community-contact rate (%)<xref ref-type="table-fn" rid="t004fn002">**</xref></td><td align="center" rowspan="1" colspan="1">0–100</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">50 </td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref031" ref-type="bibr">31</xref>, <xref rid="pone.0179315.ref060" ref-type="bibr">60</xref>, <xref rid="pone.0179315.ref073" ref-type="bibr">73</xref>, <xref rid="pone.0179315.ref074" ref-type="bibr">74</xref>] </td></tr><tr><td align="center" rowspan="2" colspan="1">Hand hygiene</td><td align="center" rowspan="1" colspan="1">Effectiveness (%)<xref ref-type="table-fn" rid="t004fn001">*</xref></td><td align="center" rowspan="1" colspan="1">0–100</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref075" ref-type="bibr">75</xref>–<xref rid="pone.0179315.ref079" ref-type="bibr">79</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Adherence (%)<xref ref-type="table-fn" rid="t004fn001">*</xref></td><td align="center" rowspan="1" colspan="1">0–100</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">38 </td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref075" ref-type="bibr">75</xref>, <xref rid="pone.0179315.ref080" ref-type="bibr">80</xref>–<xref rid="pone.0179315.ref082" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" rowspan="2" colspan="1">Mask use</td><td align="center" rowspan="1" colspan="1">Effectiveness (%)<xref ref-type="table-fn" rid="t004fn001">*</xref></td><td align="center" rowspan="1" colspan="1">0–100</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref083" ref-type="bibr">83</xref>–<xref rid="pone.0179315.ref087" ref-type="bibr">87</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Adherence (%)<xref ref-type="table-fn" rid="t004fn001">*</xref></td><td align="center" rowspan="1" colspan="1">0–100</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3 </td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref088" ref-type="bibr">88</xref>, <xref rid="pone.0179315.ref089" ref-type="bibr">89</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Voluntary isolation</td><td align="center" rowspan="1" colspan="1">Adherence (%)<xref ref-type="table-fn" rid="t004fn002">**</xref></td><td align="center" rowspan="1" colspan="1">0–100</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">30 </td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref090" ref-type="bibr">90</xref>, <xref rid="pone.0179315.ref091" ref-type="bibr">91</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Quarantine (subtracted from VI adherence</td><td align="center" rowspan="1" colspan="1">Adherence (%)<xref ref-type="table-fn" rid="t004fn003">***</xref></td><td align="center" rowspan="1" colspan="1">0–100</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">15 </td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">[<xref rid="pone.0179315.ref092" ref-type="bibr">92</xref>] </td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p><sup>τ:</sup> * approximated from empirical studies</p></fn><fn id="t004fn002"><p>** approximated from modelling studies</p></fn><fn id="t004fn003"><p>*** approximated from qualitative studies</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec011"><title>2.5 Analysis</title><p>We present summary values for six key outcome measures—cases of illness, hospitalization, ICU admission, peak acute care demand as a percentage of capacity, peak ICU demand as a percentage of capacity and death—across all 192 simulations conducted. Multivariate sensitivity analyses were conducted to evaluate how changes in disease and intervention characteristics might affect the evolution, progression and control of the pandemic. The effect of disease parameters was evaluated by conducting simulations under different transmissibility and pathogenicity assumptions. The effect of intervention parameters was evaluated by comparing BC and WC intervention scenarios to the BG scenario.</p><p>We also present the results of a complete analysis for seven key intervention bundles of interest. The scenarios and reasons for their emphasis are indicated below. Taken together, this two-tiered analysis should provide the breadth and depth of analysis needed to inform future pandemic planning.</p><list list-type="order"><list-item><p>No intervention: establish a baseline prediction.</p></list-item><list-item><p>Vaccination and antiviral treatment: assess the impact of commonly implemented pharmaceutical interventions in the absence of any non-pharmaceutical measures.</p></list-item><list-item><p>Vaccination, antiviral treatment and antiviral prophylaxis: assess the impact of the full range of pharmaceutical interventions that could be employed.</p></list-item><list-item><p>Community-contact reduction, personal protective measures and voluntary isolation: assess the impact of minimally invasive non-pharmaceutical interventions in cases where pharmaceutical measures may be unavailable.</p></list-item><list-item><p>School closure, community-contact reduction, personal protective measures, voluntary isolation and quarantine: assess the impact of the full scope of non-pharmaceutical measures in cases where pharmaceutical measures may be unavailable.</p></list-item><list-item><p>Community-contact reduction, personal protective measures, voluntary isolation and antiviral treatment: assess the impact of minimally disruptive non-pharmaceutical measures and antiviral treatment in cases where vaccination may not yet be available.</p></list-item><list-item><p>All interventions: assess the impact of implementing the full range of available interventions.</p></list-item></list></sec><sec id="sec012"><title>2.6 Validation</title><p>The InFluNet model was validated using four approaches, as informed by a recent review of mathematical modelling validation protocols [<xref rid="pone.0179315.ref029" ref-type="bibr">29</xref>]: parameterization, sensitivity analysis, structural validation and predictive validation. Parameterization involves the selection of values from empirical data; this was done wherever possible, prioritizing Canadian contexts where data were available. Multivariate sensitivity analyses were conducted to evaluate the impact of change in certain disease and intervention parameters, as described in Section 2.5. Structural validity refers to the extent to which the model is consistent with current theory and practices, reflecting the way in which the real-world system works: InFluNet is based in epidemic theory and builds on the work of previously published transmission [<xref rid="pone.0179315.ref038" ref-type="bibr">38</xref>, <xref rid="pone.0179315.ref041" ref-type="bibr">41</xref>] and intervention [<xref rid="pone.0179315.ref033" ref-type="bibr">33</xref>, <xref rid="pone.0179315.ref056" ref-type="bibr">56</xref>, <xref rid="pone.0179315.ref093" ref-type="bibr">93</xref>, <xref rid="pone.0179315.ref094" ref-type="bibr">94</xref>] modelling research.</p><p>Predictive validation assesses the extent to which the model will produce accurate data: this is the most difficult element of mathematical modelling validation, particularly in the case of pandemic influenza, where there is such heterogeneity in the disease, population and intervention parameters, and the majority of disease transmission processes are unreported and invisible to health-surveillance agencies. In an effort to overcome this challenge, we fit the model to past experiences of the 2009 pandemic by estimating values for the transmissibility parameter τ, which was estimated numerically from initial conditions and contact rates [<xref rid="pone.0179315.ref038" ref-type="bibr">38</xref>, <xref rid="pone.0179315.ref041" ref-type="bibr">41</xref>]. We then conducted an assessment of the model’s predictive validity by comparing its predicted attack rate in a pandemic scenario with a transmissibility parameter representative of the 2009 H1N1 pandemic to both empirical data [<xref rid="pone.0179315.ref025" ref-type="bibr">25</xref>, <xref rid="pone.0179315.ref095" ref-type="bibr">95</xref>] and the results of a previously published pandemic study that calibrated its inputs to the 2009 H1N1 pandemic [<xref rid="pone.0179315.ref033" ref-type="bibr">33</xref>]. Taking Hamilton, Ontario, as a simulated study population, Andradottir <italic>et al</italic> [<xref rid="pone.0179315.ref033" ref-type="bibr">33</xref>] constructed a simulation model that predicted an illness attack rate of 36.8%; taking the Ottawa–Gatineau CMA as a study population under similar assumptions, InFluNet predicted an illness attack rate of 41.0% (95% CI: 40.9–41.2%), though it was noted that Andradottir <italic>et al</italic> assumed a higher rate of pre-existing immunity. Given this, the small differences were interpreted as supportive of the predictive validity of our model. In this way, we validated our transmissibility parameter estimates against both the basic reproduction number of previous models [<xref rid="pone.0179315.ref033" ref-type="bibr">33</xref>] and empirical Canadian pandemic H1N1 attack rates [<xref rid="pone.0179315.ref025" ref-type="bibr">25</xref>, <xref rid="pone.0179315.ref095" ref-type="bibr">95</xref>]. This was essential to anchoring a representative transmissibility parameter, as it is not enough to assume that reproductive rates will be identical across differential equation models with different transmission assumptions.</p></sec></sec><sec id="sec013"><title>3. Results</title><p>The subsections below present results related to symptomatic influenza infection, hospitalization, ICU admission, hospital resource demand, mortality and economic burden. <bold><xref ref-type="table" rid="pone.0179315.t005">Table 5</xref></bold> summarizes the basic findings of the seven key intervention scenarios of interest. Results from all 192 simulations are discussed in their respective subsections, with summary tables included in the supplementary material.</p><table-wrap id="pone.0179315.t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0179315.t005</object-id><label>Table 5</label><caption><title>Summary of health-outcome measures from simulations of seven key intervention scenarios.</title></caption><alternatives><graphic id="pone.0179315.t005g" xlink:href="pone.0179315.t005"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="center" rowspan="2" style="background-color:#BFBFBF" colspan="1"><break></break>Intervention<xref ref-type="table-fn" rid="t005fn001">*</xref></th><th align="center" colspan="4" style="background-color:#BFBFBF" rowspan="1">Outcome</th></tr><tr><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Symptomatic Cases</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Hospitalizations</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">ICU</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Deaths</th></tr></thead><tbody><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>None</bold></td><td align="center" rowspan="1" colspan="1">677,546</td><td align="center" rowspan="1" colspan="1">2,472</td><td align="center" rowspan="1" colspan="1">580</td><td align="center" rowspan="1" colspan="1">363</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>V+AVT</bold></td><td align="center" rowspan="1" colspan="1">622,681</td><td align="center" rowspan="1" colspan="1">815</td><td align="center" rowspan="1" colspan="1">192</td><td align="center" rowspan="1" colspan="1">118</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>V+AVT+AVP</bold></td><td align="center" rowspan="1" colspan="1">600,394</td><td align="center" rowspan="1" colspan="1">765</td><td align="center" rowspan="1" colspan="1">180</td><td align="center" rowspan="1" colspan="1">109</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>CCR+PPM+VI</bold></td><td align="center" rowspan="1" colspan="1">203,771</td><td align="center" rowspan="1" colspan="1">634</td><td align="center" rowspan="1" colspan="1">151</td><td align="center" rowspan="1" colspan="1">65</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>CCR+PPM+VI+AVT</bold></td><td align="center" rowspan="1" colspan="1">200,537</td><td align="center" rowspan="1" colspan="1">560</td><td align="center" rowspan="1" colspan="1">133</td><td align="center" rowspan="1" colspan="1">58</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>SC+CCR+PPM+Q</bold></td><td align="center" rowspan="1" colspan="1">189,015</td><td align="center" rowspan="1" colspan="1">550</td><td align="center" rowspan="1" colspan="1">132</td><td align="center" rowspan="1" colspan="1">56</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>SC+CCR+PPM+Q+ V+AVT+AVP</bold></td><td align="center" rowspan="1" colspan="1">104,051</td><td align="center" rowspan="1" colspan="1">108</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">11</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t005fn001"><p>*V = vaccination; AVT = antiviral treatment; AVP = antiviral prophylaxis; CCR = community-contact reduction; PPM = personal protective measures; VI = voluntary isolation; Q = voluntary isolation and quarantine; SC = school closure</p></fn></table-wrap-foot></table-wrap><sec id="sec014"><title>3.1 Symptomatic infection</title><p>Under assumptions reflective of an influenza pandemic of transmissibility similar to the 1957 H2N2 pandemic, the InFluNet model projected that, in the absence of any intervention, about 677,546 symptomatic influenza infections would occur in the Ottawa–Gatineau CMA. This amounts to an illness attack rate of 53.4%. No single intervention implemented in isolation successfully brought the attack rate under 30%. Of the eight interventions, vaccination, personal protective measures, combined voluntary isolation and quarantine procedures resulted in the greatest reductions, producing attack rates of 50.0%, 45.5% and 33.9%, respectively. Antiviral treatment, antiviral prophylaxis, school closure and community-contact reduction produced only small reductions in illness attack rate, whether implemented alone or in combination with other interventions.</p><p>The timely initiation of multiple pandemic control measures resulted in significant reductions in symptomatic case numbers. This was particularly true when vaccination was combined with personal protective measures and isolation of infected individuals. Even in the absence of any pharmaceutical intervention, adherence to rigorous non-pharmaceutical protocols—school closure, community-contact reduction, personal protective measures, voluntary isolation and quarantine—resulted in a reduction of the illness attack rate to 15.2%, by delaying peak pandemic transmission beyond the 100-day simulation interval. Modelling of all eight interventions implemented in conjunction reduced the illness attack rate to 8.4%. Results of all 192 simulations are included in <bold><xref ref-type="supplementary-material" rid="pone.0179315.s003">S2 Table</xref></bold>.</p><p>With no intervention, the relative proportions of symptomatic infection approximately mirrored the age-stratified population distribution. <bold><xref ref-type="table" rid="pone.0179315.t006">Table 6</xref></bold> presents cases of symptomatic infection by age group, along with a calculation of the percentage of all cases represented by each age group.</p><table-wrap id="pone.0179315.t006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0179315.t006</object-id><label>Table 6</label><caption><title>Predicted number of cases of symptomatic infection by intervention type, and percentage of total infections accounted for by each group.</title></caption><alternatives><graphic id="pone.0179315.t006g" xlink:href="pone.0179315.t006"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="center" rowspan="2" style="background-color:#D9D9D9" colspan="1">Intervention</th><th align="center" colspan="6" style="background-color:#D9D9D9" rowspan="1">Age group</th></tr><tr><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Infant</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Child</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Young adult</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Adult</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Senior</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="center" rowspan="2" colspan="1"><bold>None</bold></td><td align="center" rowspan="1" colspan="1">39,628</td><td align="center" rowspan="1" colspan="1">111,066</td><td align="center" rowspan="1" colspan="1">103,976</td><td align="center" rowspan="1" colspan="1">344,858</td><td align="center" rowspan="1" colspan="1">78,018</td><td align="center" rowspan="1" colspan="1">677,546</td></tr><tr><td align="center" rowspan="1" colspan="1">5.8%</td><td align="center" rowspan="1" colspan="1">16.4%</td><td align="center" rowspan="1" colspan="1">15.3%</td><td align="center" rowspan="1" colspan="1">50.9%</td><td align="center" rowspan="1" colspan="1">11.5%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" colspan="1"><bold>V+AVT</bold></td><td align="center" rowspan="1" colspan="1">36508</td><td align="center" rowspan="1" colspan="1">101985</td><td align="center" rowspan="1" colspan="1">95567</td><td align="center" rowspan="1" colspan="1">317617</td><td align="center" rowspan="1" colspan="1">71004</td><td align="center" rowspan="1" colspan="1">622681</td></tr><tr><td align="center" rowspan="1" colspan="1">5.9%</td><td align="center" rowspan="1" colspan="1">16.4%</td><td align="center" rowspan="1" colspan="1">15.3%</td><td align="center" rowspan="1" colspan="1">51.0%</td><td align="center" rowspan="1" colspan="1">11.4%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" colspan="1"><bold>V+AVT+AVP</bold></td><td align="center" rowspan="1" colspan="1">35270</td><td align="center" rowspan="1" colspan="1">98279</td><td align="center" rowspan="1" colspan="1">92158</td><td align="center" rowspan="1" colspan="1">306757</td><td align="center" rowspan="1" colspan="1">67930</td><td align="center" rowspan="1" colspan="1">600394</td></tr><tr><td align="center" rowspan="1" colspan="1">5.9%</td><td align="center" rowspan="1" colspan="1">16.4%</td><td align="center" rowspan="1" colspan="1">15.3%</td><td align="center" rowspan="1" colspan="1">51.1%</td><td align="center" rowspan="1" colspan="1">11.3%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" colspan="1"><bold>CCR+PPM+VI</bold></td><td align="center" rowspan="1" colspan="1">17427</td><td align="center" rowspan="1" colspan="1">36467</td><td align="center" rowspan="1" colspan="1">24842</td><td align="center" rowspan="1" colspan="1">105413</td><td align="center" rowspan="1" colspan="1">19622</td><td align="center" rowspan="1" colspan="1">203771</td></tr><tr><td align="center" rowspan="1" colspan="1">8.6%</td><td align="center" rowspan="1" colspan="1">17.9%</td><td align="center" rowspan="1" colspan="1">12.2%</td><td align="center" rowspan="1" colspan="1">51.7%</td><td align="center" rowspan="1" colspan="1">9.6%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" colspan="1"><bold>CCR+PPM+VI+AVT</bold></td><td align="center" rowspan="1" colspan="1">17183</td><td align="center" rowspan="1" colspan="1">35893</td><td align="center" rowspan="1" colspan="1">24427</td><td align="center" rowspan="1" colspan="1">103747</td><td align="center" rowspan="1" colspan="1">19287</td><td align="center" rowspan="1" colspan="1">200537</td></tr><tr><td align="center" rowspan="1" colspan="1">8.6%</td><td align="center" rowspan="1" colspan="1">17.9%</td><td align="center" rowspan="1" colspan="1">12.2%</td><td align="center" rowspan="1" colspan="1">51.7%</td><td align="center" rowspan="1" colspan="1">9.6%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" colspan="1"><bold>SC+CCR+PPM+Q</bold></td><td align="center" rowspan="1" colspan="1">17998</td><td align="center" rowspan="1" colspan="1">53368</td><td align="center" rowspan="1" colspan="1">25040</td><td align="center" rowspan="1" colspan="1">72406</td><td align="center" rowspan="1" colspan="1">20204</td><td align="center" rowspan="1" colspan="1">189016</td></tr><tr><td align="center" rowspan="1" colspan="1">9.5%</td><td align="center" rowspan="1" colspan="1">28.2%</td><td align="center" rowspan="1" colspan="1">13.2%</td><td align="center" rowspan="1" colspan="1">38.3%</td><td align="center" rowspan="1" colspan="1">10.7%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" colspan="1"><bold>SC+CCR+PPM+Q+V+AVT+AVP</bold></td><td align="center" rowspan="1" colspan="1">10102</td><td align="center" rowspan="1" colspan="1">28481</td><td align="center" rowspan="1" colspan="1">13196</td><td align="center" rowspan="1" colspan="1">41842</td><td align="center" rowspan="1" colspan="1">10430</td><td align="center" rowspan="1" colspan="1">104051</td></tr><tr><td align="center" rowspan="1" colspan="1">9.7%</td><td align="center" rowspan="1" colspan="1">27.4%</td><td align="center" rowspan="1" colspan="1">12.7%</td><td align="center" rowspan="1" colspan="1">40.2%</td><td align="center" rowspan="1" colspan="1">10.0%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr></tbody></table></alternatives></table-wrap><p>While pharmaceutical interventions did little to redistribute the age-specific burden of influenza infection, non-pharmaceutical interventions appear to shift the burden towards younger age groups. This may be because measures like school closure and community-contact reduction redistribute more infections to the household, where children tend to be more prone to infection than adults. <bold><xref ref-type="table" rid="pone.0179315.t007">Table 7</xref></bold> presents the distribution of transmission events by location, along with a calculation of the percentage of all cases represented by each location. Results suggest that pharmaceutical measures have little impact on the role of different locations in influenza transmission, but that non-pharmaceutical measures—school closures in particular—redistribute infection events to the household and community.</p><table-wrap id="pone.0179315.t007" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0179315.t007</object-id><label>Table 7</label><caption><title>Transmission events by location, and percentage of total infections accounted for by each location.</title></caption><alternatives><graphic id="pone.0179315.t007g" xlink:href="pone.0179315.t007"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="center" rowspan="2" style="background-color:#BFBFBF" colspan="1">Intervention</th><th align="center" colspan="4" style="background-color:#BFBFBF" rowspan="1">Location</th></tr><tr><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Household</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">School/work</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Community</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>None</bold></td><td align="center" rowspan="1" colspan="1">337,135</td><td align="center" rowspan="1" colspan="1">233,370</td><td align="center" rowspan="1" colspan="1">107,040</td><td align="center" rowspan="1" colspan="1">677,546</td></tr><tr><td align="center" rowspan="1" colspan="1">49.8%</td><td align="center" rowspan="1" colspan="1">34.4%</td><td align="center" rowspan="1" colspan="1">15.8%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>V+AVT</bold></td><td align="center" rowspan="1" colspan="1">309,759</td><td align="center" rowspan="1" colspan="1">214,515</td><td align="center" rowspan="1" colspan="1">98,407</td><td align="center" rowspan="1" colspan="1">622,681</td></tr><tr><td align="center" rowspan="1" colspan="1">49.7%</td><td align="center" rowspan="1" colspan="1">34.5%</td><td align="center" rowspan="1" colspan="1">15.8%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>V+AVT+AVP</bold></td><td align="center" rowspan="1" colspan="1">298,522</td><td align="center" rowspan="1" colspan="1">206,797</td><td align="center" rowspan="1" colspan="1">95,075</td><td align="center" rowspan="1" colspan="1">600,394</td></tr><tr><td align="center" rowspan="1" colspan="1">49.7%</td><td align="center" rowspan="1" colspan="1">34.4%</td><td align="center" rowspan="1" colspan="1">15.8%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>CCR+PPM+VI</bold></td><td align="center" rowspan="1" colspan="1">101,447</td><td align="center" rowspan="1" colspan="1">71,084</td><td align="center" rowspan="1" colspan="1">31,240</td><td align="center" rowspan="1" colspan="1">203,771</td></tr><tr><td align="center" rowspan="1" colspan="1">49.8%</td><td align="center" rowspan="1" colspan="1">34.9%</td><td align="center" rowspan="1" colspan="1">15.3%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>CCR+PPM+VI+AVT</bold></td><td align="center" rowspan="1" colspan="1">99,827</td><td align="center" rowspan="1" colspan="1">69,962</td><td align="center" rowspan="1" colspan="1">30,748</td><td align="center" rowspan="1" colspan="1">200,537</td></tr><tr><td align="center" rowspan="1" colspan="1">49.8%</td><td align="center" rowspan="1" colspan="1">34.9%</td><td align="center" rowspan="1" colspan="1">15.3%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>SC+CCR+PPM+Q</bold></td><td align="center" rowspan="1" colspan="1">105,416</td><td align="center" rowspan="1" colspan="1">42,435</td><td align="center" rowspan="1" colspan="1">41,165</td><td align="center" rowspan="1" colspan="1">189,016</td></tr><tr><td align="center" rowspan="1" colspan="1">55.8%</td><td align="center" rowspan="1" colspan="1">22.5%</td><td align="center" rowspan="1" colspan="1">21.8%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>SC+CCR+PPM+Q+V+AVT+AVP</bold></td><td align="center" rowspan="1" colspan="1">57,076</td><td align="center" rowspan="1" colspan="1">24,453</td><td align="center" rowspan="1" colspan="1">22,522</td><td align="center" rowspan="1" colspan="1">104,051</td></tr><tr><td align="center" rowspan="1" colspan="1">54.9%</td><td align="center" rowspan="1" colspan="1">23.5%</td><td align="center" rowspan="1" colspan="1">21.6%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr></tbody></table></alternatives></table-wrap><p><bold><xref ref-type="fig" rid="pone.0179315.g002">Fig 2</xref></bold> presents the number of new infections by day over the first 100 days of a pandemic influenza outbreak. Of interest is that pharmaceutical interventions alone (orange and grey lines) appear to result in a contraction of the pandemic peak without affecting its shape; under cases of pharmaceutical intervention—as with no intervention—transmission begins to accelerate about a month after infected individuals were added to the simulation, and there is only a small delay in the pandemic peak. Conversely, aggressive non-pharmaceutical interventions, which implement multiple containment measures in parallel, can delay the pandemic beyond the assumed window for the pandemic wave. Personal protective measures and voluntary isolation seem to account for the majority of this effect, with only small changes resulting from the further addition of community-contact reduction, school closure, quarantine or pharmaceutical measures.</p><fig id="pone.0179315.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0179315.g002</object-id><label>Fig 2</label><caption><title>New infections by day under seven key intervention scenarios.</title></caption><graphic xlink:href="pone.0179315.g002"></graphic></fig></sec><sec id="sec015"><title>3.2 Hospitalization</title><p>A total of 2,472 pandemic-associated hospitalizations were projected under a “no intervention” scenario. As seen in <bold><xref ref-type="table" rid="pone.0179315.t005">Table 5</xref></bold>, both pharmaceutical and non-pharmaceutical interventions were effective in reducing the number and rate of hospitalizations. As a result, there was substantial variation in the number of hospitalizations that could arise under different intervention scenarios, ranging from 2,472 (no intervention) to 108 (all eight interventions). Hospitalization projections for all 192 intervention scenarios are presented in <bold><xref ref-type="supplementary-material" rid="pone.0179315.s004">S3 Table</xref></bold>.</p><p><bold><xref ref-type="table" rid="pone.0179315.t008">Table 8</xref></bold> presents the age-stratified hospitalization totals across the seven intervention bundles of interest. Infants and seniors experienced a disproportionate number of hospitalizations given their population sizes, accounting for 7.4% and 28.8% of hospitalizations despite representing 5.7% and 12.6% of the total population, respectively. Children and adults had disproportionately low hospitalization rates, accounting for 4.2% and 7.8% of hospitalizations, despite representing 16.4% and 15.3% of the population, respectively. While pharmaceutical interventions did little to redistribute the hospitalization burden—as they were not modelled to target particular age groups—non-pharmaceutical measures resulted in higher relative burdens among infants, children and adults, though total hospitalizations decreased across all age groups.</p><table-wrap id="pone.0179315.t008" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0179315.t008</object-id><label>Table 8</label><caption><title>Predicted number of hospitalizations, and percentage of total hospitalizations accounted for by each group.</title></caption><alternatives><graphic id="pone.0179315.t008g" xlink:href="pone.0179315.t008"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="center" rowspan="2" style="background-color:#BFBFBF" colspan="1"><break></break>Intervention</th><th align="center" colspan="6" style="background-color:#BFBFBF" rowspan="1">Age group</th></tr><tr><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Infant</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Child</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Young adult</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Adult</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Senior</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>None</bold></td><td align="center" rowspan="1" colspan="1">184</td><td align="center" rowspan="1" colspan="1">104</td><td align="center" rowspan="1" colspan="1">193</td><td align="center" rowspan="1" colspan="1">1279</td><td align="center" rowspan="1" colspan="1">712</td><td align="center" rowspan="1" colspan="1">2472</td></tr><tr><td align="center" rowspan="1" colspan="1">7.4%</td><td align="center" rowspan="1" colspan="1">4.2%</td><td align="center" rowspan="1" colspan="1">7.8%</td><td align="center" rowspan="1" colspan="1">51.7%</td><td align="center" rowspan="1" colspan="1">28.8%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>V+AVT</bold></td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">423</td><td align="center" rowspan="1" colspan="1">234</td><td align="center" rowspan="1" colspan="1">816</td></tr><tr><td align="center" rowspan="1" colspan="1">7.5%</td><td align="center" rowspan="1" colspan="1">4.2%</td><td align="center" rowspan="1" colspan="1">7.8%</td><td align="center" rowspan="1" colspan="1">51.8%</td><td align="center" rowspan="1" colspan="1">28.7%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>V+AVT+AVP</bold></td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">398</td><td align="center" rowspan="1" colspan="1">218</td><td align="center" rowspan="1" colspan="1">766</td></tr><tr><td align="center" rowspan="1" colspan="1">7.6%</td><td align="center" rowspan="1" colspan="1">4.2%</td><td align="center" rowspan="1" colspan="1">7.8%</td><td align="center" rowspan="1" colspan="1">52.0%</td><td align="center" rowspan="1" colspan="1">28.5%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>CCR+PPM+VI</bold></td><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">339</td><td align="center" rowspan="1" colspan="1">154</td><td align="center" rowspan="1" colspan="1">634</td></tr><tr><td align="center" rowspan="1" colspan="1">11.2%</td><td align="center" rowspan="1" colspan="1">4.7%</td><td align="center" rowspan="1" colspan="1">6.3%</td><td align="center" rowspan="1" colspan="1">53.5%</td><td align="center" rowspan="1" colspan="1">24.3%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>CCR+PPM+VI+AVT</bold></td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">300</td><td align="center" rowspan="1" colspan="1">136</td><td align="center" rowspan="1" colspan="1">560</td></tr><tr><td align="center" rowspan="1" colspan="1">11.3%</td><td align="center" rowspan="1" colspan="1">4.7%</td><td align="center" rowspan="1" colspan="1">6.2%</td><td align="center" rowspan="1" colspan="1">53.6%</td><td align="center" rowspan="1" colspan="1">24.3%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>SC+CCR+PPM+Q</bold></td><td align="center" rowspan="1" colspan="1">74</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">234</td><td align="center" rowspan="1" colspan="1">158</td><td align="center" rowspan="1" colspan="1">550</td></tr><tr><td align="center" rowspan="1" colspan="1">13.4%</td><td align="center" rowspan="1" colspan="1">8.2%</td><td align="center" rowspan="1" colspan="1">7.2%</td><td align="center" rowspan="1" colspan="1">42.5%</td><td align="center" rowspan="1" colspan="1">28.7%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>SC+CCR+PPM+Q+V+AVT+AVP</bold></td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">108</td></tr><tr><td align="center" rowspan="1" colspan="1">13.4%</td><td align="center" rowspan="1" colspan="1">7.5%</td><td align="center" rowspan="1" colspan="1">6.9%</td><td align="center" rowspan="1" colspan="1">44.4%</td><td align="center" rowspan="1" colspan="1">27.8%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr></tbody></table></alternatives></table-wrap><p><bold><xref ref-type="fig" rid="pone.0179315.g003">Fig 3</xref></bold> presents findings relating to the demand for acute-care hospital beds over the first 100 days of a pandemic influenza outbreak. Similar to the observed effects on symptomatic infections, pharmaceutical interventions resulted in a contraction of peak demand, while layered non-pharmaceutical interventions resulted in its delay and attenuation. Peak acute care demand ranged from 13.8% (no intervention) to 0.2% (all eight interventions). The peak hospitalization demand for all 192 intervention scenarios is summarized in <bold><xref ref-type="supplementary-material" rid="pone.0179315.s005">S4 Table</xref></bold>.</p><fig id="pone.0179315.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0179315.g003</object-id><label>Fig 3</label><caption><title>Daily acute-care hospital demand, charted as the percentage of all acute-care hospital beds in the Ottawa–Gatineau CMA, under seven key intervention scenarios.</title></caption><graphic xlink:href="pone.0179315.g003"></graphic></fig></sec><sec id="sec016"><title>3.3 Intensive care unit admission</title><p>In a pandemic where no intervention measures are implemented, InFluNet simulations projected approximately 580 ICU admissions over the first 100 days of the outbreak. As with acute-care hospitalization, there is a broad range of ICU demand scenarios, dependent on the intervention scenario being simulated; total ICU admissions ranged from 580 to 26 (all eight interventions). Many moderate intervention scenarios combining a pharmaceutical and non-pharmaceutical intervention resulted in a range of 100 to 400 ICU admissions. The ICU admission estimates for all 192 intervention scenarios are presented in <bold><xref ref-type="supplementary-material" rid="pone.0179315.s006">S5 Table</xref></bold>.</p><p><bold><xref ref-type="table" rid="pone.0179315.t009">Table 9</xref></bold> presents estimates of age-stratified ICU admission, alongside a calculation of the proportion of total admissions accounted for by each age group. As with acute-care hospitalization, infants and seniors represented a disproportionately high share of the ICU admissions, reflective of our assumption that infants and seniors were more likely to experience critical illness as a result of complicated influenza infection. This distinction was even more pronounced in infants, which represented 11.9% of ICU admissions under a “no intervention” scenario, despite representing only 5.7% of the total population. Similar to acute-care hospitalization, pharmaceutical measures were not found to significantly affect the distribution of age-specific ICU admission; non-pharmaceutical measures redistributed admissions towards younger age groups, while reducing the total number of admissions.</p><table-wrap id="pone.0179315.t009" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0179315.t009</object-id><label>Table 9</label><caption><title>Predicted number of ICU admissions, and percentage of total admissions accounted for by each group.</title></caption><alternatives><graphic id="pone.0179315.t009g" xlink:href="pone.0179315.t009"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="center" rowspan="2" style="background-color:#BFBFBF" colspan="1"><break></break>Intervention</th><th align="center" colspan="6" style="background-color:#BFBFBF" rowspan="1">Age group</th></tr><tr><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Infant</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Child</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Young adult</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Adult</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Senior</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>None</bold></td><td align="center" rowspan="1" colspan="1">69</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">309</td><td align="center" rowspan="1" colspan="1">119</td><td align="center" rowspan="1" colspan="1">581</td></tr><tr><td align="center" rowspan="1" colspan="1">11.9%</td><td align="center" rowspan="1" colspan="1">6.4%</td><td align="center" rowspan="1" colspan="1">8.1%</td><td align="center" rowspan="1" colspan="1">53.2%</td><td align="center" rowspan="1" colspan="1">20.5%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>V+AVT</bold></td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">102</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">191</td></tr><tr><td align="center" rowspan="1" colspan="1">12.0%</td><td align="center" rowspan="1" colspan="1">6.3%</td><td align="center" rowspan="1" colspan="1">7.9%</td><td align="center" rowspan="1" colspan="1">53.4%</td><td align="center" rowspan="1" colspan="1">20.4%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>V+AVT+AVP</bold></td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">96</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">180</td></tr><tr><td align="center" rowspan="1" colspan="1">11.7%</td><td align="center" rowspan="1" colspan="1">6.1%</td><td align="center" rowspan="1" colspan="1">8.3%</td><td align="center" rowspan="1" colspan="1">53.3%</td><td align="center" rowspan="1" colspan="1">20.6%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>CCR+PPM+VI</bold></td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">151</td></tr><tr><td align="center" rowspan="1" colspan="1">15.9%</td><td align="center" rowspan="1" colspan="1">6.6%</td><td align="center" rowspan="1" colspan="1">6.0%</td><td align="center" rowspan="1" colspan="1">53.6%</td><td align="center" rowspan="1" colspan="1">17.9%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>CCR+PPM+VI+AVT</bold></td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">132</td></tr><tr><td align="center" rowspan="1" colspan="1">16.0%</td><td align="center" rowspan="1" colspan="1">5.7%</td><td align="center" rowspan="1" colspan="1">6.1%</td><td align="center" rowspan="1" colspan="1">54.0%</td><td align="center" rowspan="1" colspan="1">18.3%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>SC+CCR+PPM+Q</bold></td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">132</td></tr><tr><td align="center" rowspan="1" colspan="1">25.0%</td><td align="center" rowspan="1" colspan="1">13.6%</td><td align="center" rowspan="1" colspan="1">6.8%</td><td align="center" rowspan="1" colspan="1">39.4%</td><td align="center" rowspan="1" colspan="1">15.2%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>SC+CCR+PPM+Q+V+AVT+AVP</bold></td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">27</td></tr><tr><td align="center" rowspan="1" colspan="1">25.9%</td><td align="center" rowspan="1" colspan="1">11.1%</td><td align="center" rowspan="1" colspan="1">7.4%</td><td align="center" rowspan="1" colspan="1">40.7%</td><td align="center" rowspan="1" colspan="1">14.8%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr></tbody></table></alternatives></table-wrap><p><bold><xref ref-type="fig" rid="pone.0179315.g004">Fig 4</xref></bold> presents the findings relating to daily demand for ICU beds, as a percentage of the Ottawa–Gatineau CMA ICU capacity. Again, pharmaceutical measures resulted in a contraction of the pandemic peak, while layered non-pharmaceutical measures produced a dramatic attenuation of the wave itself. Peak ICU demand ranged from 90.2% (no interventions) to 1.1% (all eight interventions). The peak ICU demand for all 192 intervention scenarios is summarized in <bold><xref ref-type="supplementary-material" rid="pone.0179315.s007">S6 Table</xref></bold>.</p><fig id="pone.0179315.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0179315.g004</object-id><label>Fig 4</label><caption><title>Daily ICU demand, charted as the percentage of all ICU beds in the Ottawa–Gatineau CMA, across seven interventions of interest.</title></caption><graphic xlink:href="pone.0179315.g004"></graphic></fig></sec><sec id="sec017"><title>3.4 Mortality</title><p>The InFluNet model projected 363 pandemic-related deaths under a “no intervention” scenario. Rigorous non-pharmaceutical interventions and most intervention scenarios incorporating vaccination reduced this figure to below 100, while scenarios modelling antiviral treatment, prophylaxis and more moderate non-pharmaceutical interventions tended to predict between 100 and 300 deaths. The mortality estimates for all 192 intervention scenarios are presented in <bold><xref ref-type="supplementary-material" rid="pone.0179315.s008">S7 Table</xref></bold>.</p><p>Age-specific mortality rates are presented in <bold><xref ref-type="table" rid="pone.0179315.t010">Table 10</xref></bold>, alongside the proportion of the total mortality estimate for each age group. Seniors are over-represented with regard to mortality, accounting for 41.2% of deaths in the “no intervention” scenario. This was due in part to the assumption that additional mortality would occur in seniors outside of the hospital setting and reflects the assumption that many influenza deaths will occur among those with weaker immune systems. Interventions had relatively little effect on the age-specific distribution of mortality, suggesting that age-specific mortality rates dominate mortality distribution, rather than rates of symptomatic infection. Because influenza-related mortality is such a rare occurrence, even significant shifts in age-specific infection rates had relatively little effect on mortality distributions.</p><table-wrap id="pone.0179315.t010" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0179315.t010</object-id><label>Table 10</label><caption><title>Predicted number of deaths, and percentage of total mortality accounted for by each age group.</title></caption><alternatives><graphic id="pone.0179315.t010g" xlink:href="pone.0179315.t010"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="center" rowspan="2" style="background-color:#BFBFBF" colspan="1"><break></break>Intervention</th><th align="center" colspan="6" style="background-color:#BFBFBF" rowspan="1">Age group</th></tr><tr><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Infant</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Child</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Young adult</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Adult</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Senior</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>None</bold></td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">179</td><td align="center" rowspan="1" colspan="1">150</td><td align="center" rowspan="1" colspan="1">364</td></tr><tr><td align="center" rowspan="1" colspan="1">1.1%</td><td align="center" rowspan="1" colspan="1">1.1%</td><td align="center" rowspan="1" colspan="1">7.4%</td><td align="center" rowspan="1" colspan="1">49.2%</td><td align="center" rowspan="1" colspan="1">41.2%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>V+AVT</bold></td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">118</td></tr><tr><td align="center" rowspan="1" colspan="1">0.8%</td><td align="center" rowspan="1" colspan="1">0.8%</td><td align="center" rowspan="1" colspan="1">7.6%</td><td align="center" rowspan="1" colspan="1">49.2%</td><td align="center" rowspan="1" colspan="1">41.5%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>V+AVT+AVP</bold></td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">109</td></tr><tr><td align="center" rowspan="1" colspan="1">0.9%</td><td align="center" rowspan="1" colspan="1">0.9%</td><td align="center" rowspan="1" colspan="1">7.3%</td><td align="center" rowspan="1" colspan="1">49.5%</td><td align="center" rowspan="1" colspan="1">41.3%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>CCR+PPM+VI</bold></td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">66</td></tr><tr><td align="center" rowspan="1" colspan="1">1.5%</td><td align="center" rowspan="1" colspan="1">1.5%</td><td align="center" rowspan="1" colspan="1">6.1%</td><td align="center" rowspan="1" colspan="1">53.0%</td><td align="center" rowspan="1" colspan="1">37.9%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>CCR+PPM+VI+AVT</bold></td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">59</td></tr><tr><td align="center" rowspan="1" colspan="1">1.7%</td><td align="center" rowspan="1" colspan="1">2.4%</td><td align="center" rowspan="1" colspan="1">6.7%</td><td align="center" rowspan="1" colspan="1">52.2%</td><td align="center" rowspan="1" colspan="1">37.0%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>SC+CCR+PPM+Q</bold></td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">55</td></tr><tr><td align="center" rowspan="1" colspan="1">1.8%</td><td align="center" rowspan="1" colspan="1">1.8%</td><td align="center" rowspan="1" colspan="1">7.3%</td><td align="center" rowspan="1" colspan="1">43.6%</td><td align="center" rowspan="1" colspan="1">45.5%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1"><bold>SC+CCR+PPM+Q+V+AVT+AVP</bold></td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td align="center" rowspan="1" colspan="1">0.0%</td><td align="center" rowspan="1" colspan="1">0.0%</td><td align="center" rowspan="1" colspan="1">9.1%</td><td align="center" rowspan="1" colspan="1">45.5%</td><td align="center" rowspan="1" colspan="1">45.5%</td><td align="center" rowspan="1" colspan="1">100.0%</td></tr></tbody></table></alternatives></table-wrap><p><bold><xref ref-type="fig" rid="pone.0179315.g005">Fig 5</xref></bold> presents the cumulative number of deaths projected to occur in the first 100 days of a pandemic outbreak across the seven interventions of interest. Deaths begin accumulating almost two months after initial seeding of infected individuals. While mortality totals in “no intervention” and pharmaceutical intervention scenarios appeared to be levelling off after 100 days, non-pharmaceutical interventions did not demonstrate similar rate reductions, suggesting a threat of a prolonged first wave or more severe second wave.</p><fig id="pone.0179315.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0179315.g005</object-id><label>Fig 5</label><caption><title>Cumulative mortality over the first 100 days of a pandemic influenza outbreak across seven interventions of interest.</title></caption><graphic xlink:href="pone.0179315.g005"></graphic></fig></sec><sec id="sec018"><title>3.5 Economic analysis</title><p>Estimates of the economic burden for an influenza pandemic—for the seven intervention scenarios of interest—ranged from CAD $115 million to $2.15 billion in the Ottawa-Gatineau CMA alone. The cost breakdown for each intervention scenario is presented in <bold><xref ref-type="table" rid="pone.0179315.t011">Table 11</xref></bold>, with more detailed, intervention-specific summaries available in <bold><xref ref-type="supplementary-material" rid="pone.0179315.s009">S8 Table</xref></bold>. Of the interventions that were subject to economic evaluation, a layered non-pharmaceutical approach, in combination with antiviral therapy, seemed to reduce the overall economic burden the most. Intervention costs per life-year saved are presented in <bold><xref ref-type="table" rid="pone.0179315.t012">Table 12</xref>.</bold> Vaccination appears to be the most cost-effective approach, followed by other pharmaceutical measures, voluntary isolation and personal protective measures. Interestingly, there does not appear to be substantial cost-effectiveness either in combining antiviral therapy and prophylaxis or adding antiviral therapy to a layered non-pharmaceutical intervention. The least cost-effective approaches incorporated school closures, which resulted in massive costs associated with lost school and work days, with relatively little additional benefit in terms of life-years saved.</p><table-wrap id="pone.0179315.t011" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0179315.t011</object-id><label>Table 11</label><caption><title>Predicted costs (CAD) of pandemic-associated morbidity and mortality, as well as key intervention inputs.</title></caption><alternatives><graphic id="pone.0179315.t011g" xlink:href="pone.0179315.t011"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="center" rowspan="2" style="background-color:#BFBFBF" colspan="1"><break></break>Cost category</th><th align="center" colspan="7" style="background-color:#BFBFBF" rowspan="1">Intervention</th></tr><tr><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">None</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">V+AVT</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">V+AVT+AVP</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">CCR+PPM+VI</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">CCR+PPM+ VI+AVT</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">SC+CCR+ PPM+Q</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">SC+CCR+PPM+Q+V+AVT+ AVP</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Hospital bed days</td><td align="right" rowspan="1" colspan="1">10,303,296</td><td align="right" rowspan="1" colspan="1">3,396,920</td><td align="right" rowspan="1" colspan="1">3,188,520</td><td align="right" rowspan="1" colspan="1">2,642,512</td><td align="right" rowspan="1" colspan="1">2,334,080</td><td align="right" rowspan="1" colspan="1">2,292,400</td><td align="right" rowspan="1" colspan="1">450,144</td></tr><tr><td align="center" rowspan="1" colspan="1">ICU bed days</td><td align="right" rowspan="1" colspan="1">12,087,200</td><td align="right" rowspan="1" colspan="1">4,001,280</td><td align="right" rowspan="1" colspan="1">3,751,200</td><td align="right" rowspan="1" colspan="1">3,146,840</td><td align="right" rowspan="1" colspan="1">2,771,720</td><td align="right" rowspan="1" colspan="1">2,750,880</td><td align="right" rowspan="1" colspan="1">541,840</td></tr><tr><td align="center" rowspan="1" colspan="1">Deaths (infant)</td><td align="right" rowspan="1" colspan="1">9,420,688</td><td align="right" rowspan="1" colspan="1">2,355,172</td><td align="right" rowspan="1" colspan="1">2,355,172</td><td align="right" rowspan="1" colspan="1">2,355,172</td><td align="right" rowspan="1" colspan="1">2,355,172</td><td align="right" rowspan="1" colspan="1">2,355,172</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Deaths (child)</td><td align="right" rowspan="1" colspan="1">8,830,976</td><td align="right" rowspan="1" colspan="1">2,207,744</td><td align="right" rowspan="1" colspan="1">2,207,744</td><td align="right" rowspan="1" colspan="1">2,207,744</td><td align="right" rowspan="1" colspan="1">2,207,744</td><td align="right" rowspan="1" colspan="1">2,207,744</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Deaths (young adult)</td><td align="right" rowspan="1" colspan="1">52,830,738</td><td align="right" rowspan="1" colspan="1">17,610,246</td><td align="right" rowspan="1" colspan="1">15,653,552</td><td align="right" rowspan="1" colspan="1">7,826,776</td><td align="right" rowspan="1" colspan="1">7,826,776</td><td align="right" rowspan="1" colspan="1">7,826,776</td><td align="right" rowspan="1" colspan="1">1,956,694</td></tr><tr><td align="center" rowspan="1" colspan="1">Deaths (adult)</td><td align="right" rowspan="1" colspan="1">245,961,394</td><td align="right" rowspan="1" colspan="1">79,696,988</td><td align="right" rowspan="1" colspan="1">74,200,644</td><td align="right" rowspan="1" colspan="1">48,093,010</td><td align="right" rowspan="1" colspan="1">42,596,666</td><td align="right" rowspan="1" colspan="1">32,978,064</td><td align="right" rowspan="1" colspan="1">6,870,430</td></tr><tr><td align="center" rowspan="1" colspan="1">Deaths (seniors)</td><td align="right" rowspan="1" colspan="1">63,644,400</td><td align="right" rowspan="1" colspan="1">20,790,504</td><td align="right" rowspan="1" colspan="1">19,093,320</td><td align="right" rowspan="1" colspan="1">10,607,400</td><td align="right" rowspan="1" colspan="1">9,334,512</td><td align="right" rowspan="1" colspan="1">10,607,400</td><td align="right" rowspan="1" colspan="1">2,121,480</td></tr><tr><td align="center" rowspan="1" colspan="1">Lost school days</td><td align="right" rowspan="1" colspan="1">72,194</td><td align="right" rowspan="1" colspan="1">23,514</td><td align="right" rowspan="1" colspan="1">21,860</td><td align="right" rowspan="1" colspan="1">5,044,494</td><td align="right" rowspan="1" colspan="1">4,962,104</td><td align="right" rowspan="1" colspan="1">910,837,138</td><td align="right" rowspan="1" colspan="1">794,463,188</td></tr><tr><td align="center" rowspan="1" colspan="1">Lost work days (YA + adults)</td><td align="right" rowspan="1" colspan="1">1,819,212</td><td align="right" rowspan="1" colspan="1">600,371</td><td align="right" rowspan="1" colspan="1">566,482</td><td align="right" rowspan="1" colspan="1">38,086,197</td><td align="right" rowspan="1" colspan="1">37,429,987</td><td align="right" rowspan="1" colspan="1">1,179,410,918</td><td align="right" rowspan="1" colspan="1">1,023,034,132</td></tr><tr><td align="center" rowspan="1" colspan="1">Lost work days (seniors)</td><td align="right" rowspan="1" colspan="1">83,759</td><td align="right" rowspan="1" colspan="1">25,609</td><td align="right" rowspan="1" colspan="1">23,876</td><td align="right" rowspan="1" colspan="1">583,812</td><td align="right" rowspan="1" colspan="1">572,259</td><td align="right" rowspan="1" colspan="1">599,601</td><td align="right" rowspan="1" colspan="1">314,242</td></tr><tr><td align="center" rowspan="1" colspan="1">Vaccinations</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1">8,724,240</td><td align="right" rowspan="1" colspan="1">8,724,240</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1">8,724,240</td></tr><tr><td align="center" rowspan="1" colspan="1">Antivirals</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1">7,783,530</td><td align="right" rowspan="1" colspan="1">9,048,375</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1">2,506,608</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1">2,593,125</td></tr><tr><td align="center" rowspan="1" colspan="1">Masks</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1">747,792</td><td align="right" rowspan="1" colspan="1">747,792</td><td align="right" rowspan="1" colspan="1">747,792</td><td align="right" rowspan="1" colspan="1">747,792</td></tr><tr><td align="center" rowspan="1" colspan="1">Total</td><td align="right" rowspan="1" colspan="1">405,053,858</td><td align="right" rowspan="1" colspan="1">147,216,118</td><td align="right" rowspan="1" colspan="1">138,834,986</td><td align="right" rowspan="1" colspan="1">121,341,749</td><td align="right" rowspan="1" colspan="1">115,645,420</td><td align="right" rowspan="1" colspan="1">2,152,613,885</td><td align="right" rowspan="1" colspan="1">1,841,817,306</td></tr></tbody></table></alternatives></table-wrap><table-wrap id="pone.0179315.t012" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0179315.t012</object-id><label>Table 12</label><caption><title>Predicted life-years lost and cost per life-year saved, by intervention</title></caption><alternatives><graphic id="pone.0179315.t012g" xlink:href="pone.0179315.t012"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Intervention</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Life-years lost</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Cost per life-year saved (relative to no intervention)</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">No intervention</td><td align="center" rowspan="1" colspan="1">9,421</td><td align="center" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" rowspan="1" colspan="1">V+AVT</td><td align="center" rowspan="1" colspan="1">3,026</td><td align="center" rowspan="1" colspan="1">$2,581</td></tr><tr><td align="center" rowspan="1" colspan="1">V+AVT+AVP</td><td align="center" rowspan="1" colspan="1">2,801</td><td align="center" rowspan="1" colspan="1">$2,685</td></tr><tr><td align="center" rowspan="1" colspan="1">CCR+PPM+VI</td><td align="center" rowspan="1" colspan="1">1,767</td><td align="center" rowspan="1" colspan="1">$6,671</td></tr><tr><td align="center" rowspan="1" colspan="1">CCR+PPM+VI+AVT</td><td align="center" rowspan="1" colspan="1">1,607</td><td align="center" rowspan="1" colspan="1">$6,752</td></tr><tr><td align="center" rowspan="1" colspan="1">SC+CCR+PPM+Q</td><td align="center" rowspan="1" colspan="1">1,393</td><td align="center" rowspan="1" colspan="1">$260,472</td></tr><tr><td align="center" rowspan="1" colspan="1">All interventions</td><td align="center" rowspan="1" colspan="1">267</td><td align="center" rowspan="1" colspan="1">$199,888</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec019"><title>3.6 Sensitivity analysis</title><p>The sensitivity analyses detailed in <bold><xref ref-type="supplementary-material" rid="pone.0179315.s010">S9 Table</xref></bold> produced three main findings. First, personal protective measures, voluntary isolation, quarantine and vaccination all demonstrated a wide range of potential outcomes, depending on parameter assumptions. School closures, community-contact reduction, antiviral therapy and antiviral prophylaxis exhibited relatively little change between BG, WC and BC scenarios. Vaccination and personal protective measures showed particularly high sensitivity to shifting assumptions, with all six health outcome counts shifting over 100% between BC and WC scenarios.</p><p>Second, interventions to interrupt community transmission became less effective as transmissibility increased. As shown in <bold><xref ref-type="table" rid="pone.0179315.t013">Table 13</xref></bold>, all interventions produced a smaller reduction in the number of symptomatic cases relative to no intervention under a higher transmissibility parameter, though the order of interventions in terms of effectiveness did not change. The differential impact between BG, BC and WC intervention scenarios was also smaller at higher disease transmissibility, though a similar effect was not observed at a higher hospitalization rate.</p><table-wrap id="pone.0179315.t013" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0179315.t013</object-id><label>Table 13</label><caption><title>Percent (%) reduction in number of symptomatic cases, given influenza transmissibility parameter equivalent to R<sub>o</sub> of 1.65 or 1.80.</title></caption><alternatives><graphic id="pone.0179315.t013g" xlink:href="pone.0179315.t013"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="center" rowspan="2" style="background-color:#BFBFBF" colspan="1">Intervention</th><th align="center" colspan="2" style="background-color:#BFBFBF" rowspan="1">Transmissibility parameter (τ)</th></tr><tr><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">τ = 0.275</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">τ = 0.3</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><bold>SC</bold></td><td align="center" rowspan="1" colspan="1">-1.1</td><td align="center" rowspan="1" colspan="1">-0.8</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>CCR</bold></td><td align="center" rowspan="1" colspan="1">-0.6</td><td align="center" rowspan="1" colspan="1">-0.4</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>PPM</bold></td><td align="center" rowspan="1" colspan="1">-16.4</td><td align="center" rowspan="1" colspan="1">-8.8</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>VI</bold></td><td align="center" rowspan="1" colspan="1">-36.5</td><td align="center" rowspan="1" colspan="1">-27.5</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Q</bold></td><td align="center" rowspan="1" colspan="1">-37.7</td><td align="center" rowspan="1" colspan="1">-28.2</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>V</bold></td><td align="center" rowspan="1" colspan="1">-7.9</td><td align="center" rowspan="1" colspan="1">-6.1</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>AVT</bold></td><td align="center" rowspan="1" colspan="1">-0.2</td><td align="center" rowspan="1" colspan="1">-0.1</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>AVP</bold></td><td align="center" rowspan="1" colspan="1">-2.8</td><td align="center" rowspan="1" colspan="1">-0.9</td></tr></tbody></table></alternatives></table-wrap><p>Third, increasing the hospitalization rate had a much more dramatic effect on health outcomes than did increasing disease transmissibility. <bold><xref ref-type="table" rid="pone.0179315.t014">Table 14</xref></bold> presents the “no intervention” findings for the four scenarios. The higher transmissibility in Scenario 2 led to more infections, but only relatively small increases in mortality and hospital-resource use. The higher hospitalization rate in Scenario 3, however, led to large increases in predicted hospital resource demand and mortality relative to Scenario 1, despite having the same transmissibility and fewer symptomatic cases.</p><table-wrap id="pone.0179315.t014" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0179315.t014</object-id><label>Table 14</label><caption><title>Health outcome summaries for four pandemic scenarios [Scenario 1: τ = 0.275; hospitalization rate = 0.4%; Scenario 2: τ = 0.3; hospitalization rate = 0.4%; Scenario 3: τ = 0.275; hospitalization rate = 1.0%; Scenario 4: τ = 0.3; hospitalization rate = 1.0%].</title></caption><alternatives><graphic id="pone.0179315.t014g" xlink:href="pone.0179315.t014"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="center" rowspan="2" style="background-color:#BFBFBF" colspan="1">Outcome</th><th align="center" colspan="4" style="background-color:#BFBFBF" rowspan="1">Scenario</th></tr><tr><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">1</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">2</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">3</th><th align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">4</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Symptomatic cases</td><td align="center" rowspan="1" colspan="1">677,546</td><td align="center" rowspan="1" colspan="1">713,920</td><td align="center" rowspan="1" colspan="1">675,699</td><td align="center" rowspan="1" colspan="1">712,553</td></tr><tr><td align="center" rowspan="1" colspan="1">Hospitalizations</td><td align="center" rowspan="1" colspan="1">2,472</td><td align="center" rowspan="1" colspan="1">2,633</td><td align="center" rowspan="1" colspan="1">4,893</td><td align="center" rowspan="1" colspan="1">5,217</td></tr><tr><td align="center" rowspan="1" colspan="1">ICU</td><td align="center" rowspan="1" colspan="1">580</td><td align="center" rowspan="1" colspan="1">612</td><td align="center" rowspan="1" colspan="1">1,149</td><td align="center" rowspan="1" colspan="1">1,200</td></tr><tr><td align="center" rowspan="1" colspan="1">Peak hospital demand (%)</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">32</td></tr><tr><td align="center" rowspan="1" colspan="1">Peak ICU demand (%)</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">103</td><td align="center" rowspan="1" colspan="1">179</td><td align="center" rowspan="1" colspan="1">204</td></tr><tr><td align="center" rowspan="1" colspan="1">Deaths</td><td align="center" rowspan="1" colspan="1">363</td><td align="center" rowspan="1" colspan="1">400</td><td align="center" rowspan="1" colspan="1">717</td><td align="center" rowspan="1" colspan="1">791</td></tr></tbody></table></alternatives></table-wrap></sec></sec><sec id="sec020"><title>4. Discussion</title><p>The objective of this study was to assess the threat posed by the emergence of a novel, transmissible pandemic influenza strain, with respect to potential health and economic burdens. A key area of focus was the assessment of the adequacy of hospital-resource capacity to accommodate expected increases in patient demand, both in acute and intensive-care settings. To accomplish this, we developed and validated InFluNet, a novel mathematical model, which incorporates stochastic elements to account for uncertainty in disease transmission dynamics.</p><p>Using a simulated population representative of the Ottawa–Gatineau CMA, we suggest that the timely implementation of a layered, multi-pronged intervention strategy will effectively control pandemic transmission and protect hospital resource adequacy. However, even aggressive intervention simulations produced illness attack rates over 10% and over 100 deaths. The economic burden is expected to be high, estimated between CAD $115 and $405 million, with costs rising into the billions when extended school closure is implemented. Our model suggests that the most cost-effective approach to pandemic control is early pandemic vaccination combined with antiviral therapy and prophylaxis. However, a review of the results from all 192 scenarios (<bold><xref ref-type="supplementary-material" rid="pone.0179315.s003">S2</xref>–<xref ref-type="supplementary-material" rid="pone.0179315.s008">S7</xref> Tables</bold>) showed a steep diminishing return on investment associated with the addition of antiviral treatment and prophylaxis to an effective vaccination campaign, suggesting that much of the cost-effectiveness of pharmaceutical interventions is driven by strong vaccination campaigns. In situations where vaccines may be unavailable or in short supply, a combination of community-contact reduction, personal protective measures, voluntary isolation and antiviral therapy was also found to be highly cost-effective. However, our estimates did not account for the potential costs of community-contact reduction, which may include shifts in consumer behaviour.</p><p>Vaccination, personal protective measures and isolation of infected individuals were found to be the most effective interventions, whereas school closure, community-contact reduction, antiviral therapy and antiviral prophylaxis had less effect on pandemic burden. Sensitivity analysis suggested that the most effective interventions were also those most susceptible to change under shifting assumptions of effectiveness, adherence and timing. All interventions became less effective in limiting transmission as disease transmissibility increased. In all cases, delayed interventions were significantly less effective than cases in which the intervention was implemented from the start of the simulation, suggesting the need for strong and proactive preparedness planning. Sensitivity analysis also suggested that a more virulent strain, with a higher hospitalization rate, is of greater concern than a more transmissible one, with a hospitalization rate of 1% threatening to overwhelm hospital resource capacity even under moderate transmissibility assumptions.</p><p>Pharmaceutical and non-pharmaceutical interventions resulted in different effects on the evolution and progression of the pandemic. While pharmaceutical interventions did little to alter the location of transmission events or age-specific burden, non-pharmaceutical interventions tended to redistribute more transmission events to the household and community, as well as to younger age groups. This may be because we did not model age-specific targeting of pharmaceutical interventions and assumed that young adults and adults had a higher community-contact rate than did other age groups; as a result, community-contact reduction and voluntary isolation seemed to disproportionately benefit these age groups.</p><p>A common simplification in modelling studies is the assumption of homogenous mixing, wherein individuals are assumed to interact equally across age and geographic groups [<xref rid="pone.0179315.ref096" ref-type="bibr">96</xref>]. This is problematic, as it can overestimate the final pandemic size, leading to unrealistic predictions of hospital-resource strain and the scale of intervention required for transmission containment [<xref rid="pone.0179315.ref041" ref-type="bibr">41</xref>, <xref rid="pone.0179315.ref097" ref-type="bibr">97</xref>]. Further, it precludes analysis of particular interventions targeted towards specific age groups, such as vaccination campaigns prioritizing children or the elderly. To avoid this, InFluNet models a two-layered system of heterogeneous mixing, wherein individuals in different age groups interact at different rates depending on their location, reflecting the age- and location-dependent forces that will influence disease transmission rates.</p><p>Our vaccination simulations assumed that a well-matched pandemic vaccine would be available at the onset of the pandemic; this may represent an unlikely scenario, as vaccine production, development and distribution can take over six months [<xref rid="pone.0179315.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0179315.ref031" ref-type="bibr">31</xref>]. However, we included this intervention as a means of evaluating the impact of the intervention were it to be available. It should also be noted that logistical challenges, vaccine hesitancy and limited stockpiles of consumables can further constrain the achievement of optimal coverage levels. The effectiveness of timely vaccination suggests value in strengthening international collaboration with regard to surveillance and sharing of circulating influenza strains. Also, by assuming that older age groups maintain some immunity to the pandemic strain, we are modelling the emergence of a pandemic strain that is not entirely novel: this reflects the experience of the past four pandemics but could underestimate population susceptibility to an entirely novel strain, such as an avian influenza. It should also be noted that antiviral prophylaxis may only be available in the early stages of an outbreak, after which contract tracing may become infeasible [<xref rid="pone.0179315.ref030" ref-type="bibr">30</xref>]; we do not account for this in our model.</p><p>Pharmaceutical interventions tended to reduce the overall burden of the pandemic without affecting its timing. Non-pharmaceutical interventions, by contrast, tended to delay the development of the pandemic to an extent that the pandemic was not completed after 100 days. We used 100 days as the upper limit of pandemic-wave duration, but such containment of transmission could lead to either a prolonged wave or more severe second wave. This is because pharmaceutical measures contribute to shifting the susceptibility profile of a population, whereas non-pharmaceutical measures contain transmission without affecting the population profile. As a result, if non-pharmaceutical measures are retracted prematurely, there is the risk of disease re-emergence.</p><p>The present study is subject to certain limitations. First, we do not account for possible adverse side effects from pharmaceutical interventions, which may marginally reduce the health benefit of mass vaccination [<xref rid="pone.0179315.ref033" ref-type="bibr">33</xref>] and antiviral prophylaxis [<xref rid="pone.0179315.ref098" ref-type="bibr">98</xref>]. We assumed that these associated risks would be insignificant in the context of other unavoidable uncertainties in model assumptions.</p><p>Second, we treat the entire CMA as a single homogenous area. While individuals are likely to mix preferentially in neighbourhood and workplace pockets, we decided that the most effective method of evaluating macro-level threats to the community and health system would be to treat the CMA as a single unit.</p><p>Third, we have excluded analysis of preferential targeting of at-risk individuals—and associated ethical considerations—as outside the scope of this analysis, prioritizing instead an assessment of community-level practices to control pandemic burden.</p><p>Fourth, we do not include every conceivable intervention, excluding for example hospital triage protocols and influenza helplines. Hospital triage and influenza helplines were excluded because we view their main benefit as being a reduction in unnecessary hospital visitation, and our hospitalization rate already assumed that only those needing hospitalization would be admitted. However, we note that triage protocols could increase the proportion of individuals—especially seniors—that die outside of hospital settings. We also did not model nosocomial infection and therefore did not examine the value of hospital-infection control practices.</p><p>Fifth, we chose to model social-contact behaviour based upon empirical data from the United States, as none were available in Canadian contexts. While this may skew our estimates slightly, similar contact-rate assumptions in previous modelling studies of the mid-sized Ontario cities London [<xref rid="pone.0179315.ref039" ref-type="bibr">39</xref>] and Hamilton [<xref rid="pone.0179315.ref033" ref-type="bibr">33</xref>] suggest that the same contact structure would apply in Ottawa.</p><p>Sixth, while agent-models (ABMs) are more effective at modelling the stochasticity inherent in disease transmission, the decision was made to pursue a differential equation models (DEMs). ABM models require a large computational burden and, given the number of InFluNet compartments alongside the age-specific and location-specific transmission dynamics, an ABM would have obstructed the depth of analysis, limited sensitivity analysis and impeded its uptake among public-health practitioners with limited modelling training [<xref rid="pone.0179315.ref099" ref-type="bibr">99</xref>]. As a secondary objective of this project was to construct a model that was scalable to different populations and accessible to policy audiences, and considering the output differences between DEMs and ABMs are small within the larger scope of parameter uncertainty, we chose to construct a DEM.</p><p>Lastly, as with all prospective mathematical models, InFluNet is subject to a high degree of uncertainty; this is particularly true in our case, where a high level of analytical complexity necessitates numerous assumptions relating to disease and intervention characteristics. We therefore emphasize that the results of our model should be interpreted with caution and are best interpreted as general patterns of intervention effectiveness rather than specific predictions of the number of likely cases, hospitalizations and deaths. Future research can add to this analysis through in-depth assessment of targeted interventions, based on age or risk profile and evaluation of other communities to assess community characteristics that may lead to higher pandemic burdens and strain on health system capacity.</p><p>The strength of InFluNet is its incorporation of empirical social contact, disease and intervention data to chart pandemic progression against real-world hospital-capacity data. It also allows the most complex analysis of mitigation strategies, helping to inform pandemic preparedness planning in both community and hospital settings. We are aware of no other mathematical models that incorporated such diverse intervention bundles alongside our broad range of health and economic endpoints. The results of this initial analysis suggest that the hospital capacity of the Ottawa–Gatineau region will be adequate to accommodate a transmissible but mild pandemic influenza under most intervention strategies but that it could quickly become overwhelmed by a more virulent strain.</p></sec><sec id="sec021"><title>5. Conclusion</title><p>This study provides valuable new insights in pandemic preparedness, presenting a novel model of pandemic transmission as it relates to health and economic outcomes and hospital-surge capacity. Our analysis suggests that personal protective measures, isolation of infected individuals and vaccination are most effective at containing pandemic transmission. Even in situations where vaccines are unavailable, a layered approach incorporating the timely implementation of multiple non-pharmaceutical interventions is likely to effectively contain pandemic transmission and maintain the adequacy of hospital resource capacity in the Ottawa–Gatineau area. However, we found that even small increases in disease transmissibility or virulence constitute a significant threat, both in terms of surges in patient demand and overall burden. Given the need for timely interventions, future studies are needed to assess optimal intervention strategies under a broad range of disease, intervention, population and resource assumptions.</p></sec><sec sec-type="supplementary-material" id="sec022"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0179315.s001"><label>S1 File</label><caption><title>InFluNet model description.</title><p>(PDF)</p></caption><media xlink:href="pone.0179315.s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0179315.s002"><label>S1 Table</label><caption><title>Ottawa–Gatineau CMA profile.</title><p>(PDF)</p></caption><media xlink:href="pone.0179315.s002.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0179315.s003"><label>S2 Table</label><caption><title>Results of Basic Analysis: Symptomatic infection.</title><p>(PDF)</p></caption><media xlink:href="pone.0179315.s003.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0179315.s004"><label>S3 Table</label><caption><title>Results of Basic Analysis: Acute care hospital admissions.</title><p>(PDF)</p></caption><media xlink:href="pone.0179315.s004.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0179315.s005"><label>S4 Table</label><caption><title>Results of Basic Analysis: Peak acute care hospitalization demand.</title><p>(PDF)</p></caption><media xlink:href="pone.0179315.s005.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0179315.s006"><label>S5 Table</label><caption><title>Results of Basic Analysis: Intensive care unit admissions.</title><p>(PDF)</p></caption><media xlink:href="pone.0179315.s006.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0179315.s007"><label>S6 Table</label><caption><title>Results of Basic Analysis: Peak ICU demand.</title><p>(PDF)</p></caption><media xlink:href="pone.0179315.s007.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0179315.s008"><label>S7 Table</label><caption><title>Results of Basic Analysis: Mortality.</title><p>(PDF)</p></caption><media xlink:href="pone.0179315.s008.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0179315.s009"><label>S8 Table</label><caption><title>Economic analyses for seven intervention bundles of interest.</title><p>(PDF)</p></caption><media xlink:href="pone.0179315.s009.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0179315.s010"><label>S9 Table</label><caption><title>Results of sensitivity analysis.</title><p>(PDF)</p></caption><media xlink:href="pone.0179315.s010.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors thank Lindy Samson for her comments on the manuscript draft. They also thank Doug Coyle and Mike Sawada for their respective comments on the economic analysis and mapping components of the project. For citation purposes, please note that the question mark in “Smith?” is part of the author’s name.</p></ack><ref-list><title>References</title><ref id="pone.0179315.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Kuszewski</surname><given-names>K</given-names></name>, <name><surname>Brydak</surname><given-names>L</given-names></name>. <article-title>The epidemiology and history of influenza</article-title>. <source>Biomedicine and Pharmacotherapy</source>. <year>2000</year>;<volume>54</volume>(<issue>4</issue>):<fpage>188</fpage>–<lpage>95</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0753-3322(00)89025-3">10.1016/S0753-3322(00)89025-3</ext-link></comment><pub-id pub-id-type="pmid">10872717</pub-id></mixed-citation></ref><ref id="pone.0179315.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Lau</surname><given-names>JTF</given-names></name>, <name><surname>Griffiths</surname><given-names>S</given-names></name>, <name><surname>Choi</surname><given-names>K</given-names></name>, <name><surname>Lin</surname><given-names>C</given-names></name>. <article-title>Prevalence of preventive behaviors and associated factors during early phase of the H1N1 influenza epidemic</article-title>. <source>American Journal of Infection Control</source>. <year>2010</year>;<volume>38</volume>(<issue>i5</issue>):<fpage>374</fpage>–<lpage>80</lpage> 7p. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ajic.2010.03.002">10.1016/j.ajic.2010.03.002</ext-link></comment> . Language: English. Entry Date: 20100813. Revision Date: 20150819. Publication Type: Journal Article.<pub-id pub-id-type="pmid">20569849</pub-id></mixed-citation></ref><ref id="pone.0179315.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Fiore</surname><given-names>A</given-names></name>, <name><surname>Shay</surname><given-names>D</given-names></name>, <name><surname>Broder</surname><given-names>K</given-names></name>, <name><surname>Iskander</surname><given-names>J</given-names></name>, <name><surname>Uyeki</surname><given-names>T</given-names></name>, <name><surname>Mootrey</surname><given-names>G</given-names></name>, <etal>et al</etal><article-title>Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008</article-title>. <source>Morbidity and Mortality Weekly Report</source>. <year>2008</year>;<volume>57</volume>:<fpage>1</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">18185492</pub-id></mixed-citation></ref><ref id="pone.0179315.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>K</given-names></name>. <article-title>Concern as revived 1918 flu virus kills monkeys</article-title>. <source>Nature</source>. <year>2007</year>;<volume>445</volume>(<issue>7125</issue>):<fpage>237</fpage>-. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/445237a">10.1038/445237a</ext-link></comment><pub-id pub-id-type="pmid">17230157</pub-id></mixed-citation></ref><ref id="pone.0179315.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Thompson</surname><given-names>M</given-names></name>, <name><surname>Shay</surname><given-names>D</given-names></name>, <name><surname>Zhou</surname><given-names>H</given-names></name>, <name><surname>Bridges</surname><given-names>C</given-names></name>, <name><surname>Cheng</surname><given-names>P</given-names></name>, <name><surname>Burns</surname><given-names>E</given-names></name>, <etal>et al</etal><article-title>Updated estimates of mortality associated with seasonal influenza through the 2006–2007 influenza season</article-title>. <source>MMWR</source>. <year>2010</year>;<volume>59</volume>(<issue>33</issue>):<fpage>1057</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">20798667</pub-id></mixed-citation></ref><ref id="pone.0179315.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Schanzer</surname><given-names>DL</given-names></name>, <name><surname>McGeer</surname><given-names>A</given-names></name>, <name><surname>Morris</surname><given-names>K</given-names></name>. <article-title>Statistical estimates of respiratory admissions attributable to seasonal and pandemic influenza for Canada</article-title>. <source>Influenza and other respiratory viruses</source>. <year>2013</year>;<volume>7</volume>(<issue>5</issue>):<fpage>799</fpage>–<lpage>808</lpage>. Epub 2012/11/06. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/irv.12011">10.1111/irv.12011</ext-link></comment> ; PubMed Central PMCID: PMCPMC3796862.<pub-id pub-id-type="pmid">23122189</pub-id></mixed-citation></ref><ref id="pone.0179315.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Schanzer</surname><given-names>DL</given-names></name>, <name><surname>Sevenhuysen</surname><given-names>C</given-names></name>, <name><surname>Winchester</surname><given-names>B</given-names></name>, <name><surname>Mersereau</surname><given-names>T</given-names></name><article-title>. Estimating influenza deaths in Canada, 1992–2009</article-title>. <source>PloS one</source>. <year>2013</year>;<volume>8</volume>(<issue>11</issue>):<fpage>e80481</fpage> Epub 2013/12/07. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0080481">10.1371/journal.pone.0080481</ext-link></comment> ; PubMed Central PMCID: PMCPMC3842334.<pub-id pub-id-type="pmid">24312225</pub-id></mixed-citation></ref><ref id="pone.0179315.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Zambon</surname><given-names>M</given-names></name>. <article-title>Epidemiology and pathogenesis of influenza</article-title>. <source>Journal of Antimicrobial Chemotherapy</source>. <year>1999</year>;<volume>44</volume>:<fpage>3</fpage>–<lpage>9</lpage>.</mixed-citation></ref><ref id="pone.0179315.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Guan</surname><given-names>Y</given-names></name>, <name><surname>Vijaykrishna</surname><given-names>D</given-names></name>, <name><surname>Bahl</surname><given-names>J</given-names></name>, <name><surname>Zhu</surname><given-names>H</given-names></name>, <name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Smith</surname><given-names>GJ</given-names></name>. <article-title>The emergence of pandemic influenza viruses</article-title>. <source>Protein Cell</source>. <year>2010</year>;<volume>1</volume>(<issue>1</issue>):<fpage>9</fpage>–<lpage>13</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s13238-010-0008-z">10.1007/s13238-010-0008-z</ext-link></comment> .<pub-id pub-id-type="pmid">21203993</pub-id></mixed-citation></ref><ref id="pone.0179315.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Henderson</surname><given-names>D</given-names></name>, <name><surname>Courtney</surname><given-names>B</given-names></name>, <name><surname>Inglesby</surname><given-names>T</given-names></name>, <name><surname>Toner</surname><given-names>E</given-names></name>, <name><surname>Nuzzo</surname><given-names>J</given-names></name>. <article-title>Public health and medical responses to the 1957–58 influenza pandemic. Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and</article-title><source>Science</source>. <year>2009</year>;<volume>7</volume>(<issue>3</issue>):<fpage>265</fpage>–<lpage>73</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1089/bsp.2009.0729">10.1089/bsp.2009.0729</ext-link></comment><pub-id pub-id-type="pmid">19656012</pub-id></mixed-citation></ref><ref id="pone.0179315.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Humphries</surname><given-names>M</given-names></name>. <article-title>Paths of infection: The First World War and the origins of the 1918 influenza pandemic</article-title>. <source>War in History</source>. <year>2013</year>;<volume>21</volume>(<issue>1</issue>):<fpage>55</fpage>–<lpage>81</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1177/0968344513504525">10.1177/0968344513504525</ext-link></comment></mixed-citation></ref><ref id="pone.0179315.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Simonsen</surname><given-names>L</given-names></name>, <name><surname>Spreeuwenberg</surname><given-names>P</given-names></name>, <name><surname>Lustig</surname><given-names>R</given-names></name>, <name><surname>Taylor</surname><given-names>RJ</given-names></name>, <name><surname>Fleming</surname><given-names>DM</given-names></name>, <name><surname>Kroneman</surname><given-names>M</given-names></name>, <etal>et al</etal><article-title>Global Mortality Estimates for the 2009 Influenza Pandemic from the GLaMOR Project: A Modeling Study</article-title>. <source>PLoS Med</source>. <year>2013</year>;<volume>10</volume>(<issue>11</issue>):<fpage>e1001558</fpage><comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pmed.1001558">10.1371/journal.pmed.1001558</ext-link></comment><pub-id pub-id-type="pmid">24302890</pub-id></mixed-citation></ref><ref id="pone.0179315.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Saunders-Hastings</surname><given-names>P</given-names></name>, <name><surname>Krewski</surname><given-names>D</given-names></name>. <article-title>Reviewing the History of Pandemic Influenza: Understanding Patterns of Emergence and Transmission</article-title>. <source>Pathogens</source>. <year>2016</year>;<volume>5</volume>(<issue>66</issue>).</mixed-citation></ref><ref id="pone.0179315.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Dawood</surname><given-names>F</given-names></name>, <name><surname>Luliano</surname><given-names>D</given-names></name>, <name><surname>Reed</surname><given-names>C</given-names></name>, <name><surname>Meltzer</surname><given-names>M</given-names></name>, <name><surname>Shay</surname><given-names>D</given-names></name>, <name><surname>Cheng</surname><given-names>P</given-names></name>, <etal>et al</etal><article-title>Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study</article-title>. <source>The Lancet Infectious Diseases</source>. <year>2012</year>;<volume>12</volume>(<issue>9</issue>):<fpage>687</fpage>–<lpage>85</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1473-3099(12)70121-4">10.1016/S1473-3099(12)70121-4</ext-link></comment><pub-id pub-id-type="pmid">22738893</pub-id></mixed-citation></ref><ref id="pone.0179315.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>House</surname><given-names>T</given-names></name>, <name><surname>Baguelin</surname><given-names>M</given-names></name>, <name><surname>Van Hoek</surname><given-names>AJ</given-names></name>, <name><surname>White</surname><given-names>PJ</given-names></name>, <name><surname>Sadique</surname><given-names>Z</given-names></name>, <name><surname>Eames</surname><given-names>K</given-names></name>, <etal>et al</etal><article-title>Modelling the impact of local reactive school closures on critical care provision during an influenza pandemic</article-title>. <source>Proc Biol Sci</source>. <year>2011</year>;<volume>278</volume>(<issue>1719</issue>):<fpage>2753</fpage>–<lpage>60</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1098/rspb.2010.2688">10.1098/rspb.2010.2688</ext-link></comment> ; PubMed Central PMCID: PMCPMC3145187.<pub-id pub-id-type="pmid">21288945</pub-id></mixed-citation></ref><ref id="pone.0179315.ref016"><label>16</label><mixed-citation publication-type="other">Madhav N. Modelling a modern-day spanish flu pandemic. 2013.</mixed-citation></ref><ref id="pone.0179315.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Daly</surname><given-names>P</given-names></name>, <name><surname>Gustafson</surname><given-names>R</given-names></name>, <name><surname>Kendall</surname><given-names>P</given-names></name>. <article-title>Introduction to pandemic influenza</article-title>. <source>BC Medical Journal</source>. <year>2007</year>;<volume>49</volume>(<issue>5</issue>):<fpage>240</fpage>–<lpage>4</lpage>.</mixed-citation></ref><ref id="pone.0179315.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Potter</surname><given-names>C</given-names></name>. <article-title>A history of influenza</article-title>. <source>Journal of Applied Microbiology</source>. <year>2001</year>;<volume>91</volume>:<fpage>572</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="pmid">11576290</pub-id></mixed-citation></ref><ref id="pone.0179315.ref019"><label>19</label><mixed-citation publication-type="other">Garfors G. 100,000 flights a day 2014 [cited 2016 April 7]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.garfors.com/2014/06/100000-flights-day.html">http://www.garfors.com/2014/06/100000-flights-day.html</ext-link>.</mixed-citation></ref><ref id="pone.0179315.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Horimoto</surname><given-names>T</given-names></name>, <name><surname>Kawaoka</surname><given-names>Y</given-names></name>. <article-title>Influenza: lessons from past pandemics, warnings from current incidents</article-title>. <source>Nat Rev Micro</source>. <year>2005</year>;<volume>3</volume>(<issue>8</issue>):<fpage>591</fpage>–<lpage>600</lpage>.</mixed-citation></ref><ref id="pone.0179315.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Myers</surname><given-names>KP</given-names></name>, <name><surname>Olsen</surname><given-names>CW</given-names></name>, <name><surname>Gray</surname><given-names>GC</given-names></name>. <article-title>Cases of swine influenza in humans: A review of the literature</article-title>. <source>Clinical Infectious Diseases</source>. <year>2007</year>;<volume>44</volume>(<issue>8</issue>):<fpage>1084</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1086/512813">10.1086/512813</ext-link></comment><pub-id pub-id-type="pmid">17366454</pub-id></mixed-citation></ref><ref id="pone.0179315.ref022"><label>22</label><mixed-citation publication-type="book"><name><surname>Reperant</surname><given-names>LA</given-names></name>, <name><surname>Osterhaus</surname><given-names>AD</given-names></name>. <chapter-title>Influenza in birds and mammals</chapter-title> In: <name><surname>Van-Tam</surname><given-names>J</given-names></name>, <name><surname>Sellwood</surname><given-names>C</given-names></name>, editors. <source>Pandemic Influenza</source>. <publisher-loc>Boston, MA</publisher-loc>: <publisher-name>CAB International</publisher-name>; <year>2013</year> p. <fpage>31</fpage>–<lpage>9</lpage>.</mixed-citation></ref><ref id="pone.0179315.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Wan</surname><given-names>X-F</given-names></name>, <name><surname>Dong</surname><given-names>L</given-names></name>, <name><surname>Lan</surname><given-names>Y</given-names></name>, <name><surname>Long</surname><given-names>L-P</given-names></name>, <name><surname>Xu</surname><given-names>C</given-names></name>, <name><surname>Zou</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>Indications that Live Poultry Markets Are a Major Source of Human H5N1 Influenza Virus Infection in China</article-title>. <source>Journal of Virology</source>. <year>2011</year>;<volume>85</volume>(<issue>24</issue>):<fpage>13432</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JVI.05266-11">10.1128/JVI.05266-11</ext-link></comment><pub-id pub-id-type="pmid">21976646</pub-id></mixed-citation></ref><ref id="pone.0179315.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Watson</surname><given-names>SJ</given-names></name>, <name><surname>Langat</surname><given-names>P</given-names></name>, <name><surname>Reid</surname><given-names>SM</given-names></name>, <name><surname>Lam</surname><given-names>TT-Y</given-names></name>, <name><surname>Cotten</surname><given-names>M</given-names></name>, <name><surname>Kelly</surname><given-names>M</given-names></name>, <etal>et al</etal><article-title>Molecular Epidemiology and Evolution of Influenza Viruses Circulating within European Swine between 2009 and 2013</article-title>. <source>Journal of Virology</source>. <year>2015</year>;<volume>89</volume>(<issue>19</issue>):<fpage>9920</fpage>–<lpage>31</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JVI.00840-15">10.1128/JVI.00840-15</ext-link></comment> .<pub-id pub-id-type="pmid">26202246</pub-id></mixed-citation></ref><ref id="pone.0179315.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Tuite</surname><given-names>AR</given-names></name>, <name><surname>Fisman</surname><given-names>DN</given-names></name>, <name><surname>Kwong</surname><given-names>JC</given-names></name>, <name><surname>Greer</surname><given-names>AL</given-names></name>. <article-title>Optimal pandemic influenza vaccine allocation strategies for the Canadian population</article-title>. <source>PloS one</source>. <year>2010</year>;<volume>5</volume>(<issue>5</issue>):<fpage>e10520</fpage><comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0010520">10.1371/journal.pone.0010520</ext-link></comment> ; PubMed Central PMCID: PMCPMC2865540.<pub-id pub-id-type="pmid">20463898</pub-id></mixed-citation></ref><ref id="pone.0179315.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Coburn</surname><given-names>B</given-names></name>, <name><surname>Wagner</surname><given-names>B</given-names></name>, <name><surname>Blower</surname><given-names>S</given-names></name>. <article-title>Modeling Influenza epidemics and pandemics: insights into the future of swine flu (H1N1)</article-title>. <source>BMC Medicine</source>. <year>2009</year>;<volume>7</volume>(<issue>30</issue>). <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1741-7015-7-30">10.1186/1741-7015-7-30</ext-link></comment><pub-id pub-id-type="pmid">19545404</pub-id></mixed-citation></ref><ref id="pone.0179315.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Arino</surname><given-names>J</given-names></name>, <name><surname>Brauer</surname><given-names>F</given-names></name>, <name><surname>Driessche</surname><given-names>P</given-names></name>, <name><surname>Watmough</surname><given-names>J</given-names></name>, <name><surname>Wu</surname><given-names>J</given-names></name>. <article-title>Simple models for containment of a pandemic</article-title>. <source>The Royal Society Interface</source>. <year>2006</year>;<volume>3</volume>:<fpage>453</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1098/rsif.2006.0112">10.1098/rsif.2006.0112</ext-link></comment><pub-id pub-id-type="pmid">16849273</pub-id></mixed-citation></ref><ref id="pone.0179315.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Wallinga</surname><given-names>J</given-names></name>, <name><surname>Lipsitch</surname><given-names>M</given-names></name>. <article-title>How generation intervals shape the relationship between growth rates and reproductive numbers. Proceedings of the Royal Society B</article-title>: <source>Biological Sciences</source>. <year>2007</year>;<volume>274</volume>(<issue>1609</issue>):<fpage>599</fpage>–<lpage>604</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1098/rspb.2006.3754">10.1098/rspb.2006.3754</ext-link></comment><pub-id pub-id-type="pmid">17476782</pub-id></mixed-citation></ref><ref id="pone.0179315.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Carrasco</surname><given-names>L</given-names></name>, <name><surname>Jit</surname><given-names>M</given-names></name>, <name><surname>Chen</surname><given-names>M</given-names></name>, <name><surname>Lee</surname><given-names>V</given-names></name>, <name><surname>Milne</surname><given-names>G</given-names></name>, <name><surname>Cook</surname><given-names>A</given-names></name>. <article-title>Trends in parameterization, economics and host behaviour in influenza pandemic modelling: a review and reporting protocol</article-title>. <source>Emerging Themes in Epidemiology</source>. <year>2013</year>;<volume>10</volume>(<issue>3</issue>). <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1742-7622-10-3">10.1186/1742-7622-10-3</ext-link></comment><pub-id pub-id-type="pmid">23651557</pub-id></mixed-citation></ref><ref id="pone.0179315.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Germann</surname><given-names>TC</given-names></name>, <name><surname>Kadau</surname><given-names>K</given-names></name>, <name><surname>Longini</surname><given-names>IM</given-names></name>., <name><surname>Macken</surname><given-names>CA</given-names></name><article-title>. Mitigation strategies for pandemic influenza in the United States</article-title>. <source>Proceedings of the National Academy of Sciences USA</source>. <year>2006</year>;<volume>103</volume>(<issue>15</issue>):<fpage>5935</fpage>–<lpage>40</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.0601266103">10.1073/pnas.0601266103</ext-link></comment> ; PubMed Central PMCID: PMCPMC1458676.<pub-id pub-id-type="pmid">16585506</pub-id></mixed-citation></ref><ref id="pone.0179315.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Longini</surname><given-names>I</given-names></name>, <name><surname>Halloran</surname><given-names>ME</given-names></name>, <name><surname>Nizam</surname><given-names>A</given-names></name>, <name><surname>Yang</surname><given-names>Y</given-names></name>. <article-title>Containing pandemic influenza with antiviral agents</article-title>. <source>American Journal of Epidemiology</source>. <year>2004</year>;<volume>159</volume>:<fpage>623</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="pmid">15033640</pub-id></mixed-citation></ref><ref id="pone.0179315.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Longini</surname><given-names>I</given-names></name>, <name><surname>Nizam</surname><given-names>A</given-names></name>, <name><surname>Xu</surname><given-names>S</given-names></name>, <name><surname>Ungchusak</surname><given-names>K</given-names></name>, <name><surname>Hanshaoworakul</surname><given-names>W</given-names></name>, <name><surname>Cummings</surname><given-names>DA</given-names></name>, <etal>et al</etal><article-title>Containing Pandemic Influenza at the source</article-title>. <source>Science</source>. <year>2005</year>;<volume>309</volume>:<fpage>1083</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.1115717">10.1126/science.1115717</ext-link></comment><pub-id pub-id-type="pmid">16079251</pub-id></mixed-citation></ref><ref id="pone.0179315.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Andradottir</surname><given-names>S</given-names></name>, <name><surname>Chiu</surname><given-names>W</given-names></name>, <name><surname>Goldsman</surname><given-names>D</given-names></name>, <name><surname>Lee</surname><given-names>ML</given-names></name>, <name><surname>Tsui</surname><given-names>KL</given-names></name>, <name><surname>Sander</surname><given-names>B</given-names></name>, <etal>et al</etal><article-title>Reactive strategies for containing developing outbreaks of pandemic influenza</article-title>. <source>BMC public health</source>. <year>2011</year>;<volume>11</volume><issue>Suppl 1</issue>:<fpage>S1</fpage><comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1471-2458-11-S1-S1">10.1186/1471-2458-11-S1-S1</ext-link></comment> ; PubMed Central PMCID: PMCPMC3317583.<pub-id pub-id-type="pmid">21356128</pub-id></mixed-citation></ref><ref id="pone.0179315.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Halloran</surname><given-names>ME</given-names></name>, <name><surname>Ferguson</surname><given-names>NM</given-names></name>, <name><surname>Eubank</surname><given-names>S</given-names></name>, <name><surname>Longini</surname><given-names>IM</given-names></name>., <name><surname>Cummings</surname><given-names>DA</given-names></name>, <name><surname>Lewis</surname><given-names>B</given-names></name>, <etal>et al</etal><article-title>Modeling targeted layered containment of an influenza pandemic in the United States</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>. <year>2008</year>;<volume>105</volume>(<issue>12</issue>):<fpage>4639</fpage>–<lpage>44</lpage>. Epub 2008/03/12. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.0706849105">10.1073/pnas.0706849105</ext-link></comment> ; PubMed Central PMCID: PMCPmc2290797.<pub-id pub-id-type="pmid">18332436</pub-id></mixed-citation></ref><ref id="pone.0179315.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>Y</given-names></name>, <name><surname>Sugimoto</surname><given-names>JD</given-names></name>, <name><surname>Halloran</surname><given-names>ME</given-names></name>, <name><surname>Basta</surname><given-names>NE</given-names></name>, <name><surname>Chao</surname><given-names>DL</given-names></name>, <name><surname>Matrajt</surname><given-names>L</given-names></name>, <etal>et al</etal><article-title>The transmissibility and control of pandemic influenza A (H1N1) virus</article-title>. <source>Science</source>. <year>2009</year>;<volume>326</volume>(<issue>5953</issue>):<fpage>729</fpage>–<lpage>33</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.1177373">10.1126/science.1177373</ext-link></comment> ; PubMed Central PMCID: PMCPMC2880578.<pub-id pub-id-type="pmid">19745114</pub-id></mixed-citation></ref><ref id="pone.0179315.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Chao</surname><given-names>DL</given-names></name>, <name><surname>Halloran</surname><given-names>ME</given-names></name>, <name><surname>Obenchain</surname><given-names>VJ</given-names></name>, <name><surname>Longini</surname><given-names>IM</given-names></name>. <article-title>FluTE, a publicly available stochastic influenza epidemic simulation model</article-title>. <source>PLoS computational biology</source>. <year>2010</year>;<volume>6</volume>(<issue>1</issue>):<fpage>e1000656</fpage><comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pcbi.1000656">10.1371/journal.pcbi.1000656</ext-link></comment> ; PubMed Central PMCID: PMCPMC2813259.<pub-id pub-id-type="pmid">20126529</pub-id></mixed-citation></ref><ref id="pone.0179315.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Chao</surname><given-names>DL</given-names></name>, <name><surname>Matrajt</surname><given-names>L</given-names></name>, <name><surname>Basta</surname><given-names>NE</given-names></name>, <name><surname>Sugimoto</surname><given-names>JD</given-names></name>, <name><surname>Dean</surname><given-names>B</given-names></name>, <name><surname>Bagwell</surname><given-names>DA</given-names></name>, <etal>et al</etal><article-title>Planning for the control of pandemic influenza A (H1N1) in Los Angeles County and the United States</article-title>. <source>American Journal of Epidemiology</source>. <year>2011</year>;<volume>173</volume>(<issue>10</issue>):<fpage>1121</fpage>–<lpage>30</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/aje/kwq497">10.1093/aje/kwq497</ext-link></comment> ; PubMed Central PMCID: PMCPMC3121321.<pub-id pub-id-type="pmid">21427173</pub-id></mixed-citation></ref><ref id="pone.0179315.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Del Valle</surname><given-names>SY</given-names></name>, <name><surname>Hyman</surname><given-names>JM</given-names></name>, <name><surname>Hethcote</surname><given-names>HW</given-names></name>, <name><surname>Eubank</surname><given-names>SG</given-names></name>. <article-title>Mixing patterns between age groups in social networks</article-title>. <source>Social Networks</source>. <year>2007</year>;<volume>29</volume>(<issue>4</issue>):<fpage>539</fpage>–<lpage>54</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.socnet.2007.04.005">10.1016/j.socnet.2007.04.005</ext-link></comment></mixed-citation></ref><ref id="pone.0179315.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Gojovic</surname><given-names>MZ</given-names></name>, <name><surname>Sander</surname><given-names>B</given-names></name>, <name><surname>Fisman</surname><given-names>D</given-names></name>, <name><surname>Krahn</surname><given-names>MD</given-names></name>, <name><surname>Bauch</surname><given-names>CT</given-names></name>. <article-title>Modelling mitigation strategies for pandemic (H1N1) 2009</article-title>. <source>CMAJ</source>. <year>2009</year>;<volume>181</volume>(<issue>10</issue>):<fpage>673</fpage>–<lpage>80</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1503/cmaj.091641">10.1503/cmaj.091641</ext-link></comment> ; PubMed Central PMCID: PMCPMC2774362.<pub-id pub-id-type="pmid">19825923</pub-id></mixed-citation></ref><ref id="pone.0179315.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Basta</surname><given-names>NE</given-names></name>, <name><surname>Chao</surname><given-names>DL</given-names></name>, <name><surname>Halloran</surname><given-names>ME</given-names></name>, <name><surname>Matrajt</surname><given-names>L</given-names></name>, <name><surname>Longini</surname><given-names>IM</given-names></name>. <article-title>Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States</article-title>. <source>Am J Epidemiol</source>. <year>2009</year>;<volume>170</volume>(<issue>6</issue>):<fpage>679</fpage>–<lpage>86</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/aje/kwp237">10.1093/aje/kwp237</ext-link></comment> ; PubMed Central PMCID: PMCPMC2737588.<pub-id pub-id-type="pmid">19679750</pub-id></mixed-citation></ref><ref id="pone.0179315.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Del Valle</surname><given-names>SY</given-names></name>, <name><surname>Hyman</surname><given-names>J</given-names></name>, <name><surname>Chitnis</surname><given-names>N</given-names></name>. <article-title>Mathematical models of contact patterns between age groups for predicting the spread of infectious diseases</article-title>. <source>Mathematical Biosciences and Engineering</source>. <year>2013</year>;<volume>10</volume>(<issue>0</issue>):<fpage>1475</fpage>–<lpage>97</lpage>.<pub-id pub-id-type="pmid">24245626</pub-id></mixed-citation></ref><ref id="pone.0179315.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>van den Driessche</surname><given-names>P</given-names></name>, <name><surname>Watmough</surname><given-names>J</given-names></name>. <article-title>Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission</article-title>. <source>Mathematical biosciences</source>. <year>2002</year>;<volume>180</volume>:<fpage>29</fpage>–<lpage>48</lpage>. Epub 2002/10/22. .<pub-id pub-id-type="pmid">12387915</pub-id></mixed-citation></ref><ref id="pone.0179315.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Hancock</surname><given-names>K</given-names></name>, <name><surname>Veguilla</surname><given-names>V</given-names></name>, <name><surname>Lu</surname><given-names>X</given-names></name>, <name><surname>Zhong</surname><given-names>W</given-names></name>, <name><surname>Butler</surname><given-names>EN</given-names></name>, <name><surname>Sun</surname><given-names>H</given-names></name>, <etal>et al</etal><article-title>Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1</article-title><source>Influenza Virus. New England Journal of Medicine</source>. <year>2009</year>;<volume>361</volume>(<issue>20</issue>):<fpage>1945</fpage>–<lpage>52</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa0906453">10.1056/NEJMoa0906453</ext-link></comment><pub-id pub-id-type="pmid">19745214</pub-id></mixed-citation></ref><ref id="pone.0179315.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Mills</surname><given-names>C</given-names></name>, <name><surname>Robins</surname><given-names>J</given-names></name>, <name><surname>Lipsitch</surname><given-names>M</given-names></name>. <article-title>Transmissibility of 1918 pandemic influenza</article-title>. <source>Nature</source>. <year>2004</year>;<volume>432</volume>:<fpage>904</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature03063">10.1038/nature03063</ext-link></comment><pub-id pub-id-type="pmid">15602562</pub-id></mixed-citation></ref><ref id="pone.0179315.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Viboud</surname><given-names>C</given-names></name>, <name><surname>Tam</surname><given-names>T</given-names></name>, <name><surname>Fleming</surname><given-names>D</given-names></name>, <name><surname>Handel</surname><given-names>A</given-names></name>, <name><surname>Miller</surname><given-names>M</given-names></name>, <name><surname>Simonsen</surname><given-names>L</given-names></name>. <article-title>Transmissibility and mortality impact of epidemic and pandemic influenza, with emphasis on the unusually deadly 1951 epidemic</article-title>. <source>Vaccine</source>. <year>2006</year>;<volume>24</volume>:<fpage>6701</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.vaccine.2006.05.067">10.1016/j.vaccine.2006.05.067</ext-link></comment><pub-id pub-id-type="pmid">16806596</pub-id></mixed-citation></ref><ref id="pone.0179315.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Chowell</surname><given-names>G</given-names></name>, <name><surname>Ammon</surname><given-names>C</given-names></name>, <name><surname>Hengartner</surname><given-names>N</given-names></name>, <name><surname>Hyman</surname><given-names>J</given-names></name>. <article-title>Transmission dynamics of the great influenza pandemic of 1918 in Geneva, Switzerland: Assessing the effects of hypothetical interventions</article-title>. <source>Journal of theoretical biology</source>. <year>2006</year>;<volume>241</volume>:<fpage>193</fpage>–<lpage>204</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jtbi.2005.11.026">10.1016/j.jtbi.2005.11.026</ext-link></comment><pub-id pub-id-type="pmid">16387331</pub-id></mixed-citation></ref><ref id="pone.0179315.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Flahault</surname><given-names>A</given-names></name>, <name><surname>Deguen</surname><given-names>S</given-names></name>, <name><surname>Valleron</surname><given-names>A</given-names></name>. <article-title>A mathematical model for the European spread of influenza</article-title>. <source>European Journal of Epidemiology</source>. <year>1994</year>;<volume>10</volume>:<fpage>471</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="pmid">7843359</pub-id></mixed-citation></ref><ref id="pone.0179315.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Hall</surname><given-names>I</given-names></name>, <name><surname>Gani</surname><given-names>R</given-names></name>, <name><surname>Hughes</surname><given-names>H</given-names></name>, <name><surname>Leach</surname><given-names>S</given-names></name>. <article-title>Real-time epidemic forecasting for pandemic influenza</article-title>. <source>Epidmiology and Infection</source>. <year>2007</year>;<volume>3</volume>:<fpage>372</fpage>–<lpage>85</lpage>.</mixed-citation></ref><ref id="pone.0179315.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Sertsou</surname><given-names>G</given-names></name>, <name><surname>Wilson</surname><given-names>N</given-names></name>, <name><surname>Baker</surname><given-names>M</given-names></name>, <name><surname>Nelson</surname><given-names>P</given-names></name>, <name><surname>Roberts</surname><given-names>M</given-names></name>. <article-title>Key transmission parameters of an institutional outbreak during the 1918 influenza pandemic estimated by mathematical modelling</article-title>. <source>Theoretical Biology and Medical Modeling</source>. <year>2006</year>;<volume>3</volume>:<fpage>38</fpage>.</mixed-citation></ref><ref id="pone.0179315.ref050"><label>50</label><mixed-citation publication-type="other">CIHI. Number of Hospital Beds Staffed and In Operation: Breakdown by grouped functional centre. Canadian MIS Database; 2016.</mixed-citation></ref><ref id="pone.0179315.ref051"><label>51</label><mixed-citation publication-type="other">SSSQ. Institutions: Legal entities 2016 [cited 2016 October 4]. Available from: <ext-link ext-link-type="uri" xlink:href="http://wpp01.msss.gouv.qc.ca/appl/M02/M02ListeEtab.asp">http://wpp01.msss.gouv.qc.ca/appl/M02/M02ListeEtab.asp</ext-link>.</mixed-citation></ref><ref id="pone.0179315.ref052"><label>52</label><mixed-citation publication-type="book"><name><surname>Burgess</surname><given-names>D</given-names></name>, <name><surname>Jenkins</surname><given-names>G</given-names></name>, (eds). <source>Discount rates for the evaluation of public private partnerships</source>. <name><surname>Burgess</surname><given-names>D</given-names></name>, <name><surname>Jenkins</surname><given-names>G</given-names></name>, editors. <publisher-loc>Kingston, ON</publisher-loc>: <publisher-name>John Deutsch Institute</publisher-name>; <year>2010</year>.</mixed-citation></ref><ref id="pone.0179315.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Winquist</surname><given-names>E</given-names></name>, <name><surname>Bell</surname><given-names>CM</given-names></name>, <name><surname>Clarke</surname><given-names>JT</given-names></name>, <name><surname>Evans</surname><given-names>G</given-names></name>, <name><surname>Martin</surname><given-names>J</given-names></name>, <name><surname>Sabharwal</surname><given-names>M</given-names></name>, <etal>et al</etal><article-title>An evaluation framework for funding drugs for rare diseases</article-title>. <source>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research</source>. <year>2012</year>;<volume>15</volume>(<issue>6</issue>):<fpage>982</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jval.2012.06.009">10.1016/j.jval.2012.06.009</ext-link></comment> .<pub-id pub-id-type="pmid">22999151</pub-id></mixed-citation></ref><ref id="pone.0179315.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Neumann</surname><given-names>PJ</given-names></name>, <name><surname>Cohen</surname><given-names>JT</given-names></name>, <name><surname>Weinstein</surname><given-names>MC</given-names></name>. <article-title>Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold</article-title>. <source>The New England journal of medicine</source>. <year>2014</year>;<volume>371</volume>(<issue>9</issue>):<fpage>796</fpage>–<lpage>7</lpage>. Epub 2014/08/28. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMp1405158">10.1056/NEJMp1405158</ext-link></comment> .<pub-id pub-id-type="pmid">25162885</pub-id></mixed-citation></ref><ref id="pone.0179315.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Owens</surname><given-names>DK</given-names></name>. <article-title>Interpretation of Cost-Effectiveness Analyses</article-title>. <source>Journal of General Internal Medicine</source>. <year>1998</year>;<volume>13</volume>(<issue>10</issue>):<fpage>716</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1046/j.1525-1497.1998.00211.x">10.1046/j.1525-1497.1998.00211.x</ext-link></comment> .<pub-id pub-id-type="pmid">9798822</pub-id></mixed-citation></ref><ref id="pone.0179315.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Sander</surname><given-names>B</given-names></name>, <name><surname>Bauch</surname><given-names>CT</given-names></name>, <name><surname>Fisman</surname><given-names>D</given-names></name>, <name><surname>Fowler</surname><given-names>RA</given-names></name>, <name><surname>Kwong</surname><given-names>JC</given-names></name>, <name><surname>Maetzel</surname><given-names>A</given-names></name>, <etal>et al</etal><article-title>Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience</article-title>. <source>Vaccine</source>. <year>2010</year>;<volume>28</volume>(<issue>38</issue>):<fpage>6210</fpage>–<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.vaccine.2010.07.010">10.1016/j.vaccine.2010.07.010</ext-link></comment> .<pub-id pub-id-type="pmid">20643091</pub-id></mixed-citation></ref><ref id="pone.0179315.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Sander</surname><given-names>B</given-names></name>, <name><surname>MecDev</surname><given-names>MBA</given-names></name>, <name><surname>Nizam</surname><given-names>A</given-names></name>, <name><surname>Garisson</surname><given-names>LP</given-names></name>, <name><surname>Postma</surname><given-names>MJ</given-names></name>, <name><surname>Halloran</surname><given-names>ME</given-names></name>, <etal>et al</etal><article-title>Economic Evaluation of Influenza Pandemic Mitigation Strategies in the United States Using a Stochastic Microsimulation transmission model</article-title>. <source>Value in Health</source>. <year>2009</year>;<volume>12</volume><comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1524-4733.2008.00437.x">10.1111/j.1524-4733.2008.00437.x</ext-link></comment><pub-id pub-id-type="pmid">18671770</pub-id></mixed-citation></ref><ref id="pone.0179315.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Perlroth</surname><given-names>DJ</given-names></name>, <name><surname>Glass</surname><given-names>RJ</given-names></name>, <name><surname>Davey</surname><given-names>VJ</given-names></name>, <name><surname>Cannon</surname><given-names>D</given-names></name>, <name><surname>Garber</surname><given-names>AM</given-names></name>, <name><surname>Owens</surname><given-names>DK</given-names></name>. <article-title>Health Outcomes and Costs of Community Mitigation Strategies for an Influenza Pandemic in the United States</article-title>. <source>Clinical Infectious Diseases</source>. <year>2010</year>;<volume>50</volume>(<issue>2</issue>):<fpage>165</fpage>–<lpage>74</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1086/649867">10.1086/649867</ext-link></comment><pub-id pub-id-type="pmid">20021259</pub-id></mixed-citation></ref><ref id="pone.0179315.ref059"><label>59</label><mixed-citation publication-type="other">StatsCan. Earnings, average weekly, by province and territory 2016 [cited 2016 October 26]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/labr79-eng.htm">http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/labr79-eng.htm</ext-link>.</mixed-citation></ref><ref id="pone.0179315.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Kelso</surname><given-names>JK</given-names></name>, <name><surname>Halder</surname><given-names>N</given-names></name>, <name><surname>Postma</surname><given-names>MJ</given-names></name>, <name><surname>Milne</surname><given-names>GJ</given-names></name>. <article-title>Economic analysis of pandemic influenza mitigation strategies for five pandemic severity categories</article-title>. <source>BMC public health</source>. <year>2013</year>;<volume>13</volume>:<fpage>211</fpage>-. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1471-2458-13-211">10.1186/1471-2458-13-211</ext-link></comment><pub-id pub-id-type="pmid">23496898</pub-id></mixed-citation></ref><ref id="pone.0179315.ref061"><label>61</label><mixed-citation publication-type="other">PHAC. Vaccine coverage amongst adult Canadians: Results from the 2012 adult National Immunization Coverage (aNIC) survey 2014 [cited 2016 November 7]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.phac-aspc.gc.ca/im/nics-enva/vcac-cvac-eng.php">http://www.phac-aspc.gc.ca/im/nics-enva/vcac-cvac-eng.php</ext-link>.</mixed-citation></ref><ref id="pone.0179315.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Jefferson</surname><given-names>T</given-names></name>, <name><surname>Rivetti</surname><given-names>A</given-names></name>, <name><surname>Di Pietrantonj</surname><given-names>C</given-names></name>, <name><surname>Demicheli</surname><given-names>V</given-names></name>, <name><surname>Ferroni</surname><given-names>E</given-names></name>. <article-title>Vaccines for preventing influenza in healthy children</article-title>. <source>Cochrane Database of Systematic Reviews</source>. <year>2014</year>;(<issue>8</issue>):N.PAG-N.PAG 1p. . Language: English. Entry Date: 20101029. Revision Date: 20150711. Publication Type: Journal Article.</mixed-citation></ref><ref id="pone.0179315.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Osterholm</surname><given-names>MT</given-names></name>, <name><surname>Kelley</surname><given-names>NS</given-names></name>, <name><surname>Sommer</surname><given-names>A</given-names></name>, <name><surname>Belongia</surname><given-names>EA</given-names></name>. <article-title>Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis</article-title>. <source>The Lancet Infectious Diseases</source>. <year>2012</year>;<volume>12</volume>(<issue>1</issue>):<fpage>36</fpage>–<lpage>44</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1473-3099(11)70295-X">10.1016/S1473-3099(11)70295-X</ext-link></comment><pub-id pub-id-type="pmid">22032844</pub-id></mixed-citation></ref><ref id="pone.0179315.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Yin</surname><given-names>JK</given-names></name>, <name><surname>Chow</surname><given-names>MYK</given-names></name>, <name><surname>Khandaker</surname><given-names>G</given-names></name>, <name><surname>King</surname><given-names>C</given-names></name>, <name><surname>Richmond</surname><given-names>P</given-names></name>, <name><surname>Heron</surname><given-names>L</given-names></name>, <etal>et al</etal><article-title>Impacts on influenza A(H1N1)pdm09 infection from cross-protection of seasonal trivalent influenza vaccines and A(H1N1)pdm09 vaccines: Systematic review and meta-analyses</article-title>. <source>Vaccine</source>. <year>2012</year>;<volume>30</volume>(<issue>21</issue>):<fpage>3209</fpage>–<lpage>22</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.vaccine.2012.02.048">10.1016/j.vaccine.2012.02.048</ext-link></comment><pub-id pub-id-type="pmid">22387221</pub-id></mixed-citation></ref><ref id="pone.0179315.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Basta</surname><given-names>NE</given-names></name>, <name><surname>Halloran</surname><given-names>ME</given-names></name>, <name><surname>Matrajt</surname><given-names>L</given-names></name>, <name><surname>Longini</surname><given-names>IM</given-names></name>. <article-title>Estimating influenza vaccine efficacy from challenge and community-based study data</article-title>. <source>Am J Epidemiol</source>. <year>2008</year>;<volume>168</volume>(<issue>12</issue>):<fpage>1343</fpage>–<lpage>52</lpage>. Epub 2008/11/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/aje/kwn259">10.1093/aje/kwn259</ext-link></comment> ; PubMed Central PMCID: PMCPMC2638553.<pub-id pub-id-type="pmid">18974084</pub-id></mixed-citation></ref><ref id="pone.0179315.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Fiore</surname><given-names>A</given-names></name>, <name><surname>Uyeki</surname><given-names>T</given-names></name>, <name><surname>Broder</surname><given-names>K</given-names></name>, <name><surname>Finelli</surname><given-names>L</given-names></name>, <name><surname>Euler</surname><given-names>GL</given-names></name>, <name><surname>Singleton</surname><given-names>JA</given-names></name>, <etal>et al</etal> P<article-title>revention and Control of Influenza with Vaccines Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010</article-title>. <source>Morbidity and Mortality Weekly Report</source>. <year>2010</year>;<volume>59</volume>:<fpage>1</fpage>–<lpage>64</lpage>.<pub-id pub-id-type="pmid">20075837</pub-id></mixed-citation></ref><ref id="pone.0179315.ref067"><label>67</label><mixed-citation publication-type="journal"><name><surname>Greer</surname><given-names>AL</given-names></name>, <name><surname>Schanzer</surname><given-names>D</given-names></name>. <article-title>Using a Dynamic Model to Consider Optimal Antiviral Stockpile Size in the Face of Pandemic Influenza Uncertainty</article-title>. <source>PloS one</source>. <year>2013</year>;<volume>8</volume>(<issue>6</issue>):<fpage>e67253</fpage><comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0067253">10.1371/journal.pone.0067253</ext-link></comment><pub-id pub-id-type="pmid">23805303</pub-id></mixed-citation></ref><ref id="pone.0179315.ref068"><label>68</label><mixed-citation publication-type="journal"><name><surname>Flahault</surname><given-names>A</given-names></name>, <name><surname>Vergu</surname><given-names>E</given-names></name>, <name><surname>Boelle</surname><given-names>PY</given-names></name>. <article-title>Potential for a global dynamic of Influenza A (H1N1)</article-title>. <source>BMC infectious diseases</source>. <year>2009</year>;<volume>9</volume>:<fpage>129</fpage><comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1471-2334-9-129">10.1186/1471-2334-9-129</ext-link></comment> ; PubMed Central PMCID: PMCPMC2739855.<pub-id pub-id-type="pmid">19674455</pub-id></mixed-citation></ref><ref id="pone.0179315.ref069"><label>69</label><mixed-citation publication-type="journal"><name><surname>Fraser</surname><given-names>C</given-names></name>, <name><surname>Donnelly</surname><given-names>CA</given-names></name>, <name><surname>Cauchemez</surname><given-names>S</given-names></name>, <name><surname>Hanage</surname><given-names>WP</given-names></name>, <name><surname>Van Kerkhove</surname><given-names>MD</given-names></name>, <name><surname>Hollingsworth</surname><given-names>TD</given-names></name>, <etal>et al</etal><article-title>Pandemic potential of a strain of influenza A (H1N1): early findings</article-title>. <source>Science</source>. <year>2009</year>;<volume>324</volume>(<issue>5934</issue>):<fpage>1557</fpage>–<lpage>61</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.1176062">10.1126/science.1176062</ext-link></comment> ; PubMed Central PMCID: PMCPMC3735127.<pub-id pub-id-type="pmid">19433588</pub-id></mixed-citation></ref><ref id="pone.0179315.ref070"><label>70</label><mixed-citation publication-type="journal"><name><surname>Khazeni</surname><given-names>N</given-names></name>, <name><surname>Bravata</surname><given-names>DM</given-names></name>, <name><surname>Holty</surname><given-names>JE</given-names></name>, <name><surname>Uyeki</surname><given-names>TM</given-names></name>, <name><surname>Stave</surname><given-names>CD</given-names></name>, <name><surname>Gould</surname><given-names>MK</given-names></name>. <article-title>Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza</article-title>. <source>Annals of internal medicine</source>. <year>2009</year>;<volume>151</volume>(<issue>7</issue>):<fpage>464</fpage>–<lpage>73</lpage>. Epub 2009/08/05. .<pub-id pub-id-type="pmid">19652173</pub-id></mixed-citation></ref><ref id="pone.0179315.ref071"><label>71</label><mixed-citation publication-type="journal"><name><surname>Jefferson</surname><given-names>T</given-names></name>, <name><surname>Jones</surname><given-names>MA</given-names></name>, <name><surname>Doshi</surname><given-names>P</given-names></name>, <name><surname>Del Mar</surname><given-names>CB</given-names></name>, <name><surname>Hama</surname><given-names>R</given-names></name>, <name><surname>Thompson</surname><given-names>MJ</given-names></name>, <etal>et al</etal><article-title>Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children</article-title>. <source>The Cochrane database of systematic reviews</source>. <year>2014</year>;<volume>4</volume>:<fpage>CD008965</fpage><comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/14651858.CD008965.pub4">10.1002/14651858.CD008965.pub4</ext-link></comment> .<pub-id pub-id-type="pmid">24718923</pub-id></mixed-citation></ref><ref id="pone.0179315.ref072"><label>72</label><mixed-citation publication-type="journal"><name><surname>Borse</surname><given-names>RH</given-names></name>, <name><surname>Behravesh</surname><given-names>CB</given-names></name>, <name><surname>Dumanovsky</surname><given-names>T</given-names></name>, <name><surname>Zucker</surname><given-names>JR</given-names></name>, <name><surname>Swerdlow</surname><given-names>D</given-names></name>, <name><surname>Edelson</surname><given-names>P</given-names></name>, <etal>et al</etal><article-title>Closing schools in response to the 2009 pandemic influenza A H1N1 virus in New York City: economic impact on households</article-title>. <source>Clinical infectious diseases: an official publication of the Infectious Diseases Society of America</source>. <year>2011</year>;<volume>52</volume><issue>Suppl 1</issue>:<fpage>S168</fpage>–<lpage>72</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/cid/ciq033">10.1093/cid/ciq033</ext-link></comment> .<pub-id pub-id-type="pmid">21342890</pub-id></mixed-citation></ref><ref id="pone.0179315.ref073"><label>73</label><mixed-citation publication-type="journal"><name><surname>Arino</surname><given-names>J</given-names></name>, <name><surname>Brauer</surname><given-names>F</given-names></name>, <name><surname>Driessche</surname><given-names>P</given-names></name>, <name><surname>Watmough</surname><given-names>J</given-names></name>, <name><surname>Jianhong</surname><given-names>W</given-names></name>. <article-title>A model for influenza with vaccination and antiviral treatment</article-title>. <source>Journal of theoretical biology</source>. <year>2008</year>;<volume>253</volume>(<issue>1</issue>):<fpage>118</fpage>–<lpage>30</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jtbi.2008.02.026">10.1016/j.jtbi.2008.02.026</ext-link></comment><pub-id pub-id-type="pmid">18402981</pub-id></mixed-citation></ref><ref id="pone.0179315.ref074"><label>74</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>J</given-names></name>, <name><surname>Jung</surname><given-names>E</given-names></name>. <article-title>A spatial-temporal transmission model and early intervention policies of 2009 A/H1N1 influenza in South Korea</article-title>. <source>Journal of theoretical biology</source>. <year>2015</year>;<volume>380</volume>:<fpage>60</fpage>–<lpage>73</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jtbi.2015.05.008">10.1016/j.jtbi.2015.05.008</ext-link></comment> .<pub-id pub-id-type="pmid">25981631</pub-id></mixed-citation></ref><ref id="pone.0179315.ref075"><label>75</label><mixed-citation publication-type="journal"><name><surname>Godoy</surname><given-names>P</given-names></name>, <name><surname>Castilla</surname><given-names>J</given-names></name>, <name><surname>Delgado-Rodriguez</surname><given-names>M</given-names></name>, <name><surname>Martin</surname><given-names>V</given-names></name>, <name><surname>Soldevila</surname><given-names>N</given-names></name>, <name><surname>Alonso</surname><given-names>J</given-names></name>, <etal>et al</etal><article-title>Effectiveness of hand hygiene and provision of information in preventing influenza cases requiring hospitalization</article-title>. <source>Preventive medicine</source>. <year>2012</year>;<volume>54</volume>(<issue>6</issue>):<fpage>434</fpage>–<lpage>9</lpage>. Epub 05/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ypmed.2012.04.009">10.1016/j.ypmed.2012.04.009</ext-link></comment> .<pub-id pub-id-type="pmid">22548868</pub-id></mixed-citation></ref><ref id="pone.0179315.ref076"><label>76</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>T</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Di</surname><given-names>B</given-names></name>, <name><surname>Wang</surname><given-names>M</given-names></name>, <name><surname>Shen</surname><given-names>J</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <etal>et al</etal><article-title>Epidemiological investigation of an outbreak of pandemic influenza A (H1N1) 2009 in a boarding school: Serological analysis of 1570 cases</article-title>. <source>Journal of Clinical Virology</source>. <year>2011</year>;<volume>50</volume>(<issue>3</issue>):<fpage>235</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jcv.2010.11.012">10.1016/j.jcv.2010.11.012</ext-link></comment><pub-id pub-id-type="pmid">21195022</pub-id></mixed-citation></ref><ref id="pone.0179315.ref077"><label>77</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>WT</given-names></name>, <name><surname>Pang</surname><given-names>XH</given-names></name>, <name><surname>Deng</surname><given-names>Y</given-names></name>, <name><surname>Yang</surname><given-names>P</given-names></name>, <name><surname>Li</surname><given-names>XY</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <etal>et al</etal> [<article-title>A case-control study of the transmission of pandemic influenza A (H1N1) virus in families</article-title>]. <source>Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases</source>. <year>2011</year>;<volume>34</volume>(<issue>7</issue>):<fpage>509</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="pmid">22041776</pub-id></mixed-citation></ref><ref id="pone.0179315.ref078"><label>78</label><mixed-citation publication-type="journal"><name><surname>Torner</surname><given-names>N</given-names></name>, <name><surname>Soldevila</surname><given-names>N</given-names></name>, <name><surname>Garcia</surname><given-names>JJ</given-names></name>, <name><surname>Launes</surname><given-names>C</given-names></name>, <name><surname>Godoy</surname><given-names>P</given-names></name>, <name><surname>Castilla</surname><given-names>J</given-names></name>, <etal>et al</etal><article-title>Effectiveness of non-pharmaceutical measures in preventing pediatric influenza: a case-control study</article-title>. <source>BMC public health</source>. <year>2015</year>;<volume>15</volume>:<fpage>543</fpage> Epub 06/10. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12889-015-1890-3">10.1186/s12889-015-1890-3</ext-link></comment> .<pub-id pub-id-type="pmid">26055522</pub-id></mixed-citation></ref><ref id="pone.0179315.ref079"><label>79</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Seale</surname><given-names>H</given-names></name>, <name><surname>Yang</surname><given-names>P</given-names></name>, <name><surname>MacIntyre</surname><given-names>CR</given-names></name>, <name><surname>Blackwell</surname><given-names>B</given-names></name>, <name><surname>Tang</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>Factors associated with the transmission of pandemic (H1N1) 2009 among hospital healthcare workers in Beijing, China</article-title>. <source>Influenza and other respiratory viruses</source>. <year>2012</year>;<volume>7</volume>(<issue>3</issue>):<fpage>466</fpage>–<lpage>71</lpage>. Epub 10/20. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/irv.12025">10.1111/irv.12025</ext-link></comment> .<pub-id pub-id-type="pmid">23078163</pub-id></mixed-citation></ref><ref id="pone.0179315.ref080"><label>80</label><mixed-citation publication-type="journal"><name><surname>Merk</surname><given-names>H</given-names></name>, <name><surname>Kuhlmann-Berenzon</surname><given-names>S</given-names></name>, <name><surname>Linde</surname><given-names>A</given-names></name>, <name><surname>Nyren</surname><given-names>O</given-names></name>. <article-title>Associations of hand-washing frequency with incidence of acute respiratory tract infection and influenza-like illness in adults: a population-based study in Sweden</article-title>. <source>BMC infectious diseases</source>. <year>2014</year>;<volume>14</volume>:<fpage>509</fpage> Epub 2014/09/23. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1471-2334-14-509">10.1186/1471-2334-14-509</ext-link></comment> ; PubMed Central PMCID: PMCPMC4177698.<pub-id pub-id-type="pmid">25234544</pub-id></mixed-citation></ref><ref id="pone.0179315.ref081"><label>81</label><mixed-citation publication-type="journal"><name><surname>Tooher</surname><given-names>R</given-names></name>, <name><surname>Collins</surname><given-names>JE</given-names></name>, <name><surname>Street</surname><given-names>JM</given-names></name>, <name><surname>Braunack-Mayer</surname><given-names>A</given-names></name>, <name><surname>Marshall</surname><given-names>H</given-names></name>. <article-title>Community knowledge, behaviours and attitudes about the 2009 H1N1 Influenza pandemic: a systematic review</article-title>. <source>Influenza and other respiratory viruses</source>. <year>2013</year>;<volume>7</volume>(<issue>6</issue>):<fpage>1316</fpage>–<lpage>27</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/irv.12103">10.1111/irv.12103</ext-link></comment> .<pub-id pub-id-type="pmid">23560537</pub-id></mixed-citation></ref><ref id="pone.0179315.ref082"><label>82</label><mixed-citation publication-type="journal"><name><surname>Seale</surname><given-names>H</given-names></name>, <name><surname>Heywood</surname><given-names>AE</given-names></name>, <name><surname>McLaws</surname><given-names>M-L</given-names></name>, <name><surname>Ward</surname><given-names>KF</given-names></name>, <name><surname>Lowbridge</surname><given-names>CP</given-names></name>, <name><surname>Van</surname><given-names>D</given-names></name>, <etal>et al</etal><article-title>Why do I need it? I am not at risk! Public perceptions towards the pandemic (H1N1) 2009 vaccine</article-title>. <source>BMC infectious diseases</source>. <year>2010</year>;<volume>10</volume>(<issue>1</issue>):<fpage>99</fpage><comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1471-2334-10-99">10.1186/1471-2334-10-99</ext-link></comment><pub-id pub-id-type="pmid">20403201</pub-id></mixed-citation></ref><ref id="pone.0179315.ref083"><label>83</label><mixed-citation publication-type="journal"><name><surname>Cheng</surname><given-names>VCC</given-names></name>, <name><surname>Tai</surname><given-names>JWM</given-names></name>, <name><surname>Wong</surname><given-names>LMW</given-names></name>, <name><surname>Chan</surname><given-names>JFW</given-names></name>, <name><surname>Li</surname><given-names>IWS</given-names></name>, <name><surname>To</surname><given-names>KKW</given-names></name>, <etal>et al</etal><article-title>Prevention of nosocomial transmission of swine-origin pandemic influenza virus A/H1N1 by infection control bundle</article-title>. <source>The Journal of hospital infection</source>. <year>2010</year>;<volume>74</volume>(<issue>3</issue>):<fpage>271</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jhin.2009.09.009">10.1016/j.jhin.2009.09.009</ext-link></comment><pub-id pub-id-type="pmid">20061056</pub-id></mixed-citation></ref><ref id="pone.0179315.ref084"><label>84</label><mixed-citation publication-type="journal"><name><surname>Deng</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>XL</given-names></name>, <name><surname>Liu</surname><given-names>WT</given-names></name>, <name><surname>Duan</surname><given-names>W</given-names></name>, <name><surname>Yang</surname><given-names>P</given-names></name>, <etal>et al</etal> [<article-title>Pandemic influenza A (H1N1) virus infection factors among healthcare workers—a case-control study</article-title>]. <source>Zhonghua Yu Fang Yi Xue Za Zhi</source>. <year>2010</year>;<volume>44</volume>(<issue>12</issue>):<fpage>1075</fpage>–<lpage>8</lpage>. Epub 2011/01/11. .<pub-id pub-id-type="pmid">21215106</pub-id></mixed-citation></ref><ref id="pone.0179315.ref085"><label>85</label><mixed-citation publication-type="journal"><name><surname>Jaeger</surname><given-names>JL</given-names></name>, <name><surname>Patel</surname><given-names>M</given-names></name>, <name><surname>Dharan</surname><given-names>N</given-names></name>, <name><surname>Hancock</surname><given-names>K</given-names></name>, <name><surname>Meites</surname><given-names>E</given-names></name>, <name><surname>Mattson</surname><given-names>C</given-names></name>, <etal>et al</etal><article-title>Transmission of 2009 Pandemic Influenza A (H1N1) Virus among Healthcare Personnel-Southern California, 2009</article-title>. <source>Infection Control & Hospital Epidemiology</source>. <year>2011</year>;<volume>32</volume>(<issue>12</issue>):<fpage>1149</fpage>–<lpage>57</lpage> 9p. . Language: English. Entry Date: 20120127. Revision Date: 20150818. Publication Type: Journal Article.<pub-id pub-id-type="pmid">22080652</pub-id></mixed-citation></ref><ref id="pone.0179315.ref086"><label>86</label><mixed-citation publication-type="journal"><name><surname>Remschmidt</surname><given-names>C</given-names></name>, <name><surname>Stocker</surname><given-names>P</given-names></name>, <name><surname>Mad</surname><given-names>Heiden</given-names></name>, <name><surname>Suess</surname><given-names>T</given-names></name>, <name><surname>Luchtenberg</surname><given-names>M</given-names></name>, <name><surname>Schink</surname><given-names>SB</given-names></name>, <etal>et al</etal><article-title>Preventable and non-preventable risk factors for influenza transmission and hygiene behavior in German influenza households, pandemic season (H1N1) 2009/2010</article-title>. <source>Influenza and other respiratory viruses</source>. <year>2013</year>;<volume>7</volume>(<issue>3</issue>):<fpage>418</fpage>–<lpage>25</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1750-2659.2012.00407.x">10.1111/j.1750-2659.2012.00407.x</ext-link></comment><pub-id pub-id-type="pmid">22804954</pub-id></mixed-citation></ref><ref id="pone.0179315.ref087"><label>87</label><mixed-citation publication-type="journal"><name><surname>Suess</surname><given-names>T</given-names></name>, <name><surname>Remschmidt</surname><given-names>C</given-names></name>, <name><surname>Schink</surname><given-names>SB</given-names></name>, <name><surname>Schweiger</surname><given-names>B</given-names></name>, <name><surname>Nitsche</surname><given-names>A</given-names></name>, <name><surname>Schroeder</surname><given-names>K</given-names></name>, <etal>et al</etal><article-title>The role of facemasks and hand hygiene in the prevention of influenza transmission in households: results from a cluster randomised trial; Berlin, Germany, 2009–2011</article-title>. <source>BMC infectious diseases</source>. <year>2012</year>;<volume>12</volume>:<fpage>26</fpage> Epub 01/28. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1471-2334-12-26">10.1186/1471-2334-12-26</ext-link></comment> .<pub-id pub-id-type="pmid">22280120</pub-id></mixed-citation></ref><ref id="pone.0179315.ref088"><label>88</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>CO</given-names></name>, <name><surname>Nam</surname><given-names>CM</given-names></name>, <name><surname>Lee</surname><given-names>DC</given-names></name>, <name><surname>Chang</surname><given-names>J</given-names></name>, <name><surname>Lee</surname><given-names>JW</given-names></name>. <article-title>Is abdominal obesity associated with the 2009 influenza A (H1N1) pandemic in Korean school-aged children?</article-title><source>Influenza and other respiratory viruses</source>. <year>2012</year>;<volume>6</volume>(<issue>5</issue>):<fpage>313</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1750-2659.2011.00318.x">10.1111/j.1750-2659.2011.00318.x</ext-link></comment><pub-id pub-id-type="pmid">22151080</pub-id></mixed-citation></ref><ref id="pone.0179315.ref089"><label>89</label><mixed-citation publication-type="journal"><name><surname>Bults</surname><given-names>M</given-names></name>, <name><surname>Beaujean</surname><given-names>DJ</given-names></name>, <name><surname>de Zwart</surname><given-names>O</given-names></name>, <name><surname>Kok</surname><given-names>G</given-names></name>, <name><surname>van Empelen</surname><given-names>P</given-names></name>, <name><surname>van Steenbergen</surname><given-names>JE</given-names></name>, <etal>et al</etal><article-title>Perceived risk, anxiety, and behavioural responses of the general public during the early phase of the Influenza A (H1N1) pandemic in the Netherlands: results of three consecutive online surveys</article-title>. <source>BMC public health</source>. <year>2011</year>;<volume>11</volume>(<issue>1</issue>):<fpage>2</fpage><comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1471-2458-11-2">10.1186/1471-2458-11-2</ext-link></comment><pub-id pub-id-type="pmid">21199571</pub-id></mixed-citation></ref><ref id="pone.0179315.ref090"><label>90</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Q</given-names></name>, <name><surname>Wang</surname><given-names>D</given-names></name>. <article-title>Assessing the Role of Voluntary Self-Isolation in the Control of Pandemic Influenza Using a Household Epidemic Model</article-title>. <source>International Journal of Environmental Research and Public Health</source>. <year>2015</year>;<volume>12</volume>(<issue>8</issue>):<fpage>9750</fpage>–<lpage>67</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/ijerph120809750">10.3390/ijerph120809750</ext-link></comment> .<pub-id pub-id-type="pmid">26295248</pub-id></mixed-citation></ref><ref id="pone.0179315.ref091"><label>91</label><mixed-citation publication-type="journal"><name><surname>Michael</surname><given-names>JH</given-names></name>, <name><surname>Davis</surname><given-names>KS</given-names></name>, <name><surname>Xiaohong</surname><given-names>MD</given-names></name>, <name><surname>Rajan</surname><given-names>P</given-names></name>, <name><surname>Xiaoping</surname><given-names>J</given-names></name>, <name><surname>Eric</surname><given-names>W</given-names></name>, <etal>et al</etal><article-title>Effectiveness of Interventions to Reduce Contact Rates during a Simulated Influenza Pandemic</article-title>. <source>Emerging Infectious Disease journal</source>. <year>2007</year>;<volume>13</volume>(<issue>4</issue>):<fpage>581</fpage><comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3201/eid1304.060828">10.3201/eid1304.060828</ext-link></comment><pub-id pub-id-type="pmid">17553273</pub-id></mixed-citation></ref><ref id="pone.0179315.ref092"><label>92</label><mixed-citation publication-type="journal"><name><surname>Bondy</surname><given-names>SJ</given-names></name>, <name><surname>Russell</surname><given-names>ML</given-names></name>, <name><surname>Lafleche</surname><given-names>JM</given-names></name>, <name><surname>Rea</surname><given-names>E</given-names></name>. <article-title>Quantifying the impact of community quarantine on SARS transmission in Ontario: estimation of secondary case count difference and number needed to quarantine</article-title>. <source>BMC public health</source>. <year>2009</year>;<volume>9</volume>:<fpage>488</fpage><comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1471-2458-9-488">10.1186/1471-2458-9-488</ext-link></comment> ; PubMed Central PMCID: PMCPMC2808319.<pub-id pub-id-type="pmid">20034405</pub-id></mixed-citation></ref><ref id="pone.0179315.ref093"><label>93</label><mixed-citation publication-type="journal"><name><surname>Gojovic</surname><given-names>MZ</given-names></name>, <name><surname>Sande</surname><given-names>B</given-names></name>, <name><surname>Fisman</surname><given-names>D</given-names></name>, <name><surname>Krahn</surname><given-names>MD</given-names></name>, <name><surname>Bauch</surname><given-names>CT</given-names></name>. <article-title>Modeling mitigation strategies for pandemic (H1N1)</article-title>. <source>CMAJ</source>. <year>2009</year>;<volume>181</volume><comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1503/cmaj.091641">10.1503/cmaj.091641</ext-link></comment><pub-id pub-id-type="pmid">19825923</pub-id></mixed-citation></ref><ref id="pone.0179315.ref094"><label>94</label><mixed-citation publication-type="journal"><name><surname>Sander</surname><given-names>B</given-names></name>, <name><surname>Kwing</surname><given-names>JC</given-names></name>, <name><surname>Bauch</surname><given-names>CT</given-names></name>, <name><surname>Maetzel</surname><given-names>A</given-names></name>, <name><surname>McGeer</surname><given-names>A</given-names></name>, <name><surname>Raboud</surname><given-names>JM</given-names></name>, <etal>et al</etal><article-title>Economic appraisal of Ontario’s universal influenza immunization program: cost-utility analysis</article-title>. <source>Plos Med</source>. <year>2010</year>;<volume>7</volume><comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pmed.1000256">10.1371/journal.pmed.1000256</ext-link></comment><pub-id pub-id-type="pmid">20386727</pub-id></mixed-citation></ref><ref id="pone.0179315.ref095"><label>95</label><mixed-citation publication-type="journal"><name><surname>Tuite</surname><given-names>AR</given-names></name>, <name><surname>Greer</surname><given-names>AL</given-names></name>, <name><surname>Whelan</surname><given-names>M</given-names></name>, <name><surname>Winter</surname><given-names>AL</given-names></name>, <name><surname>Lee</surname><given-names>B</given-names></name>, <name><surname>Yan</surname><given-names>P</given-names></name>, <etal>et al</etal><article-title>Estimated epidemiologic parameters and morbidity associated with pandemic H1N1 influenza</article-title>. <source>CMAJ</source>. <year>2010</year>;<volume>182</volume>(<issue>2</issue>):<fpage>131</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1503/cmaj.091807">10.1503/cmaj.091807</ext-link></comment> ; PubMed Central PMCID: PMCPMC2817319.<pub-id pub-id-type="pmid">19959592</pub-id></mixed-citation></ref><ref id="pone.0179315.ref096"><label>96</label><mixed-citation publication-type="journal"><name><surname>Chowell</surname><given-names>G</given-names></name>, <name><surname>Sattenspiel</surname><given-names>L</given-names></name>, <name><surname>Bansal</surname><given-names>S</given-names></name>, <name><surname>Viboud</surname><given-names>C</given-names></name>. <article-title>Mathematical models to characterize early epidemic growth: a review</article-title>. <source>Physics of Life Reviews</source>. <year>2016</year>.</mixed-citation></ref><ref id="pone.0179315.ref097"><label>97</label><mixed-citation publication-type="journal"><name><surname>Stroud</surname><given-names>P</given-names></name>, <name><surname>Sydoriak</surname><given-names>S</given-names></name>, <name><surname>Riese</surname><given-names>J</given-names></name>, <name><surname>Smith</surname><given-names>J</given-names></name>, <name><surname>Mniszewski</surname><given-names>S</given-names></name>, <name><surname>Romero</surname><given-names>P</given-names></name>. <article-title>Semi-empirical power-law scaling of new infection rate to model epidemic dynamics with inhomogenous mixing</article-title>. <source>Mathematical Biosciences and Engineering</source>. <year>2006</year>;<volume>203</volume>:<fpage>301</fpage>–<lpage>18</lpage>.</mixed-citation></ref><ref id="pone.0179315.ref098"><label>98</label><mixed-citation publication-type="journal"><name><surname>Jefferson</surname><given-names>T</given-names></name>, <name><surname>Demicheli</surname><given-names>V</given-names></name>, <name><surname>Di Pietrantonj</surname><given-names>C</given-names></name>, <name><surname>Rivetti</surname><given-names>D</given-names></name>. <article-title>Amantadine and rimantadine for influenza A in adults</article-title>. <source>Cochrane Database of Systematic Reviews</source> [Internet]. <year>2006</year>; (<issue>2</issue>). Available from: <ext-link ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001169.pub3/abstract">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001169.pub3/abstract</ext-link>.</mixed-citation></ref><ref id="pone.0179315.ref099"><label>99</label><mixed-citation publication-type="journal"><name><surname>Rahmandad</surname><given-names>H</given-names></name>, <name><surname>Sterman</surname><given-names>J</given-names></name>. <article-title>Heterogeneity and network structure in the dynamics of diffusion: comparing agent-based and differential equation models</article-title>. <source>Management Science</source>. <year>2008</year>;<volume>54</volume>(<issue>5</issue>):<fpage>998</fpage>–<lpage>1014</lpage>.</mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A74 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000A74 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:5470707
|texte= Modelling community-control strategies to protect hospital resources during an influenza pandemic in Ottawa, Canada
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:28614365" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |